<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.66, http://www.edgar-online.com -->
<TITLE> Ohr Pharmaceutical Inc (Form: 10-K, Received: 12/22/2016 17:22:47) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_BUSINESS **FIS_RISK_FACTORS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_LIQUIDITY_CAPITAL **FIS_RESULTS_OF_OPERATIONS **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_AUDITORS_OPINION **FIS_BALANCE_SHEET **FIS_BALANCE_SHEET_2 **FIS_BALANCE_SHEET_3 **FIS_INCOME_STATEMENT **FIS_STOCKHOLDERS_EQUITY **FIS_CASH_FLOW **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_SUBSEQUENT_EVENTS **FIS_PART_III **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_OTHER_INFORMATION **FIS_DIRECTORS_AND_OFFICERS **FIS_NAME_AND_TITLE **FIS_COMPENSATION **FIS_COMPENSATION_TABLE **FIS_OPTIONS **FIS_SECURITY_OWNERS **FIS_BENEFICIAL_OWNERS **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_PART_IV **FIS_EXHIBITS **FIS_SIGNATURES FIS_EXHIBIT_21 FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 FIS_EXHIBIT_32_2 **FIS_CERTIFICATION_4 ">
<META NAME="DETECTED PAGES" CONTENT="120">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="OHRP-10K_093016_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 4PX SOLID; BORDER-BOTTOM: BLACK 1PX SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 14PT">
<B>
	UNITED
	STATES
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 14PT">
<B>
	SECURITIES
	AND EXCHANGE COMMISSION
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 12PT">
	&nbsp;
<B>
	WASHINGTON,
	D.C. 20549
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 12PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P STYLE="FONT: 18PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 18PT">
<B>
	FORM
	10-K
</B>
</FONT>
</P>
<P STYLE="FONT: 18PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(Mark
	One)
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 12PT">
<B>
	&#9746;&nbsp;&nbsp;&nbsp;ANNUAL
	REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	For
	the fiscal year ended September 30, 2016
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 12PT; BACKGROUND-COLOR: WHITE">
<B>
	&#9744;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
<B>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 12PT">
	TRANSITION
	REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</FONT>
</B>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	For
	the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Commission
	File No: 333-88480
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 24PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 24PT">
<B>
	OHR
	PHARMACEUTICAL, INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 24PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	(Exact
	Name of Registrant as Specified in its Charter)
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 45%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Delaware
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 45%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	46-5622433
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	(State or Other Jurisdiction of
</I>
<BR>
<I>
	Incorporation or Organization)
</I>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	(I.R.S. Employer Identification
	No.)
</I>
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	800
	Third Ave, 11th Floor
</B>
<BR>
<B>
	New York, NY 10022
</B>
<BR>
<I>
	(Address of Principal Executive Offices)
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	212-682-8452
</B>
<BR>
<I>
	Registrant&rsquo;s telephone number, including area code
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Securities
	registered under Section 12(b) of the Exchange Act: Common Stock, par value $0.0001 per share
<BR>
	Name of each exchange on which registered: NASDAQ Capital Market
<BR>
	Securities registered under to Section 12(g) of the Exchange Act: None
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; &nbsp;&nbsp;No
	&#9746;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes &#9744; &nbsp;&nbsp;No &#9746;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
	Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such
	reports), and (2) has been subject to such filing requirements for past 90 days. Yes &#9746; &nbsp;&nbsp;No &#9744;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
	Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this Chapter) during the
	preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes &#9746; &nbsp;&nbsp;No
	&#9744;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&sect; 229.405) is not contained herein,
	and will not be contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated
	by reference in Part III of this Form 10-K or any amendment to this Form 10-K. Yes &#9746; &nbsp;&nbsp;No &#9744;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
	reporting company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; and &ldquo;smaller
	reporting company&rdquo; in Rule 12b-2 of the Exchange Act.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(Check
	One): Large accelerated filer &#9744; Accelerated filer &#9746; Non-accelerated &#9744; Smaller reporting company &#9744;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate
	by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &#9744; No &#9746;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	aggregate market value of the voting and non-voting common equity held by non-affiliates at March 31, 2016, the last business
	day of the registrant&rsquo;s most recently completed second fiscal quarter, was $87,714,938 (based on the closing price of the
	registrant&rsquo;s common stock on the NASDAQ Capital Market on such date). Shares of common stock held by each executive officer
	and director and by each person who owns 10% or more of the outstanding common stock of the registrant have been excluded in that
	such person might be deemed to be an affiliate. This determination of affiliate status might not be conclusive for other purposes.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	At
	December 20, 2016, the registrant had 35,961,396 shares of common stock outstanding.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	DOCUMENTS
	INCORPORATED BY REFERENCE
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	None.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PX SOLID; BORDER-BOTTOM: BLACK 4PX SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage2"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 5.75PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE">
<B>
	Table
	of Contents
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.5IN; TEXT-INDENT: -0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.5IN; TEXT-INDENT: -0.5IN">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 92%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 6%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Page
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA001">
<FONT STYLE="FONT-SIZE: 10PT">
	PART I
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA002">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM 1 BUSINESS
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA003">
<FONT STYLE="FONT-SIZE: 10PT; FONT-VARIANT: SMALL-CAPS">
	ITEM
	1A. RISK FACTORS
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	15
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA004">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM 2 PROPERTIES
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	43
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA005">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM 3 LEGAL
	PROCEEDINGS
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	43
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	ITEM 4 MINE SAFETY DISCLOSURES
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	43
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA006">
<FONT STYLE="FONT-SIZE: 10PT">
	PART II
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	44
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA007">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM 5 MARKET
	FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	44
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA008">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM 6 SELECTED
	FINANCIAL DATA
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	46
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA009">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM 7 MANAGEMENT&rsquo;S
	DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	47
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA010">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM 7A QUANTITATIVE
	AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	50
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA011">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM 8 FINANCIAL
	STATEMENTS AND SUPPLEMENTARY DATA
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	50
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA012">
<FONT STYLE="FONT-SIZE: 10PT">
	PART III
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	69
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA013">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM 9 CHANGES
	IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	69
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA014">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM 9A CONTROLS
	AND PROCEDURES
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	69
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA015">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM 9B OTHER
	INFORMATION
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	70
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA016">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM 10 DIRECTORS,
	EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	70
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA017">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM 11 EXECUTIVE
	COMPENSATION
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	74
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA018">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM 12 SECURITY
	OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	100
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA019">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM 13 CERTAIN
	RELATIONSHIPS, RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	103
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA020">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM 14 PRINCIPAL
	ACCOUNTANT FEES AND SERVICES
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	106
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA021">
<FONT STYLE="FONT-SIZE: 10PT">
	PART IV
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	107
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#OHRP-10K_093016_HTM_OHRPA022">
<FONT STYLE="FONT-SIZE: 10PT">
	ITEM 15 EXHIBITS,
	FINANCIAL STATEMENT SCHEDULES
</FONT>
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	107
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.5IN; TEXT-INDENT: -0.5IN">
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.5IN; TEXT-INDENT: -0.5IN">
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.5IN; TEXT-INDENT: -0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 34%; TEXT-ALIGN: CENTER">
	&nbsp;-
<!-- FIELD: SEQUENCE; TYPE: LOWERROMAN; NAME: PAGENO -->
	i
<!-- FIELD: /SEQUENCE -->
	-
</TD>
<TD STYLE="WIDTH: 33%">
	&nbsp;
</TD>
</TR>
</TABLE>
</DIV>
<A NAME="eolPage3"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 6PT">
<P STYLE="MARGIN: 0PT">
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A NAME="OHRP-10K_093016_HTM_OHRPA001">
</A>
	Part
	I
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Our
	discussion and analysis of the business and subsequent discussion of financial conditions may contain forward-looking
	statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
	Exchange Act of 1934, as amended. Statements that are not historical in nature, including statements about beliefs and
	expectations, are forward-looking statements. Words such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo;
	&ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;believes,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;plans,&rdquo;
	&ldquo;expects,&rdquo; &ldquo;intends&rdquo; and similar expressions are intended to identify these forward-looking
	statements, but are not the exclusive means of identifying such statements. Such statements are based on currently available
	operating, financial and competitive information and are subject to various risks and uncertainties as described in greater
	detail in our &ldquo;Risk Factors&rdquo; on page 15 of this Annual Report. You are cautioned that these forward-looking
	statements reflect management&rsquo;s estimates only as of the date hereof, and we assume no obligation to update these
	statements, even if new information becomes available or other events occur in the future, except as required by law. Actual
	future results, events and trends may differ materially from those expressed in or implied by such statements depending on a
	variety of factors, including, but not limited to those set forth in our filings with the Securities and Exchange
	Commission (&ldquo;SEC&rdquo;). Specifically, and not in limitation of these factors, we may alter our plans, strategies,
	objectives or business.
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A NAME="OHRP-10K_093016_HTM_OHRPA002">
</A>
	ITEM
	1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BUSINESS
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	GENERAL
	AND HISTORICAL
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Summary
</B>
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 60PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Ohr
	Pharmaceutical, Inc. (&ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;Ohr,&rdquo; or the &ldquo;Company&rdquo;)
	is a pharmaceutical company focused on the development of novel therapeutics and delivery technologies for the treatment of ocular
	disease. Our development pipeline consists of several programs and indications at various stages of development. Our lead clinical
	asset, topical Squalamine (also known as squalamine lactate ophthalmic solution, 0.2%, or OHR-102), is a novel therapeutic product
	which could provide a non-invasive therapy to improve vision outcomes beyond that achieved with current standard of care, without
	requiring multiple injections per office visit. We are conducting a Phase 3 registration program evaluating Squalamine in combination
	with Lucentis&reg; injections for the treatment of wet-AMD. This clinical program is proceeding based on the data from a Phase
	2 clinical trial in wet-AMD which demonstrated a positive and clinically meaningful treatment effect of Squalamine combination
	therapy in classic containing choroidal neovascularization (classic CNV) as well as those with occult neovascularization (occult
	CNV) less than 10mm
<SUP>
	2
</SUP>
	.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	preclinical stage pipeline is focused on the development of sustained release therapeutics utilizing the platform technology we
	acquired in May 2014. There are several active programs evaluating molecules and approaches for the treatment of glaucoma, steroid
	induced glaucoma, ocular allergy, and retinal disease. These programs have been identified by Ohr as large markets with unmet
	medical needs or where sustained release therapeutics can greatly improve upon the way ocular disease is currently being treated,
	including increasing compliance rates and reducing treatment burden.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 3; OPTIONS: NEWSECTION; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	1
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage4"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Corporate
	and Historical Information
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	are a Delaware corporation that was organized on August 4, 2009, as successor to BBM Holdings, Inc. (formerly Prime
	Resource, Inc., which was organized March 29, 2002 as a Utah corporation) pursuant to a reincorporation merger. On August 4,
	2009, we reincorporated in Delaware as Ohr Pharmaceutical, Inc.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On
	May 30, 2014, we completed the ophthalmology assets acquisition (the &ldquo;SKS Acquisition&rdquo;) of the privately
	held SKS Ocular LLC and its affiliate, SKS Ocular 1 LLC (&ldquo;SKS&rdquo;). Under the terms of the acquisition agreement, in
	exchange for substantially all the assets of SKS, Ohr made an upfront payment of $3.5 million in cash and issued 1,194,862 shares
	of Ohr common stock to SKS. In addition, SKS is eligible to receive up to an aggregate of 1,493,577 additional shares of Ohr common
	stock in three contingent milestone payments, each milestone resulting in the issuance of 497,859 shares of Ohr common stock.
	Milestone 1 required Ohr to demonstrate a consistent long-term release of a therapeutic agent above threshold therapeutic levels
	in the targeted ocular tissues of an animal model. Ohr met this milestone in December 2015. Milestone 2 required the completion
	of a pharmacodynamic study in an animal model showing clinically relevant efficacy from a drug substance released from SKS microparticles
	within 24 months of the date of the closing of the SKS Acquisition. Ohr achieved the study results in May 2016, and the Board
	reviewed and approved Milestone 2 in July 2016. Milestone 3 requires, among other things, the approval of an Investigational New
	Drug Application (&ldquo;IND&rdquo;) within three years of the date of the closing of the SKS Acquisition. We do not expect such
	Milestone 3 to be achieved within the timeline provided for in the agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	SKS transaction provided Ohr with a proprietary, patent protected, sustained release technology platform under development as
	well as a pipeline of pre-clinical sustained release drug product candidates that address ocular indications including glaucoma,
	ocular allergy, retinal disease and other ophthalmic indications. As part of the SKS Acquisition, Ohr retained the SKS employees
	and continued the SKS operations at the SKS research laboratory facility in San Diego, CA.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Simultaneous
	with the SKS Acquisition, Ohr completed a holding company reorganization in which Ohr merged with a wholly-owned subsidiary and
	a new parent corporation succeeded Ohr as a public holding company under the same name. The business operations of Ohr did not
	change as a result of the reorganization. The new holding company retained the name &ldquo;Ohr Pharmaceutical, Inc.&rdquo; Outstanding
	shares of the capital stock of the former Ohr Pharmaceutical, Inc. were automatically converted, on a share for share basis, into
	identical shares of common stock of the new holding company.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 4; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	2
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage5"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	PRODUCT
	PIPELINE
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SQUALAMINE
	LACTATE OPHTHALMIC SOLUTION 0.2%
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Squalamine
	Lactate Ophthalmic Solution 0.2% (&ldquo;Squalamine&rdquo;, also known as OHR-102)
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Squalamine
	lactate is a small molecule anti-angiogenic drug with a novel intracellular mechanism of action. The drug acts against the development
	of aberrant neovascularization by inhibiting multiple protein growth factors of angiogenesis, including vascular endothelial growth
	factor (&ldquo;VEGF&rdquo;), platelet-derived growth factor (&ldquo;PDGF&rdquo;) and basic fibroblast growth factor (&ldquo;bFGF&rdquo;).
	Scientific evidence has shown PDGF to be an additional target for the treatment of wet-AMD and bFGF levels have been shown
	to be elevated in retinal vein occlusion and wet-AMD patients.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Ohr
	formulated squalamine lactate as a topical solution for ophthalmic indications and optimized the formulation for enhanced uptake
	into the back of the eye, and to potentially provide increased comfort in an elderly patient population. The Company is advancing
	its clinical wet-AMD program with this topical formulation. Unlike other combination therapy approaches being evaluated in clinical
	studies, Squalamine does not require direct injection into the eye.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	believe that Squalamine used in combination with an anti-VEGF agent may provide several potential advantages over other combination
	therapy approaches currently being investigated in clinical studies including:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Daily
	topical therapy compared to additional monthly intravitreal injections.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Potential
	use in combination with as-needed (PRN) anti-VEGF injections or treat-and-extend regimens
	as well as a monthly/bi-monthly anti-VEGF injection regimens.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Adaptable
	for use in combination with future longer acting anti-VEGF agents.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Inhibition
	of multiple growth factor pathways of angiogenesis.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cost
	efficiency of manufacturing a small molecule when compared to large molecule proteins
	and antibodies.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company has conducted a preclinical program which consisted of pharmacology, pharmacokinetic, and toxicology studies which support
	the ongoing clinical development of Squalamine.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 5; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	3
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage6"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Completed
	Phase 2 Trial in wet-AMD: the IMPACT Study (formerly OHR-002)
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	commenced a clinical study, Study OHR-002 (or IMPACT Study), which began enrolling patients in late 2012. The IMPACT Study was
	a multi-center, randomized, double masked, placebo controlled Phase 2 study to evaluate the efficacy and safety of Squalamine
	combination therapy for the treatment of wet-AMD. The study enrolled treatment na&iuml;ve wet-AMD patients at more than 20 clinical
	sites in the U.S. who were randomly assigned to treatment with Squalamine lactate ophthalmic solution 0.2% (&ldquo;Squalamine&rdquo;),
	or placebo eye drops for a nine month period, along with Lucentis&reg; injections, as necessary, following an initial baseline
	Lucentis&reg; injection. Full enrollment was completed in April 2014. In March 2015, we completed the IMPACT Study and announced
	topline results. The final data from the IMPACT Study was presented at multiple scientific conferences and forums in 2015 and
	2016. In a prespecified analysis, data from the IMPACT study demonstrated that, in the intent-to-treat (ITT-LOCF) population with
	lesions containing classic choroidal neovascularization (&ldquo;classic CNV&rdquo;) (Squalamine combination treatment n=38, Lucentis&reg;
	monotherapy n=32), 42% of the patients receiving Squalamine achieved a &ge;3 line gain at nine months, as compared to 28% in the
	Lucentis&reg; monotherapy group. In patients with classic CNV (ITT-LOCF), mean gains in visual acuity were +10.5 letters for the
	Squalamine combination arm and +5.4 letters with Lucentis&reg; monotherapy, a clinically meaningful benefit of +5.1 letters. The
	positive effect on visual acuity in classic CNV was seen early in the course of treatment and continued to increase through the
	end of the study. Less of a visual acuity benefit was seen in the overall population (all lesion types). The mean number of injections
	between the treatment arms, the primary endpoint of the study, was not meaningfully different.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Further
	analyses were conducted to determine the patient population most likely to benefit from combination treatment. Patients with lesions
	containing classic CNV are a heterogeneous population and, within the enrollment criteria of our study, could have encompassed
	small classic lesions with no occult component as well as lesions up to 12 disc areas (~30mm
<SUP>
	2
</SUP>
	) in size made up almost
	entirely of occult CNV. These diverse lesions would both fall under the same category of &ldquo;classic containing lesion&rdquo;
	even though they would be expected to respond differently to treatment. Correlation analyses determined that the occult CNV size
	at baseline, regardless of whether there was a classic CNV component present, directly correlated with improved visual acuity
	outcomes in the Squalamine combination group (p=&lt;0.0001), which was not seen in the Lucentis&reg; monotherapy group. This suggests
	that the occult CNV size was a more important predictor of success for combination therapy than the presence of classic CNV, and
	a cutoff less than 10mm
<SUP>
	2
</SUP>
	of occult size at baseline was determined to be the optimal size to include in future clinical
	studies. In those patients with occult CNV less than 10mm
<SUP>
	2
</SUP>
	in area (n=94 of 128 completing the phase 2 study), 40%
	of those treated with Squalamine combination therapy achieved a gain of 3 or more lines of vision, compared with 26% of patients
	in the Lucentis&reg; monotherapy arm, a 54% additional benefit. In addition, mean gains in visual acuity compared to baseline
	were +11.0 letters for the Squalamine combination arm and +5.7 letters with Lucentis&reg; monotherapy, a clinically meaningful
	benefit of +5.3 letters (exploratory p-value, p=.033). Subjects with occult CNV &lt;10mm
<SUP>
	2
</SUP>
	achieved a final mean visual
	acuity outcome of 71.7 letters with Squalamine combination therapy compared to 67.4 letters with Lucentis&reg; monotherapy. The
	final mean visual acuity outcomes in the combination therapy group translates to approximately 20/40 vision (snellen equivalent),
	an important level of visual function. Importantly, this group of patients represents a larger proportion of the subjects enrolled
	in the IMPACT study than the classic containing group. We are enrolling this optimized patient population in our Phase 3 clinical
	program.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Regulatory
	(FDA) Status of Squalamine Program in Wet-AMD
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	March 2016, the Company reached an agreement on a Special Protocol Assessment (SPA) with the United States Food and Drug Administration
	(US FDA) on the design of the Phase 3 trial. The FDA awarded Fast Track Designation to the Squalamine eye drop program for the
	potential treatment of wet-AMD in 2012.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 6; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	4
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage7"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Phase
	3 Trials in Wet-AMD
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Phase 3 program is being conducted to evaluate the efficacy and safety of Squalamine given in combination with Lucentis&reg; for
	treatment naive patients with wet-AMD. The comprehensive clinical program is comprised of double-masked, placebo-controlled, multicenter,
	international studies of Squalamine administered twice a day in patients with newly diagnosed wet AMD, in combination with Lucentis&reg;
	injections. The primary endpoint will be a measurement of visual acuity gains at nine months, with patients followed to two years
	for safety. We are enrolling a patient population that we believe is the most likely to benefit from Squalamine combination therapy
	based on our full analysis of the IMPACT study. During the first year of the study, patients will be randomized 1:1 to receive
	monthly Lucentis&reg; plus Squalamine twice a day or Lucentis&reg; plus placebo eye drops twice a day. During the second year
	they will continue to use Squalamine or placebo eye drops twice a day and receive Lucentis&reg; PRN (as needed) as determined
	by monthly monitoring visits. The Company began enrolling patients in the first phase III study in April 2016.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	OHR&ndash;1501
	Study
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	OHR-1501
	is an ongoing exploratory, double-masked, randomized, placebo-controlled study designed to assess safety and efficacy of
	treatment with squalamine lactate ophthalmic solution in combination with monthly anti-VEGF (both Lucentis&reg; and
	Eylea&reg;) injections in patients with neovascular AMD. Approximately 40 subjects will participate for a six-month duration.
	Safety, functional, and anatomical parameters will be evaluated including retinal imaging modalities and functional visual
	acuity (BCVA). The primary endpoints of the study are the outcome measures at Week 12.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Completed
	Trial in Proliferative Diabetic Retinopathy (&ldquo;PDR&rdquo;) - Study 003
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Study
	003 was an open-label monotherapy investigator sponsored trial (&ldquo;IST&rdquo;) evaluating Squalamine in five patients with
	PDR. Patients enrolled in the study received Squalamine for a six month treatment period and were then followed for an additional
	two months. The endpoints included regression of neovascularization, anatomical measurements, visual acuity, and safety parameters.
	The principal investigator of Study 003 presented a case report from the first patient to complete the protocol in February 2014.
	In this case report, the oral presentation discussed the case of a treatment na&iuml;ve patient diagnosed with PDR. The data demonstrated
	that topical application of Squalamine in a monotherapy regimen, twice daily and then four times daily, was associated with regression
	of retinal neovascularization within two months. The retinal neovascularization remained regressed throughout the six months of
	four times daily Squalamine therapy. One month after cessation of treatment, the abnormal blood vessels returned in this patient&rsquo;s
	retina in the absence of Squalamine treatment, and continued to grow through the second month, the latest time point measured.
	Final data may be disseminated by the investigator, at his discretion, in a scientific publication.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 7; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	5
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage8"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Completed
	Trial in Branch and Central Retinal Vein Occlusion -Study 004
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Study
	004 was an IST evaluating squalamine lactate ophthalmic solution, 0.2%, in 20 patients with branch and central retinal vein
	occlusion. All patients in the study received Squalamine for 10 weeks, with injections of Lucentis&reg; at weeks two and six,
	and a data readout at week 10. At week 10, the patients entered into the extension phase and were randomized 1:1 to
	either continue or discontinue taking Squalamine through week 38 (&ldquo;extension phase&rdquo;). During the extension phase,
	the patients received Lucentis&reg; injections on a PRN basis as determined by fluid based OCT criteria. The
	principal investigator presented the 10 week data from the study in August 2014. The data demonstrated that, at week 10 (1)
	the mean gain in visual acuity was 20.3 letters for all 20 patients using the combination therapy, (2) the mean visual acuity
	for all 20 patients at was 20/32, (3) the average central foveal thickness for all 20 patients was reduced to 270u, and (4)
	only one of 20 patients qualified for an injection of Lucentis&reg;, indicating dryness of the retina and a 95%
	macular deturgescence rate.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	July 2015, final data was presented demonstrating that at week 38, (1) the mean gain in visual acuity from baseline for patients
	randomized (at week 10) to treatment with Squalamine + Lucentis&reg; PRN was +27.8 letters compared with +23.3 for patients randomized
	to treatment with Lucentis&reg; plus PRN alone (control group), a clinically meaningful difference of +4.5 letters, (2) 80% of
	patients in the Squalamine + Lucentis&reg; treated group had a gain in visual acuity, compared with 50% of patients treated with
	Lucentis&reg; alone, and (3) none of the patients in the Squalamine + Lucentis&reg; treated group lost any vision as compared
	to 50% of the patients receiving Lucentis&reg; alone. After the initial combination therapy phase, the mean gain in visual acuity
	from week 10 to week 38 was +7.4 letters for patients who continued treatment with Squalamine + Lucentis&reg; PRN compared with
	+3.1 letters in those receiving Lucentis&reg; PRN alone. The Study was published by the investigator in the Ophthalmic Surgery,
	Lasers, and Imaging Retina (OSLI) journal in October 2016.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<FONT STYLE="TEXT-TRANSFORM: UPPERCASE">
	SKS Sustained Release Ocular Drug Delivery Platform Technology
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	SKS sustained release technology employs a hydrogel template approach to prepare nano, micro and macroparticles of
	predefined size and shape and with homogeneous size distribution. The size and shape of the particles can be adjusted,
	providing flexibility in controlling the drug load and release rate in drug delivery formulations. The drug loading capacity
	is much higher than that achieved by conventional methods, with a controlled initial burst release of drug that is minimal.
	Simplicity in processing makes the hydrogel template method useful for scale-up manufacturing of particles. We believe the
	technology has significant advantages over currently available microparticle drug delivery systems prepared by emulsion and
	other methods. This technology platform is adaptable to multiple routes of ocular delivery and amenable to multiple different
	polymers.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	SKS sustained release technology was designed to develop best-in-class drug formulations for ocular disease. The technology
	employs micro fabrication techniques to create nano, micro and macroparticle drug formulations that can provide sustained
	and predictable release of a therapeutic drug over a 3 &ndash; 6 month period. The versatility of this delivery technology
	makes it well suited to deliver hydrophilic or hydrophobic small molecules, as well as proteins with complex structures.
	Ohr&rsquo;s preclinical pipeline of sustained release programs include sustained release formulations of small molecule and
	protein therapeutics for the treatment of ocular diseases, including glaucoma, steroid induced glaucoma, ocular allergy, and
	retinal disease.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 8; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	6
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage9"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	December 2015, we announced the achievement of Milestone 1, demonstrating sustained release in vivo proof of concept in one of
	our internal programs, and data from this study was presented at the Association for Research in Vision and Ophthalmology (ARVO)
	in May 2016. In this study, we dosed rabbits with a single intravitreal dose of our SKS sustained release formulation of a novel
	small molecule anti-angiogenic compound (OHR3031), and then followed the rabbits over a six week period. The study showed that
	sustained supratherapeutic levels of active drug could be achieved in the retina and choroid, which are the target ocular tissues
	for back of the eye disease. These observations were made at all time points in the study which demonstrates a prolonged pharmacokinetic
	profile. Furthermore, vitreous concentrations remained at stable, high levels throughout the six week study indicating that the
	true duration of effect is potentially longer.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	May 2016, we completed an in vivo study demonstrating sustained pharmacological anti-angiogenic activity of OHR3031 in
	a rabbit model of laser-induced CNV (Milestone 2). A single intravitreal injection of OHR3031 produced clinically meaningful and
	statistically significant efficacy six weeks after dose administration in the CNV rabbit model. A dose response in the reduction
	of average CNV lesion areas with the OHR3031 containing microparticles compared to vehicle treatment was evident, with the highest
	dose exhibiting a statistically significant effect at Week 6. The magnitude of the difference in average CNV lesion size for the
	high dose of OHR3031 compared to the vehicle treatment at 6 weeks was comparable to that seen at 2 weeks with a currently approved
	anti-VEGF agent conducted in a previous study. These studies serve as an important validation of our SKS sustained release technology
	which we believe holds the promise of improving the standard of care in a number of ocular conditions by allowing for physician
	administration of drugs at convenient treatment intervals. We anticipate presenting additional in-vivo proof of concept data on
	our internal programs in calendar 2017.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Animal
	Model for Dry-AMD
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As
	part of the SKS Acquisition, we acquired the exclusive rights to an animal model for dry-AMD whereby mice are immunized with a
	carboxyethylpyrrole (&ldquo;CEP&rdquo;) which is bound to mouse serum albumin (&ldquo;MSA&rdquo;). CEP is produced following the
	oxidation of docosahexaenoic acid, which is abundant in the photoreceptor outer segments that are phagocytosed by the retinal
	pigment epithelium (&ldquo;RPE&rdquo;). A number of CEP-adducted proteins have been identified in proteomic studies examining
	the composition of drusen and other subretinal deposits found in the eyes of patients with dry-AMD. Studies have shown that immunization
	of CEP-MSA can lead to an ophthalmic phenotype very similar to dry-AMD, including deposition of complement in the RPE, thickening
	of the Bruch&rsquo;s membrane, upregulation of inflammatory cytokines, and immune cell influx into the eye. Upon immunization
	with CEP, a marked decrease in contrast sensitivity which precedes a loss of visual acuity, was observed, similar to what occurs
	in many patients with dry AMD.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 9; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	7
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage10"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Ophthalmology
	Assets
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Ohr
	also owns various other compounds in earlier stages of development, including the PTP1b inhibitor Trodusquemine and related analogs.
	See &ldquo;Corporate Strategy&rdquo; concerning the Trodusquemine joint venture. During fiscal 2015, we ceased all development
	of OHR/AVR 118 and recognized an impairment on the patent portfolio in the amount of $338,906.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Competitive
	Factors
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: ITALIC BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0 0PT 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Competition
	in General
</FONT>
</P>
<P STYLE="FONT: ITALIC BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0 0PT 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Competition
	in the area of biomedical and pharmaceutical research and development is intense and significantly depends on scientific and technological
	factors. These factors include the availability of patent and other protection for technology and products, the ability to commercialize
	technological developments and the ability to obtain regulatory approval for testing, manufacturing and marketing. Our competitors
	include major pharmaceutical and specialized biotechnology companies, many of which have financial, technical and marketing resources
	significantly greater than ours. In addition, many biotechnology companies have formed collaborations with large, established
	companies to support research, development and commercialization of products that may be competitive with ours. Academic institutions,
	governmental agencies and other public and private research organizations are also conducting research activities and seeking
	patent protection and may commercialize products on their own or through joint ventures. We are aware of certain other products
	manufactured or under development by competitors that are used for the treatment of the health conditions that we have targeted
	for product development. We can provide no assurance that developments by others will not render our technology obsolete or noncompetitive,
	that we will be able to keep pace with new technological developments or that our technology will be able to supplant established
	products and methodologies in the therapeutic areas that are targeted by us. The foregoing factors could have a material adverse
	effect on our business, prospects, financial condition and results of operations. These companies, as well as academic institutions,
	governmental agencies and private research organizations, also compete with us in recruiting and retaining highly qualified scientific
	personnel and consultants.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Competition
	within our sector is increasing, so we will encounter competition from existing firms that offer competitive solutions in ocular
	diseases. These competitive companies could develop products that are superior to, or have greater market acceptance, than the
	products being developed by us. We will have to compete against other biotechnology and pharmaceutical companies with greater
	market recognition and greater financial, marketing and other resources.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: ITALIC BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0 0PT 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Wet-AMD
	Market
</FONT>
</P>
<P STYLE="FONT: ITALIC BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0 0PT 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Age-related
	macular degeneration (&ldquo;AMD&rdquo;) is a medical condition which usually affects older adults and generally results in a
	loss of vision. AMD occurs in &ldquo;dry&rdquo; (non-exudative) and &ldquo;wet&rdquo; (exudative) forms. Wet-AMD is the advanced
	form of macular degeneration that involves the formation of abnormal and leaky blood vessels in the back of the eye behind the
	retina, through a process known as choroidal neovascularization (&ldquo;CNV&rdquo;). The wet form accounts for approximately 15
	percent of all AMD cases, yet is responsible for 90 percent of severe vision loss associated with AMD. According to the National
	Eye Institute (NEI), the prevalence of wet-AMD among adults 40 years or older in the U.S. alone is estimated at 1.75 million people.
	In addition, more than 200,000 new cases are diagnosed annually in the U.S.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 10; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	8
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage11"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: ITALIC BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0 0PT 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Competitive
	Landscape in Wet-AMD
</FONT>
</P>
<P STYLE="FONT: ITALIC BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0 0PT 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	current FDA approved market leaders for the treatment of wet AMD are VEGF inhibitors, including Lucentis&reg;, Eylea&reg; and
	(off-label) Avastin&reg;. In 2015, annual revenue (worldwide) was more than $3 billion for Lucentis&reg;, despite significant
	off-label use of Avastin&reg; (estimated to be 45-60% of the overall market). Eylea&reg;, is approved for use in wet-AMD and other
	retinal indications and achieved 2015 revenues of approximately $4 billion. Both Lucentis&reg; and Eylea&reg; are administered
	via frequent intravitreal injections directly into the eye. We are developing Squalamine for use in combination with Lucentis&reg;
	and other anti-VEGF agents to improve visual function beyond that achieved with anti-VEGF therapy alone. There is no assurance
	that we will receive FDA approval for Squalamine for the treatment of wet-AMD, and if we receive it, there is no assurance we
	will be able to displace the market leaders as a treatment in a significant percentage of patients.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	There
	are various other companies with drugs in Phase 1, 2, and 3 trials for the treatment of wet-AMD. We cannot assure that none of
	them will get to market before us or that Squalamine will be a better treatment. Programs currently in Phase 2 or Phase 3 trials include:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 57PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Fovista&reg;, a PDGF targeting aptamer being developed by Ophthotech in partnership with Novartis and Roche;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 57PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Abicipar
	Pegol, a VEGF targeting DARPin molecule being developed by Allergan;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 57PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	RTH258,
	an anti-VEGF agent being developed by Alcon/Novartis;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 57PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	X-82,
	an oral tyrosine kinase inhibitor being developed by Tyrogenex;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 57PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ALG-1001,
	an integrin targeting peptide being developed by Allegro Ophthalmics;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 57PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	REG-2176,
	a combination injection of anti-VEGF and PDGF agents being developed by Regeneron;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 57PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	REG-910,
	an anti-Ang2 agent to be used with Eylea&reg; being developed by Regeneron;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 11; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	9
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage12"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 57PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	RG7716,
	a bispecific antibody to both VEGF-A and Ang2 being developed by Roche;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 57PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	OPT-302,
	an inhibitor of VEGF-C and VEGF-D being developed by Opthea; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 57PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	PAN-90806, a selective inhibitor of VEGF being developed by Panoptica Inc.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	All
	of these products in clinical development, with the exception of X-82 and PAN-90806, use an intravitreal route
	of administration much like the current standards of care. We believe that squalamine has potential competitive
	advantages through its intracellular mechanism of action, multiple growth factor inhibition, and non invasive delivery. We
	also believe we have reduced the risk in our Phase 3 program by utilizing our exploratory Phase 2 trial to identify and
	enroll a patient population that has the greatest potential for visual acuity benefits
	with combination therapy.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: ITALIC BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0 0PT 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Competitive
	Landscape in Sustained Release Drug Delivery
</FONT>
</P>
<P STYLE="FONT: ITALIC BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0 0PT 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	There
	are a number of companies developing various forms of sustained release drug delivery platforms for ophthalmic applications. These
	include:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 57PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	GreyBug
	with a biodegradable polymer microsphere/nanoparticle matrix system,
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 57PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Envisia
	Therapeutics with the PRINT&reg; technology system for microparticle and nanoparticle
	formulations
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 57PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Kala
	Pharmaceuticals with a mucus-penetrating particle (MPP) technology; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 57PT">
</TD>
<TD STYLE="WIDTH: 18PT">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Ocular
	Therapeutix with a proprietary hydrogel technology.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	All
	of these programs are in the preclinical or clinical development stages. Each of these may prove to be effective means to deliver
	drugs in a sustained manner and we cannot assure that none of them will get to market before us or that the SKS technology will
	be a better drug delivery approach.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Corporate
	Strategy
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We are currently actively developing our pipeline products for applications in ophthalmology. Beginning in fiscal 2014, we
	transitioned Ohr to a core focus on ophthalmology indications and building an ophthalmology-focused pipeline, and we expect to
	continue to see progress in our pipeline and ophthalmology initiatives.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	are in an ongoing business development process to seek and implement strategic alternatives with respect to Squalamine, based
	on the Phase 2 study demonstrating a visual acuity benefit of Squalamine combination therapy, including licenses, business collaborations
	and other business combinations or transactions with other pharmaceutical and biotechnology companies. Several third parties with
	whom we have been in discussions have expressed interest in a potential licensing or partnering transaction for the Squalamine
	program. We continue to make progress in these discussions.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We are also in preliminary discussions regarding potential collaborations for the SKS sustained release platform technology
	with potential strategic partners.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 12; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	10
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage13"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As
	part of this core strategy, on February 26, 2014, we entered into a Joint Venture Agreement and related agreements with Cold
	Spring Harbor Laboratory (&ldquo;CSHL&rdquo;) pursuant to which a joint venture, DepYmed Inc. (&ldquo;DepYmed&rdquo;),
	was formed to further preclinical and clinical development of Ohr&rsquo;s Trodusquemine and analogues as PTP1B inhibitors for
	oncology indications. DepYmed licenses research from CSHL and intellectual property from us. In December 2014, DepYmed hired
	a full time CEO to run the operations of DepYmed and in October 2016 raised $1 million in a private placement transaction,
	with an additional $1 million to be received upon the achievement of specific development milestones. The proceeds of the
	private placement will fund the ongoing operations of DepYmed. Ohr is a passive joint venturer in DepYmed.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Patents
	and Other Proprietary Rights
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Patents
	and other proprietary rights are important to our business. It is our policy to seek patent protection for our assets, and also
	to rely upon trade secrets, know-how and licensing opportunities to develop and maintain our competitive position.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	generally seek worldwide patent protection for our products and have foreign patent rights corresponding to most of our U.S. patents.
	We currently own or have exclusively licensed several issued U.S. patents and non-US patents and have additional U.S. and non-U.S.
	pending patent applications. U.S. patents and U.S. patent applications 7981876, 8716270, 6262283, 7728157, 20130281420 and 20150342874
	cover the Squalamine formulations, composition of matter, combination therapy with other agents, methods of manufacture, and uses. Additional patent applications covering Squalamine have been filed.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Under
	an agreement with Akina, Inc (&ldquo;Akina&rdquo;), we license patents, with an estimated expiration date of May 28, 2029, relating
	to nano/micro/macro particle fabrication technology for sustained release of molecules. The worldwide, exclusive,
	sub-licensable license was granted to SKS (now Ohr) for use in developing ocular products. Under the agreement with Akina, the
	parties will collaborate on at least three nano/micro particulate products and SKS (now Ohr) agreed to use commercially reasonable
	efforts to either develop the licensed technology by means of a partnership with a third party or by the filing of an investigational
	new drug application. Additional patent applications have been filed that expand on this platform technology and that are specific
	to our active development programs using the sustained release technology.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Pursuant
	to the terms of the Uruguay Round Agreements Act, the term of a U.S. patent is 20 years and is measured from the effective date
	that the patent application was filed rather than the prior calculation of term which was 17 years from the date that the patent
	issued. Patent term may be extended beyond the 20-year period by patent term adjustment when the U.S. Patent Office fails to examine
	the patent application in a timely manner before issuance of the patent. We take advantage of patent term adjustment whenever
	available and expect to seek patent term extensions following marketing approval. Under the Drug Price Competition and Patent
	Term Restoration Act of 1984 (the &ldquo;Hatch-Waxman Act&rdquo;) and the Generic Animal Drug and Patent Term Restoration Act
	of 1988 (the &ldquo;GADPTR Act&rdquo;), a patent that claims a product, use or method of manufacture covering a drug may be extended
	for up to five years to compensate the patent holder for a portion of the time required for FDA review. Our issued U.S. patents
	expire between 2017 and 2029, excluding any extensions available under the Hatch-Waxman Act and the GADPTR Act.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 13; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	11
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage14"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	While
	we file and prosecute patent applications to protect our inventions, our pending patent applications might not result in the issuance
	of patents or our issued patents might not provide competitive advantages. Also, our patent protection might not prevent others
	from developing competitive products using related or other technology.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	addition to seeking intellectual property protection via patents and licenses, we also rely upon trade secrets, know-how and continuing
	technological innovation, which we seek to protect, in part, by confidentiality agreements with employees, consultants, suppliers
	and licensees.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	scope, enforceability and effective term of issued patents can be highly uncertain and often involve complex legal and factual
	questions. No consistent policy has emerged regarding the breadth of claims in pharmaceutical patents, so that even issued patents
	might later be modified or revoked by the relevant patent authorities or courts. Moreover, the issuance of a patent in one country
	does not assure the issuance of a patent with a similar claim scope in another country, and claim interpretation and infringement
	laws vary among countries, so we are unable to predict the extent of patent protection in any country. The patents we obtain and
	the unpatented proprietary technology we hold might not afford us significant commercial protection. Additional information regarding
	risks associated with our patents and other proprietary rights that affect our business is contained under the heading &ldquo;Intellectual
	property litigation is increasingly common and increasingly expensive and may result in restrictions on our business and substantial
	costs, even if we prevail&rdquo; and under the heading &ldquo;Risk Factors&rdquo;.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	There
	are no contested proceedings and/or third-party claims over any of our patents or patent applications.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	NUMBER
	OF PERSONS EMPLOYED
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	At
	present, we have 14 full-time employees. In addition, we use numerous high level scientific, administrative,
	operations, and financial consultants, as well as Contract Research Organizations, on an as needed basis, to augment our internal
	resources and provide a cost efficient alternative to a large infrastructure build out to support our ongoing preclinical and
	clinical development programs. The Company anticipates hiring additional staff during fiscal 2017 to support the Phase 3 trials
	for Squalamine and the sustained release platform programs.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ENVIRONMENTAL
	COMPLIANCE
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	are not aware of any environmental claims or liabilities.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 14; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	12
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage15"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	GOVERNMENT
	COMPLIANCE
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Drug Development Process
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Regulation
	by government authorities in the United States and foreign countries is a significant factor in the research, development, manufacture,
	and marketing of our product candidates. All of our product candidates will require regulatory approval before they can be commercialized.
	In particular, human therapeutic products are subject to rigorous preclinical and clinical trials and other pre-market approval
	requirements by the FDA and foreign authorities. Many aspects of the structure and substance of the FDA and foreign pharmaceutical
	regulatory practices have been reformed during recent years, and continued reform is under consideration in a number of jurisdictions.
	The ultimate outcome and impact of such reforms and potential reforms cannot be predicted.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	activities required before a product candidate may be marketed in the United States begin with preclinical tests. Preclinical
	tests include laboratory evaluations and animal studies to assess the potential safety and efficacy of the product candidate and
	its formulations. The results of these studies must be submitted to the FDA as part of an IND, which must be reviewed by the FDA
	before proposed clinical testing can begin. Typically, clinical testing involves a three-phase process. In Phase 1, trials are
	conducted with a small number of subjects to determine the early safety profile of the product candidate. In Phase 2, clinical
	trials are conducted with subjects afflicted with a specific disease or disorder to provide enough data to evaluate the preliminary
	safety, tolerability, and efficacy of the product candidate. In Phase 3, large-scale clinical trials are conducted with patients
	afflicted with the specific disease or disorder in order to provide enough data to understand the efficacy and safety profile
	of the product candidate, as required by the FDA. The results of the preclinical and clinical testing of a therapeutic product
	candidate are then submitted to the FDA in the form of an NDA for evaluation to determine whether the product candidate may be
	approved for commercial sale. In responding to an NDA, the FDA may grant marketing approval, request additional information, or
	deny the application.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Any
	approval required by the FDA for any of our product candidates may not be obtained on a timely basis, or at all. The designation
	of a clinical trial as being of a particular phase is not necessarily indicative that such a trial will be sufficient to satisfy
	the parameters of a particular phase, and a clinical trial may contain elements of more than one phase notwithstanding the designation
	of the trial as being of a particular phase. The results of preclinical studies or early stage clinical trials may not predict
	long-term safety or efficacy of our compounds when they are tested or used more broadly in humans.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Approval
	of a product candidate by comparable regulatory authorities in foreign countries is generally required prior to commencement of
	marketing of the product in those countries. The approval procedure varies among countries and may involve additional testing,
	and the time required to obtain such approval may differ from that required for FDA approval.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 15; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	13
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage16"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Other
	Regulations
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Various
	federal, state and local laws, regulations, and recommendations relating to safe working conditions, laboratory practices, the
	experimental use of animals, the environment and the purchase, storage, movement, import, export, use, and disposal of hazardous
	or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our
	research are applicable to our activities. They include, among others, the U.S. Atomic Energy Act, the Clean Air Act, the Clean
	Water Act, the Occupational Safety and Health Act, the National Environmental Policy Act, the Toxic Substances Control Act, and
	Resources Conservation and Recovery Act, national restrictions on technology transfer, import, export, and customs regulations,
	and other present and possible future local, state, or federal regulation. The compliance with these and other laws, regulations
	and recommendations can be time-consuming and involve substantial costs. In addition, the extent of governmental regulation which
	might result from future legislation or administrative action cannot be accurately predicted and may have a material adverse effect
	on our business, financial condition, results of operations and prospects.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AVAILABLE
	INFORMATION
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company&rsquo;s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports
	filed pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;),
	are filed with the SEC. The Company is subject to the informational requirements of the Exchange Act and files or furnishes reports,
	proxy statements and other information with the SEC. Such reports and other information filed by the Company with the SEC are
	available free of charge on the Company&rsquo;s website at
<U>
	http://ir.ohrpharmaceutical.com/all-sec-filings
</U>
	, as soon as
	reasonably practicable after we have electronically filed with, or furnished to, the SEC. The public may read and copy any materials
	filed by the Company with the SEC at the SEC&rsquo;s Public Reference Room at 100 F Street, NE, Room 1580, Washington, DC 20549.
	The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC
	maintains an internet site that contains reports, proxy and information statements and other information regarding issuers that
	file electronically with the SEC at
<U>
	www.sec.gov
</U>
	. The contents of these websites are not incorporated into this filing.
	Further, the Company&rsquo;s references to website URLs are intended to be inactive textual references only.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 16; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	14
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_BUSINESS>
<A NAME="eolPage17"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A NAME="OHRP-10K_093016_HTM_OHRPA003">
</A>
	ITEM
	1A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RISK FACTORS
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	You
	should carefully consider the following factors which may affect future results of operations. If any of the adverse events described
	below actually occur, our business, financial condition and operating results could be materially adversely affected and you may
	lose part or all of the value of your investment. If you choose to invest in our securities, you should be able to bear a complete
	loss of your investment.
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Risks
	Related to Our Business and Industry
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	currently do not have, and may never have, any products that generate revenues.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	are a development stage pharmaceutical company and currently do not have, and may never have, any products that generate revenues.
	Investment in pharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures
	and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile,
	gain regulatory approval and become commercially viable. To date, we have not generated any product revenues from our product
	candidates currently in development. We cannot guarantee that any of our product candidates currently in development will ever
	become marketable products.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	must demonstrate that our drug candidates satisfy rigorous standards of safety and efficacy for their intended uses before the
	FDA, and other regulatory authorities in the United States, the European Union and elsewhere. Significant additional research,
	preclinical testing and clinical testing is required before we can file applications with the FDA or other regulatory authorities
	for premarket approval of our drug candidates. In addition, to compete effectively, our drugs must be easy to administer, cost-effective
	and economical to manufacture on a commercial scale. We may not achieve any of these objectives. We reached an agreement
	on a Special Protocol Assessment with the FDA on the design of the Phase 3 trial for Squalamine in wet-AMD in March 2016, and
	we initiated the Phase 3 clinical program and began enrolling patients in April 2016. We cannot be certain that the clinical development
	of this or any other drug candidates in preclinical testing or clinical development will be successful, that we will receive the
	regulatory approvals required to commercialize them or that any of our other research and drug discovery programs will yield a
	drug candidate suitable for investigation through clinical trials. Our commercial revenues from our product candidates currently
	in development, if any, will be derived from sales of drugs that will not become marketable for several years, if at all.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	have incurred significant losses and anticipate that we will incur additional losses. We might never achieve or sustain revenues.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	have experienced significant net losses since our inception. As of September 30, 2016, we had an accumulated deficit of approximately
	$84.3 million. We expect to incur net losses over the next several years as we advance our programs and incur significant clinical
	development costs. We have no products approved for commercial sale and have not generated any revenue from product sales to date,
	and we continue to incur significant research and development and other expenses related to our ongoing operations. We do not
	expect to receive, for at least the next several years, any revenues from the commercialization of our product candidates.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 17; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	15
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage18"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	There
	is no guarantee that our Phase 3 clinical trials for Squalamine in wet-AMD will be completed, completed in the anticipated
	timeframe or that they will be successful.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	results of the Phase 2 clinical trial support conducting Phase 3 clinical trials for Squalamine with enrollment criteria for a
	targeted population, based on the complete analysis of the Phase 2 clinical trial. We reached an agreement on a Special
	Protocol Assessment with the FDA on the design of the Phase 3 trial in March 2016, and we initiated the Phase 3 clinical program
	and began enrolling patients in April 2016. However, there can be no assurance that the Phase 3 clinical trials will be completed
	in the anticipated timeframe, completed at all, or that they will be successful.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	historical rate of failures for product candidates in clinical development and late-stage clinical trials is high.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We reached an agreement on a Special Protocol Assessment with the FDA on the design of the Phase 3 trial in March 2016, and
	we initiated the Phase 3 clinical program and began enrolling patients in April 2016. The Phase 3 trials for Squalamine are designed
	to measure the efficacy of combination therapy with Squalamine plus Lucentis&reg; injections compared with Lucentis&reg; monotherapy
	in treatment na&iuml;ve patients with wet-AMD. All patients will be followed for safety for two years.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	During
	the first year of the study, patients will be randomized 1:1 to receive monthly Lucentis&reg; plus Squalamine (Squalamine lactate
	ophthalmic solution, 0.2%) twice a day or Lucentis&reg; plus placebo. During the second year they will receive Lucentis&reg; PRN
	(as needed) plus Squalamine or placebo twice a day. The primary endpoint will be an improvement in a visual acuity parameter,
	as measured by a standard ETDRS visual acuity chart.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	There
	can be no assurance that we will meet the goals of the Phase 3 clinical trials or that we will have the same level of
	success in the Phase 3 clinical trials as we have in our prior clinical trials, or that we will be successful at all. We
	further believe that Squalamine may also have clinical utility in indications other than wet-AMD. We have completed
	IST&rsquo;s in ophthalmic indications where a molecule that possesses anti-angiogenic properties may provide therapeutic
	benefit. These indications include branch retinal vein occlusion, central retinal vein occlusion, and proliferative
	diabetic retinopathy. However, there can be no assurance that Squalamine will realize such potential utility.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	we do not successfully complete clinical development of Squalamine, we will be unable to market and sell products derived from
	it and to generate product revenues. Even if we do successfully complete clinical trials for Squalamine in patients with wet-AMD,
	we may not achieve or complete the other requirements that may be needed before we may submit a New
	Drug Application, or NDA, to the FDA for the initial or other future indications. Of the vast number of drugs in development,
	only a small percentage result in the submission of an NDA to the FDA, and even fewer result in the NDA ultimately being approved
	by the FDA or other foreign regulatory authority for commercialization.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 18; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	16
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage19"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	will need to raise substantial additional capital to further our drug and delivery platform development programs as well as future
	trials, including our ongoing Phase 3 clinical program for Squalamine in wet-AMD, and may not be able to raise additional capital
	on favorable terms, if at all. If additional capital is not available, we may have to delay, reduce or cease operations.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	will need substantial additional capital to further our drug and delivery platform development programs as well as clinical
	trials. Specifically, we will require significant additional funds to complete our ongoing Phase 3 clinical trials for
	Squalamine in wet-AMD. In our capital-raising efforts, we may seek to sell additional equity or debt securities, obtain a
	bank credit facility, or seek a strategic commercial partner or do a combination. The incurrence of indebtedness would result in
	increased fixed obligations and could also result in covenants that would restrict our operations. However, we may not be
	able to raise additional funds on acceptable terms, or at all. If we raise capital through a strategic commercial partner, we
	may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates
	or grant licenses on terms that may not be favorable to us. If we are unable to secure sufficient capital to fund our
	research and development activities, we may have to delay, reduce or cease operations.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As
	of&nbsp;September 30, 2016, we had cash and cash equivalents of&nbsp;$12.5 million. With our financing in December 2016, we
	believe that our cash and cash equivalents will be sufficient to fund our operating expenses into June 2017. We
	have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than
	we currently expect. We are planning to spend significant funds to advance our Phase 3 trials for Squalamine. At this time,
	we cannot reasonably estimate the remaining costs necessary to complete Phase 3 trials or to complete the development of any
	other product candidate.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Raising
	additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies
	or product candidates.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Until
	such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination
	of equity offerings, debt financings, and strategic partnerships. We do not have any committed external source of funds. To the
	extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&rsquo; ownership
	interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect
	our stockholders&rsquo; rights as holders of our common stock. Debt financing and preferred equity financing, if available, may
	involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional
	debt, making capital expenditures or declaring dividends.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 19; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	17
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage20"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	strategy with respect to Squalamine is to seek a strategic commercial partner, or partners, such as large pharmaceutical companies,
	with extensive experience in the development, commercialization, and marketing of ophthalmic products. Several third parties with
	whom we have been in discussions have expressed interest in a potential licensing or partnering transaction for the Squalamine
	program. We continue to make progress in these discussions; however, there is no assurance that the Company will enter into a
	definitive agreement with respect to such a transaction. If we raise capital through such strategic commercial partner, we may
	have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant
	licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings
	when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts
	or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Results
	from early clinical trials for Squalamine in wet-AMD are not necessarily predictive of the results of later clinical trials for
	Squalamine in wet-AMD. If we cannot replicate the results from our earlier clinical trials for Squalamine in wet-AMD in our later
	clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize Squalamine in wet-AMD.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Results
	from our Phase 2 clinical trial for Squalamine in wet-AMD may not necessarily be predictive of the results from required later
	clinical trials. We may not be able to complete our ongoing Phase 3 clinical program for Squalamine in wet-AMD. Similarly, even
	if we are able to complete our Phase 3 clinical trials for Squalamine in wet-AMD according to our current development timeline,
	the results from our Phase 2 clinical trial for Squalamine in wet-AMD may not be replicated in our Phase 3 clinical trial results.
	Many companies in the pharmaceutical and biotechnology industries, including companies developing combination therapies for wet-AMD, have suffered significant setbacks in late-stage clinical trials
	after achieving positive results in early-stage development, and we cannot be certain that we will not face similar setbacks.
	These setbacks have been caused by, among other things, pre-clinical findings made while clinical trials were underway or safety
	or efficacy observations made in clinical trials, including previously unreported adverse events, and expansion of enrollment eligibility criteria from phase 2 to phase 3 studies. Moreover, pre-clinical and clinical
	data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates
	performed satisfactorily in pre-clinical studies and clinical trials nonetheless failed to obtain FDA or foreign regulatory approval.
	If we fail to produce positive results in our Phase 3 clinical trials for Squalamine in wet-AMD, the development timeline and
	regulatory approval and commercialization prospects for our leading product candidate, and, correspondingly, our business and
	financial prospects, would be materially adversely affected.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Delays,
	suspensions and terminations in our clinical trials could result in increased costs to us, delay our ability to generate product
	revenues and therefore may have a material adverse effect on our business, results of operations and future growth prospects.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	commencement of clinical trials can be delayed for a variety of reasons, including:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	delays
	in demonstrating sufficient safety and efficacy to obtain regulatory approval to commence
	a clinical trial;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	reaching
	agreement on acceptable terms with prospective contract research organizations and clinical
	trial sites;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 20; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	18
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage21"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	manufacturing
	sufficient quantities of a product candidate;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	obtaining
	clearance from the FDA to commence clinical trials pursuant to an Investigational New
	Drug application (or IND);
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	obtaining
	clearance from foreign regulatory authorities to commence clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	financial
	or strategic considerations; obtaining institutional review board approval to conduct
	a clinical trial at a prospective clinical trial site;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	obtaining institutional review board approval to conduct
	a clinical trial at a prospective clinical trial site;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	patient
	enrollment, which is a function of many factors, including the size of the patient population,
	the nature of the protocol, the proximity of patients to clinical trial sites, the availability
	of effective treatments for the relevant disease and the eligibility criteria for the
	clinical trial; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	inability
	to raise funding necessary to initiate a clinical trial.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Once
	a clinical trial has begun, it may be delayed, suspended or terminated due to a number of factors, including:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ongoing
	discussions with regulatory authorities regarding the scope or design of our clinical
	trials or requests by them for supplemental information with respect to our clinical
	trial results;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	failure
	to conduct clinical trials in accordance with regulatory requirements;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	lower
	than anticipated screening or retention rates of patients in clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	serious
	adverse events or side effects experienced by participants;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	financial
	or strategic considerations;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	insufficient
	supply or deficient quality of product candidates or other materials necessary for the
	conduct of our clinical trials; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN">
</TD>
<TD STYLE="WIDTH: 0.25IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	inability
	to raise funding necessary to continue a clinical trial.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Many
	of these factors may also ultimately lead to denial of regulatory approval of a current or potential product candidate. If we
	experience delays, suspensions or terminations in a clinical trial, the commercial prospects for the related product candidate
	will be harmed, and our ability to generate product revenues will be delayed and our business and financial prospects would be
	materially affected.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 21; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	19
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage22"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Even
	if we successfully complete the clinical trials of one or more of our product candidates, the product candidates may fail for
	other reasons.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Even
	if we successfully complete the clinical trials for one or more of our product candidates, the product candidates may fail for
	other reasons, including the possibility that the product candidates will:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	fail
	to receive the U.S. and foreign regulatory approvals required to market them as drugs;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	be
	subject to proprietary rights held by others requiring the negotiation of a license agreement
	prior to marketing;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	be
	difficult or expensive to manufacture on a commercial scale;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	have
	adverse side effects that make their use less desirable; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	fail
	to compete with product candidates or other treatments commercialized by our competitors.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	addition, our clinical trials may involve a specific patient population. Because of the small sample size, the results of these
	early clinical trials may not be indicative of future results. Adverse or inconclusive results may cause us to abandon a drug
	candidate and may delay development of other drug candidates. Any delay in, or termination of, our clinical and preclinical studies
	will delay the filing of our NDAs with the FDA and, ultimately, significantly impair our ability to commercialize our drug candidates
	and generate product revenues which would have a material adverse effect on our business and results of operations. If we are
	unable to receive the required U.S. and foreign regulatory approvals, secure our intellectual property rights, minimize the incidence
	of any adverse side effects or fail to compete with our competitors&rsquo; products, our business, financial condition, and results
	of operations could be materially and adversely affected. Additionally, even if we receive FDA approval for Squalamine for the
	treatment of wet-AMD, there is no assurance we will be able to displace the market leaders as a treatment in a significant percentage
	of patients.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	we find it difficult to enroll patients in our clinical trials, it will cause significant delays in the completion of such trials
	and may cause us to abandon one or more clinical trials.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	For
	the diseases or disorders that our product candidates are intended to treat, we expect only a subset of the patients with these
	diseases to be eligible for our clinical trials. Given that each of our product candidates is in preclinical or clinical development,
	we may not be able to initiate or continue clinical trials for each or all of our product candidates if we are unable to locate
	a sufficient number of eligible subjects to participate in the clinical trials required by the FDA or other foreign regulatory
	authorities. The requirements of our clinical testing mandate that a patient cannot be involved in another clinical trial for
	the same indication. We are aware that our competitors have ongoing clinical trials for products that are competitive with our
	product candidates and subjects who would otherwise be eligible for our clinical trials may be involved in such testing, rendering
	them unavailable for testing of our product candidates. Our inability to enroll a sufficient number of patients for any of our
	current or future clinical trials would result in significant delays or may require us to abandon one or more clinical trials
	altogether, which would have a material adverse effect on our business.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 22; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	20
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage23"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	rely, and expect that we will continue to rely, on third parties to conduct any future clinical trials for us, including our Phase
	3 clinical trial for Squalamine in wet-AMD. If such third parties do not successfully carry out their duties or if we lose our
	relationships with such third parties, our drug development efforts could be delayed.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	are dependent on contract research organizations, third-party vendors and independent investigators for preclinical testing, and
	clinical trials related to our drug discovery and development efforts, and we will likely continue to depend on them to assist
	in our future discovery and development efforts. These parties are not our employees, and we cannot control the amount or timing
	of resources that they devote to our programs. If they fail to devote sufficient time and resources to our drug development programs
	or if their performance is substandard, it will delay the development and commercialization of our product candidates. Our CRO running our phase 3 trial has also contracted with Jason S. Slakter, M.D., P.C., d/b/a Digital Angiography
	Reading Center (&ldquo;DARC&rdquo;), a well-known digital reading center, which is owned by Dr. Jason Slakter, our CEO, pursuant
	to our related party transactions policy, with the review and approval of the Audit Committee, to provide digital reading and imaging
	services in connection with the Phase 3 study. We are advised that DARC has implemented a standard operating procedure (SOP) to
	firewall interactions between DARC employees and Dr. Slakter.&nbsp; It is possible that the FDA will investigate and that this
	related party transaction may impact adversely on its approval of the trials. The parties
	with which we contract for execution of our clinical trials play a significant role in the conduct of the trials and the subsequent
	collection and analysis of data. Their failure to achieve their research goals or otherwise meet their obligations on a timely
	basis could adversely affect clinical development of our product candidates.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Communicating
	with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities.
	Outside parties may:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	have
	staffing difficulties;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	fail
	to comply with contractual obligations;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	experience
	regulatory compliance issues;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	undergo
	changes in priorities or become financially distressed; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	form
	relationships with other entities, some of which may be our competitors.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	These
	factors may materially adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject
	us to unexpected cost increases that are beyond our control. Nevertheless, we are responsible for ensuring that each of our studies
	is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on contract
	research organizations does not relieve us of our regulatory responsibilities. We and our contract research organizations are
	required to comply with current Good Clinical Practices, or cGCPs, which are regulations and guidelines enforced by the FDA and
	comparable foreign regulatory authorities for any products in clinical development. The FDA enforces these cGCP regulations through
	periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we or our contract research organizations
	fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA
	or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing
	applications. We cannot assure that, upon inspection, the FDA or any comparable foreign regulatory authority will determine that
	any of our clinical trials comply with cGCPs. In addition, our clinical trials must be conducted with product produced under current
	Good Manufacturing Practices, or cGMPs, regulations and will require a large number of test subjects. Our failure or the failure
	of our contract research organizations to comply with these regulations may require us to repeat clinical trials, which would
	delay the regulatory approval process and could also subject us to enforcement action up to and including civil and criminal penalties.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 23; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	21
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage24"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Although
	we do design our clinical trials for Squalamine in wet-AMD and other drug candidates, contract research organizations conduct
	all of the clinical trials. As a result, many important aspects of our drug development programs are outside of our direct control.
	In addition, the contract research organizations may not perform all of their obligations under arrangements with us or in compliance
	with regulatory requirements, but we remain responsible and are subject to enforcement action that may include civil penalties
	up to and including criminal prosecution for any violations of FDA or comparable foreign laws and regulations during the conduct
	of our clinical trials. If the contract research organizations do not perform clinical trials in a satisfactory manner, breach
	their obligations to us or fail to comply with regulatory requirements, the development and commercialization of Squalamine in
	wet-AMD and other drug candidates may be delayed or our development program materially and irreversibly harmed. We cannot control
	the amount and timing of resources these contract research organizations devote to our program. If we are unable to rely on clinical
	data collected by our contract research organizations, we could be required to repeat, extend the duration of, or increase the
	size of our clinical trials and this could significantly delay commercialization and require significantly greater expenditures,
	and have a material adverse effect on our business.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	our contract research organizations do not successfully carry out their duties or if we lose our relationships with contract research
	organizations, our drug development efforts could be delayed.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	we lose our relationship with any one or more of these parties, we could experience a significant delay in both identifying another
	comparable provider and then contracting for its services. We may be unable to retain an alternative provider on reasonable terms,
	if at all. Even if we locate an alternative provider, it is likely that this provider may need additional time to respond to our
	needs and may not provide the same type or level of service as the original provider. In addition, any provider that we retain
	will be subject to current Good Laboratory Practices, other regulatory standards, and similar foreign standards, and we do not
	have control over compliance with these regulations by these providers. Consequently, if these practices and standards are not
	adhered to by these providers, the development and commercialization of our product candidates could be delayed, and have a material
	adverse effect on our business.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 24; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	22
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage25"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	product candidates may not gain acceptance among physicians, patients, or the medical community, thereby limiting our potential
	to generate revenues, which will undermine our future growth prospects.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Even
	if our product candidates are approved for commercial sale by the FDA or other regulatory authorities, including foreign regulatory
	authorities, the degree of market acceptance of any approved product candidate by physicians, healthcare professionals and third-party
	payors, and our profitability and growth will depend on a number of factors, including:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the
	ability to provide acceptable evidence of safety and efficacy;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	pricing
	and cost effectiveness, which may be subject to regulatory control;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our
	ability to obtain sufficient third-party insurance coverage or reimbursement;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	effectiveness
	of our or our collaborators&rsquo; sales and marketing strategy;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	relative
	convenience and ease of administration;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the
	prevalence and severity of any adverse side effects; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	availability
	of alternative treatments.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	any product candidate that we develop does not provide a treatment regimen that is at least as beneficial as the current standard
	of care or otherwise does not provide some additional patient benefit over the current standard of care, that product will not
	achieve market acceptance and we will not generate sufficient revenues to achieve profitability.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	may not be able to continue or fully exploit our partnerships with outside scientific and clinical advisors, which could impair
	the progress of our clinical trials and our research and development efforts.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	work with scientific and clinical advisors who are experts in the field of ocular disorders. They advise us with respect to our
	clinical trials. These advisors are not our employees and may have other commitments that would limit their future availability
	to us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services,
	which may impair our reputation in the industry and delay the development or commercialization of our product candidates.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	rely completely on third-party manufacturers which may result in delays in our clinical trials, regulatory approvals and product
	introductions.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	have no manufacturing facilities and do not have extensive experience in the manufacturing of drugs or in designing drug-manufacturing
	processes. We have contracted with third-party manufacturers to produce, in collaboration with us, our product candidates, including
	Squalamine, for clinical trials. If any of our product candidates are approved by the FDA or other regulatory agencies, including
	foreign regulatory agencies for commercial sale, we may need to amend our contract with our current manufacturer or contract with
	another third party to manufacture them in larger quantities. If we need to enter into alternative arrangements, it could delay
	our product development activities. Our reliance on these third parties for development activities will reduce our control over
	these activities but will not relieve us of our responsibility to ensure compliance with all required regulations and study and
	trial protocols. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct
	our studies in accordance with regulatory requirements or our stated study and trial plans and protocols, or if there are disagreements
	between us and these third parties, we will not be able to initiate, or complete, or may be delayed in completing, the clinical
	trials required to support future approval of our product candidates. In some such cases, we may need to locate an appropriate
	replacement third-party relationship, which may not be readily available or with acceptable terms, which would cause additional
	delay with respect to the approval of our product candidates and would thereby have a material adverse effect on our business,
	financial condition, results of operations and prospects.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 25; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	23
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage26"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	have not entered into long-term agreements with our current third-party manufacturers or with any alternate suppliers. Although
	we intend to do so prior to any commercial launch of a product that is approved by the FDA or any comparable foreign regulatory
	authorities in order to ensure that we maintain adequate supplies of commercial drug product, we may be unable to enter into such
	agreements or do so on commercially reasonable terms, which could delay a product launch or subject our commercialization efforts
	to significant supply risk. In addition, reliance on third-party manufacturers entails risks to which we would not be subject
	to if we manufactured the product candidates ourselves, including:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the
	inability to negotiate manufacturing agreements with third parties under commercially
	reasonable terms;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	reduced
	control as a result of using third-party manufacturers for all aspects of manufacturing
	activities;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	termination
	or nonrenewal of manufacturing agreements with third parties in a manner or at a time
	that is costly or damaging to us; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	disruptions
	to the operations of our third-party manufacturers or suppliers caused by conditions
	unrelated to our business or operations, including regulatory enforcement actions, and
	bankruptcy of the manufacturer or supplier.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Any
	of these events could lead to clinical trial delays or failure to obtain regulatory approval, or impact our ability to successfully
	commercialize future product candidates. Some of these events could be the basis for FDA or any comparable foreign regulatory
	authority action, including injunction, recall, seizure or total or partial suspension of product manufacture.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 26; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	24
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage27"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	contract manufacturers are subject to significant regulatory oversight with respect to manufacturing our products. The manufacturing
	facilities on which we rely may not continue to meet regulatory requirements and may have limited capacity.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	manufacturers of our product candidates are obliged to operate in accordance with FDA-mandated cGMPs. In addition, the facilities
	used by our contract manufacturers or other third party manufacturers to manufacture our product candidates must be approved by
	the FDA or other foreign regulatory authority pursuant to inspections that will be conducted after we request regulatory approval
	from the FDA or other foreign regulatory authority. A failure of any of our current or future contract manufacturers to establish
	and follow cGMPs and to document their adherence to such practices may lead to significant delays in clinical trials or in obtaining
	regulatory approval of product candidates or the ultimate launch of products based on our product candidates into the market.
	Furthermore, all of our contract manufacturers are engaged with other companies to supply and/or manufacture materials or products
	for such companies, which exposes our manufacturers to regulatory risks for the production of such materials and products. As
	a result, failure to satisfy the regulatory requirements for the production of those materials and products may affect the regulatory
	clearance of our contract manufacturers&rsquo; facilities generally. Failure by our current or future third-party manufacturers
	or us to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil
	penalties, failure of the government to grant pre-market approval of drugs, delays, suspension or withdrawal of approvals, seizures
	or recalls of products, operating restrictions, and criminal prosecutions. Many aspects of the clinical trial and manufacturing
	process are outside of our control. In addition, the third-party manufacturers may not perform all of their obligations under
	arrangements with us or in compliance with regulatory requirements. If a third-party manufacturer breaches its obligations to
	us or fails to comply with regulatory requirements, the commercialization of Squalamine in wet-AMD and other drug candidates may
	be delayed or irreversibly harmed.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance
	with the applicable regulations as a condition of regulatory approval of our product candidates. In addition, the regulatory authorities
	may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or the associated
	quality systems for compliance with the regulations applicable to the activities being conducted. If these facilities do not pass
	a pre-approval plant inspection, FDA approval of the products will not be granted.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	regulatory authorities also may, at any time following approval of a product for sale, audit our manufacturing facilities or those
	of our third-party manufacturers. If any such inspection or audit identifies a failure to comply with applicable regulations or
	if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or
	the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or our third-party
	manufacturers to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales
	or the temporary or permanent closure of a manufacturing facility. Any such remedial measures imposed upon us or third parties
	with whom we contract could materially harm our business.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	are highly dependent upon our ability to enter into agreements with collaborative partners to develop, commercialize, and market
	our products.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	strategy is to seek a strategic commercial partner, or partners, such as large pharmaceutical companies, with extensive
	experience in the development, commercialization, and marketing of ophthalmic products. We are in an ongoing business
	development process to seek and implement strategic alternatives with respect to Squalamine, based on the Phase 2 study
	demonstrating a visual acuity benefit of Squalamine combination therapy, including licenses, business collaborations and
	other business combinations or transactions with other pharmaceutical and biotechnology companies. Several third parties with
	whom we have been in discussions have expressed interest in a potential licensing or partnering transaction for the
	Squalamine program. We continue to make progress in these discussions. We are also in preliminary discussions regarding
	potential collaborations for the SKS sustained release platform technology with strategic partners. Such anticipated
	strategic partnership, or partnerships, may provide a marketing and sales infrastructure for our products as well as
	financial and operational support for global clinical trials, post marketing studies, label expansions, preclinical studies,
	manufacturing capabilities, and other regulatory requirements concerning future clinical development in the United States and
	foreign territories.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 27; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	25
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage28"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	To
	date, we have not entered into any strategic partnerships for any of our products. We face significant competition in seeking
	appropriate strategic partners, and these strategic partnerships can be intricate and time consuming to negotiate and document.
	We may not be able to negotiate strategic partnerships on acceptable terms, or at all. We are unable to predict when, if ever,
	we will enter into any strategic partnerships because of the numerous risks and uncertainties associated with establishing strategic
	partnerships.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	While
	our strategy is to partner with an appropriate party, no assurance can be given that any third party would be interested in partnering
	with us. We currently lack the resources to manufacture any of our product candidates on a large scale and we have no sales, marketing
	or distribution capabilities. In the event we are not able to enter into a collaborative agreement with a partner or partners,
	on commercially reasonable terms, or at all, we may be unable to commercialize our products, which would have a material adverse
	effect upon our business, prospects, financial condition, and results of operations.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	we are ever in a position to commercialize our product candidates, of which there can be no assurance, we have no experience selling,
	marketing or distributing products and no internal capability to do so.
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	currently have no sales, marketing or distribution capabilities and no experience in building a sales force and distribution capabilities.
	If we are ever in a position to commercialize our product candidates, of which there can be no assurance, we must develop internal
	sales, marketing and distribution capabilities, which will be expensive and time consuming, or make arrangements with third parties
	to perform these services. If we decide to market any of our products directly, we must commit significant financial and managerial
	resources to develop a marketing and sales force with technical expertise and with supporting distribution capabilities. Building
	an in-house marketing and sales force with technical expertise and distribution capabilities will require significant expenditures,
	management resources and time. Factors that may inhibit our efforts to commercialize our products directly and without strategic
	partners include:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our
	inability to recruit and retain adequate numbers of effective sales and marketing personnel;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the
	inability of sales personnel to obtain access to or persuade adequate numbers of physicians
	to prescribe our products;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 28; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	26
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage29"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the
	lack of complementary products to be offered by sales personnel, which may put us at
	a competitive disadvantage relative to companies with more extensive product lines; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	unforeseen
	costs and expenses associated with creating and sustaining an independent sales and marketing
	organization.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	may not be successful in recruiting the sales and marketing personnel necessary to sell our products and even if we do build a
	sales force, they may not be successful in marketing our products, which would have a material adverse effect on our business
	and results of operations.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Developments
	by competitors may render our products or technologies obsolete or non-competitive which would have a material adverse effect
	on our business and results of operations.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	compete against fully integrated pharmaceutical companies and smaller companies that are collaborating with larger pharmaceutical
	companies, academic institutions, government agencies and other public and private research organizations. Our drug candidates
	will have to compete with existing therapies and therapies under development by our competitors. In addition, our commercial opportunities
	may be reduced or eliminated if our competitors develop and market products that are less expensive, more effective or safer than
	our drug products. Other companies have drug candidates in various stages of preclinical or clinical development to treat diseases
	for which we are also seeking to develop drug products. Some of these potential competing drugs are further advanced in development
	than our drug candidates and may be commercialized earlier. Even if we are successful in developing effective drugs, our products
	may not compete successfully with products produced by our competitors. Most of our competitors, either alone or together with
	their collaborative partners, operate larger research and development programs, have larger staffing and facilities, and have
	substantially greater financial resources than we do, as well as significantly greater experience in:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	developing
	drugs;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	undertaking
	preclinical testing and human clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	obtaining
	FDA and other regulatory approvals, including foreign regulatory approvals, of drugs;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	formulating
	and manufacturing drugs; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	launching,
	marketing and selling drugs.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	These
	organizations also compete with us to attract qualified personnel, acquisitions and joint venture candidates and for other collaborations.
	Activities of our competitors may impose unanticipated costs on our business which would have a material adverse effect on our
	business and results of operations.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 29; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	27
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage30"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	depend upon key officers and consultants in a competitive market for skilled personnel. If we are unable to attract and retain
	key personnel, it could adversely affect our ability to develop and market our products.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	are highly dependent upon the principal members of our management team, especially our Chief Executive Officer, Dr. Jason Slakter,
	Vice President of Business Development and Chief Financial Officer, Sam Backenroth, and Chief Clinical Officer, Dr. Avner Ingerman,
	as well as our directors and key consultants. A loss of any of these personnel may have a material adverse effect on aspects of
	our business and clinical development and regulatory programs.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	also depend in part on obtaining the service of scientific personnel and our ability to identify, hire and retain additional personnel.
	We experience intense competition for qualified personnel, and the existence of non-competition agreements between prospective
	employees and their former employers may prevent us from hiring those individuals or subject us to suit from their former employers.
	While we attempt to provide competitive compensation packages to attract and retain key personnel, many of our competitors are
	likely to have greater resources and more experience than we have, making it difficult for us to compete successfully for key
	personnel.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Our
	employees, partners, independent contractors, principal investigators, consultants, vendors and contract research organizations
	may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	are exposed to the risk that our employees, partners, independent contractors, principal investigators, consultants, vendors and
	contract research organizations may engage in fraudulent or other illegal activity with respect to our business. Misconduct by
	these employees could include intentional, reckless and/or negligent conduct or unauthorized activity that violates: (1)&nbsp;FDA
	or any comparable foreign regulatory authority regulations, including those laws requiring the reporting of true, complete and
	accurate information to the FDA or any comparable foreign regulatory authority; (2)&nbsp;manufacturing standards; (3) federal,
	state and foreign healthcare fraud and abuse laws and regulations; or (4) laws that require the true, complete and accurate reporting
	of financial information or data. Activities subject to these laws also involve the improper use of information obtained in the
	course of clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and serious
	harm to our reputation. Any incidents or any other conduct that leads to an employee receiving an FDA or other regulatory authority
	debarment could result in a loss of business from our partners and severe reputational harm. We have adopted a Code of Business
	Conduct and Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect
	and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental
	investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any
	such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions
	could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages,
	monetary fines, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations,
	any of which could adversely affect our ability to operate our business, operating results and financial condition.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 30; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	28
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage31"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Any
	future acquisitions we make of companies or technologies may result in disruption to our business or distraction of our management,
	due to difficulties in assimilating acquired personnel and operations.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	may acquire or make investments in complementary businesses, technologies, services or products which complement our pharmaceutical
	operations if appropriate opportunities arise. From time to time we engage in discussions and negotiations with companies regarding
	our acquiring or investing in such companies&rsquo; businesses, products, services or technologies, in the ordinary course of
	our business. We cannot be assured that we will be able to identify future suitable acquisition or investment candidates, or if
	we do identify suitable candidates, that we will be able to make such acquisitions or investments on commercially acceptable terms
	or at all. If we acquire or invest in another company, we could have difficulty in assimilating that company&rsquo;s personnel,
	operations, technology and software. In addition, the key personnel of the acquired company may decide not to work for us. If
	we make other types of acquisitions, we could have difficulty in integrating the acquired products, services or technologies into
	our operations. These difficulties could disrupt our ongoing business, distract our management and employees, increase our expenses
	and adversely affect our results of operations. Furthermore, we may incur indebtedness or issue equity securities to pay for any
	future acquisitions. The issuance of equity securities would be dilutive to our existing stockholders. However, we currently do
	not have any agreement to enter into any material investment or acquisition transaction.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	may be unsuccessful in monetizing existing assets, acquiring additional assets or entering into joint development programs.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	will continue to seek to acquire or make investments in complementary businesses, technologies, services or products and are seeking
	development partners for our existing products. Several third parties with whom we have been in discussions have expressed interest
	in a potential licensing or partnering transaction for the Squalamine program. We continue to make progress in these discussions.
	However, there is no assurance that the Company will enter into a definitive agreement with respect to such a transaction.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Security
	breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and
	reputation to suffer.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	store sensitive data, including intellectual property, our proprietary business information and personally identifiable information
	of our employees, in our data centers and on our networks. The secure maintenance of this information is critical to our operations.
	Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached
	due to employee error, malfeasance or other disruptions. Any such breach could compromise our networks and the information stored
	there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result
	in legal claims or proceedings, liability under laws that protect the privacy of personal information, regulatory penalties, and
	damage our reputation.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 31; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	29
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage32"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Our
	business and operations would suffer in the event of system failures.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Despite
	the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable
	to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures.
	Such an event could cause interruption of our operations. For example, the loss of data from completed or ongoing clinical trials
	for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs. To
	the extent that any disruption or security breach were to result in a loss of or damage to our data, or inappropriate disclosure
	of confidential or proprietary information, we could incur liability and the development of our product candidates could be delayed.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	The
	potential U.K. exit from the European Union as a result of the recent U.K. referendum could harm our business, financial condition
	or results of operations.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 27.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On
	June 23, 2016, the U.K. affirmatively voted in a non-binding referendum advising for the exit of the U.K. from the European Union
	(commonly referred to as the &ldquo;Brexit&rdquo;). The referendum is non-binding; however, if passed into law, negotiations would
	commence to determine the future terms of the U.K.&rsquo;s relationship with the European Union, including the terms of trade
	between the U.K. and the European Union. The effects of Brexit will depend on any agreements the U.K. makes to retain access to
	European Union markets either during a transitional period or more permanently. Brexit could lead to legal uncertainty and potentially
	divergent national laws and regulations as the U.K. determines which European Union laws to replace or replicate.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 27.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 27.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	announcement of Brexit also created (and the actual exit of the U.K. from the European Union may create future) global economic
	uncertainty. The actual exit of the U.K. from the European Union could cause disruptions to and create uncertainty surrounding
	our business.&nbsp;&nbsp;Any of these effects of Brexit (and the announcement thereof), and others we cannot anticipate, could
	harm our business, financial condition or results of operations.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 27.8PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<U>
	Risks
	Related to FDA, Comparable Foreign Regulatory Authority and Healthcare Regulations
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	face heavy government regulation. FDA regulatory approval and/or comparable foreign regulatory authority&rsquo;s approval of our
	products is uncertain.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	research, testing, manufacturing and marketing of drug products such as those that we are developing are subject to extensive
	regulation by federal, state and local government authorities, including the FDA or any comparable foreign regulatory authority.
	To obtain regulatory approval of a product, we must demonstrate to the satisfaction of the applicable regulatory agency that,
	among other things, the product is safe and effective for its intended use. In addition, we must show that the manufacturing facilities
	used to produce the products are in compliance with current Good Manufacturing Practices regulations (cGMP).
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 32; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	30
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage33"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	process of obtaining FDA and other required regulatory approvals, including foreign regulatory approvals and clearances, will
	require us to expend substantial time and capital. Despite the time and expense expended, regulatory approval is never guaranteed.
	The number of preclinical and clinical trials that will be required for FDA approval, or any comparable foreign regulatory authority&rsquo;s
	approval, varies depending on the drug candidate, the disease or condition for which the drug candidate is in development, and
	the requirements applicable to that particular drug candidate. The FDA or other foreign health authority can delay, limit or deny
	approval of a drug candidate for many reasons, including that:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a
	drug candidate may not be shown to be safe or effective;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the
	FDA or any comparable foreign regulatory authority may not approve our manufacturing
	process;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the
	FDA or any comparable foreign regulatory authority may interpret data from preclinical
	and clinical trials in different ways than we do; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the
	FDA may not meet, or may extend, the Prescription Drug User Fee Act date with respect
	to a particular NDA.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	For
	example, if certain of our methods for analyzing our trial data are not accepted by the FDA or foreign regulatory authority, we
	may fail to obtain regulatory approval for our product candidates. Moreover, if and when our products do obtain marketing approval,
	the marketing, distribution and manufacture of such products would remain subject to extensive ongoing regulatory requirements.
	Failure to comply with applicable regulatory requirements could result in:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	warning
	letters;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	fines;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	civil
	penalties;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	injunctions;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	recall
	or seizure of products;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	total
	or partial suspension of production;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	refusal
	of the government to grant future approvals;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	withdrawal
	of approvals; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	criminal
	prosecution.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 33; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	31
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage34"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Any
	delay or failure by us to obtain regulatory approvals for our product candidates could diminish competitive advantages that we
	may attain and would adversely affect the marketing of our products. We have not received regulatory approval to market any of
	our product candidates in any jurisdiction.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Following
	regulatory approval of any of our drug candidates, we will be subject to ongoing regulatory obligations and restrictions, which
	may result in significant expense and limit our ability to commercialize our potential products.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	With
	regard to our drug candidates, if any, approved by the FDA or by another regulatory authority, including a foreign regulatory
	authority, we are held to extensive regulatory requirements over product manufacturing, labeling, packaging, adverse event reporting,
	storage, advertising, promotion and record keeping. Regulatory approvals may also be subject to significant limitations on the
	indicated uses or marketing of the drug candidates. Potentially costly follow-up or post-marketing clinical studies may be required
	as a condition of approval to further substantiate safety or efficacy, or to investigate specific issues of interest to the regulatory
	authority. Previously unknown problems with the drug candidate, including adverse events of unanticipated severity or frequency,
	may result in restrictions on the marketing of the drug, and could include withdrawal of the drug from the market.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	addition, the law or regulatory policies governing pharmaceuticals may change. New statutory requirements may be enacted or additional
	regulations may be enacted that could prevent or delay regulatory approval of our drug candidates. We cannot predict the likelihood,
	nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the
	United States or elsewhere. If we are not able to maintain regulatory compliance, we might not be permitted to market our drugs
	and which could have a material adverse effect on our business and competitive position.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Healthcare
	policy changes, including pending legislation recently adopted and further proposals still pending to reform the U.S. healthcare
	system, may harm our future business.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Healthcare
	costs have risen significantly over the past decade. There have been and continue to be proposals by legislators, regulators and
	third-party payors to keep these costs down. Certain proposals, if passed, would impose limitations on the prices we will be able
	to charge for the products that we are developing, or the amounts of reimbursement available for these products from governmental
	agencies or third-party payors. These limitations could in turn reduce the amount of revenues that we will be able to generate
	in the future from sales of our products and licenses of our technology.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	March 2010, the U.S. Congress enacted and President Obama signed into law healthcare reform legislation that may significantly
	impact the pharmaceutical industry. In addition to requiring most individuals to have health insurance and establishing new regulations
	on health plans, this legislation will require discounts under the Medicare drug benefit program and increased rebates on drugs
	covered by Medicaid. In addition, the legislation imposes an annual fee, which will increase annually, on sales by branded pharmaceutical
	manufacturers starting in 2011. The financial impact of these discounts, increased rebates and fees and the other provisions of
	the legislation on our business is unclear and there can be no assurance that our business will not be materially adversely affected.
	In addition, these and other ongoing initiatives in the United States have increased and will continue to increase pressure on
	drug pricing. The announcement or adoption of any such initiative could have an adverse effect on potential revenues from any
	product that we may successfully develop.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 34; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	32
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage35"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Various
	healthcare reform proposals have also emerged at the state level. We cannot predict what healthcare initiatives, if any, will
	be implemented at the federal or state level, or the effect any future legislation or regulation will have on us. However, an
	expansion in government&rsquo;s role in the U.S. healthcare industry may lower the future revenues for the products we are developing
	and adversely affect our future business, possibly materially.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Risks
	Related to Our Intellectual Property
</U>
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	ability to compete may be undermined if we do not adequately protect our proprietary rights.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	commercial success depends on obtaining and maintaining proprietary rights to our product candidates and technologies and their
	uses, as well as successfully defending these rights against third-party challenges. We will be able to most effectively protect
	our product candidates, technologies, and their uses from unauthorized use by third parties to the extent that valid and enforceable
	patents, or effectively protected trade secrets, cover them. For example, we have rights under U.S. patents and patent applications
	7981876, 8716270, 6262283, 7728157, 20130281420 and 21050342874 to cover the Squalamine formulations, composition of matter, use
	in combination with other agents, methods of manufacture, and uses. Nonetheless, the issued patents and patent applications
	covering our primary technology programs remain subject to uncertainty due to a number of factors, including:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	we
	may not have been the first to make one or more of the inventions covered by our pending
	patent applications or issued patents;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	we
	may not have been the first to file patent applications for one or more of our product
	candidates or the technologies we rely upon;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	others
	may independently develop similar or alternative technologies or duplicate any of our
	technologies;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our
	disclosures in a particular patent application may be determined to be insufficient to
	meet the statutory requirements for patentability;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	one
	or more of our pending patent applications may not result in issued patents;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	we
	may not seek or obtain patent protection in all countries that will eventually provide
	a significant business opportunity;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 35; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	33
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage36"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	one
	or more patents issued to us or to our collaborators may not provide a basis for commercially
	viable products, may not provide us with any competitive advantages or may be challenged
	by third parties;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	we
	may fail to file for patent protection in all of the countries where patent protection
	will ultimately be necessary or fail to comply with other procedural, documentary, fee
	payment or other provisions during the patent process in any such country, and we may
	be precluded from filing at a later date or may lose some or all patent rights in the
	relevant jurisdiction;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	one
	or more of our technologies may not be patentable;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	others
	may design around one or more of our patent claims to produce competitive products which
	fall outside of the scope of our patents;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	others
	may identify prior art which could invalidate our patents; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	changes
	to patent laws may limit the exclusivity rights of patent holders.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Even
	if we have or obtain patents covering our product candidates or technologies, we may still be barred from making, using and selling
	one or more of our product candidates or technologies because of the patent rights of others. Others have or may have filed, and
	in the future are likely to file, patent applications covering compounds, assays, therapeutic products and delivery systems, including
	sustained release delivery, that are similar or identical to ours. Numerous U.S. and foreign issued patents and pending patent
	applications owned by others exist in the area of ocular disorders. These could materially affect our ability to develop our product
	candidates or sell our products. Because patent applications can take years to issue, there may be currently pending applications,
	unknown to us, that may later result in issued patents that our product candidates or technologies may infringe. These patent
	applications may have priority over one or more patent applications filed by us.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	our competitors have prepared and filed patent applications in the United States that claim technology we also claim, we may have
	to participate in interference proceedings required by the United States Patent and Trademark Office to determine priority of
	invention, which could result in substantial costs, even if we ultimately prevail. Results of interference proceedings are highly
	unpredictable and may result in us having to try to obtain licenses in order to continue to develop or market certain of our drug
	products.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Disputes
	may arise regarding the ownership or inventorship of our inventions. It is difficult to determine how such disputes would be resolved.
	Others may challenge the validity of our patents. If one or more of our patents are found to be invalid, we will lose the ability
	to exclude others from making, using or selling the inventions claimed therein.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Some
	of our research collaborators and scientific advisors have rights to publish data and information to which we have rights. Additionally,
	employees whose positions may be eliminated may seek future employment with our competitors. Each of our employees is required
	to sign a confidentiality agreement and invention assignment agreement with us at the time of hire. While such arrangements are
	intended to enable us to better control the use and disclosure of our proprietary property and provide for our ownership of proprietary
	technology developed on our behalf, they may not provide us with meaningful protection for such property and technology in the
	event of unauthorized use or disclosure. In addition, technology that we may in-license may become important to some aspects of
	our business. We generally will not control all of the patent prosecution, maintenance or enforcement of in-licensed technology.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 36; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	34
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage37"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	rely on confidentiality agreements that could be breached and may be difficult to enforce which could have a material adverse
	effect on our business and competitive position.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	policy is to enter agreements relating to the non-disclosure of confidential information with third parties, including our contractors,
	consultants, advisors and research collaborators, as well as agreements that purport to require the disclosure and assignment
	to us of the rights to the ideas, developments, discoveries and inventions of our employees and consultants while we employ them.
	However, these agreements can be difficult and costly to enforce. Moreover, to the extent that our contractors, consultants, advisors
	and research collaborators apply or independently develop intellectual property in connection with any of our projects, disputes
	may arise as to the proprietary rights to this type of information. If a dispute arises, a court may determine that the right
	belongs to a third party, and enforcement of our rights can be costly and unpredictable. In addition, we rely on trade secrets
	and proprietary know-how that we will seek to protect in part by confidentiality agreements with our employees, contractors, consultants,
	advisors or others. In addition, courts outside the United States may be less willing to protect trade secrets. Despite the protective
	measures we employ, we still face the risk that:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	these
	agreements may be breached;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	these
	agreements may not provide adequate remedies for the applicable type of breach; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our
	trade secrets or proprietary know-how will otherwise become known.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Any
	breach of our confidentiality agreements or our failure to effectively enforce such agreements would have a material adverse effect
	on our business and competitive position.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	we infringe the rights of third parties we could be prevented from selling products, forced to pay damages and required to defend
	against litigation which could result in substantial costs and may have a material adverse effect on our business and results
	of operations.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	have not received to date any claims of infringement by any third parties. However, as our product candidates progress into clinical
	trials and commercialization, if at all, our public profile and that of our product candidates may be raised and generate such
	claims. Defending against such claims, and occurrence of a judgment adverse to us, could result in unanticipated costs and may
	have a material adverse effect on our business and competitive position. If our products, methods, processes and other technologies
	infringe the proprietary rights of other parties, we could incur substantial costs and we may have to:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 37; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	35
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage38"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	obtain
	licenses, which may not be available on commercially reasonable terms, if at all;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	redesign
	our products or processes to avoid infringement;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	stop
	using the subject matter claimed in the patents held by others, which could cause us
	to lose the use of one or more of our drug candidates;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	defend
	litigation or administrative proceedings that may be costly whether we win or lose, and
	which could result in a substantial diversion of management resources; or
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	pay
	damages.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Any
	costs incurred in connection with such events or the inability to sell our products may have a material adverse effect on our
	business and results of operations.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Intellectual
	property litigation is increasingly common and increasingly expensive and may result in restrictions on our business and substantial
	costs, even if we prevail.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Patent
	and other intellectual property litigation is becoming more common in the pharmaceutical industry. Litigation is sometimes necessary
	to defend against or assert claims of infringement, to enforce our patent rights, including those we have licensed from others,
	to protect trade secrets or to determine the scope and validity of proprietary rights of third parties. Currently, no third party
	is asserting that we are infringing upon their patent rights or other intellectual property, nor are we aware or believe that
	we are infringing upon any third party&rsquo;s patent rights or other intellectual property. We may, however, be infringing upon
	a third party&rsquo;s patent rights or other intellectual property, and litigation asserting such claims might be initiated in
	which we would not prevail, or we would not be able to obtain the necessary licenses on reasonable terms, if at all. All such
	litigation, whether meritorious or not, as well as litigation initiated by us against third parties, is time-consuming and very
	expensive to defend or prosecute and to resolve. In addition, if we infringe the intellectual property rights of others, we could
	lose our right to develop, manufacture or sell our products or could be required to pay monetary damages or royalties to license
	proprietary rights from third parties. An adverse determination in a judicial or administrative proceeding or a failure to obtain
	necessary licenses could prevent us from manufacturing or selling our products, which could harm our business, financial condition
	and prospects.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 38; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	36
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage39"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	A
	dispute concerning the infringement or misappropriation of our proprietary rights or the proprietary rights of others could be
	time consuming and costly, and an unfavorable outcome could harm our business.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	There
	is significant litigation in our industry regarding patent and other intellectual property rights. While we are not currently
	subject to any pending intellectual property litigation, and are not aware of any such threatened litigation, we may be exposed
	to future litigation by third parties based on claims that our product candidates, technologies or activities infringe the intellectual
	property rights of others. If our drug development activities are found to infringe any such patents, we may have to pay significant
	damages or seek licenses to such patents. If our products are found to infringe any such patents, we may have to pay significant
	damages or seek licenses to such patents. A patentee could prevent us from making, using or selling the patented compounds. We
	may need to resort to litigation to enforce a patent issued to us, protect our trade secrets or determine the scope and validity
	of third-party proprietary rights. From time to time, we may hire scientific personnel formerly employed by other companies involved
	in one or more areas similar to the activities conducted by us. Either we or these individuals may be subject to allegations of
	trade secret misappropriation or other similar claims as a result of their prior affiliations. If we become involved in litigation,
	it could consume a substantial portion of our managerial and financial resources, regardless of whether we win or lose. We also
	may not be able to afford the costs of litigation.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	patent applications of pharmaceutical and biotechnology companies involve highly complex legal and factual questions, which, if
	determined adversely to us, could negatively impact our patent position.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions.
	No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date. The U.S. Patent and
	Trademark Office&rsquo;s standards are uncertain and could change in the future. Consequently, the issuance and scope of patents
	cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated or circumvented. U.S. patents and patent
	applications may also be subject to interference or derivation proceedings, and U.S. patents may be subject to inter partes review,
	post grant review and ex parte reexamination proceedings in the U.S. Patent and Trademark Office (and foreign patents may be subject
	to opposition or comparable proceedings in the corresponding foreign patent office), which proceedings could result in either
	loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent
	or patent application. Similarly, opposition or invalidity proceedings could result in loss of rights or reduction in the scope
	of one or more claims of a patent in foreign jurisdictions. Such interference, inter partes review, post grant review and ex parte
	reexamination and opposition proceedings may be costly. Accordingly, rights under any issued patents may not provide us with sufficient
	protection against competitive products or processes.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 39; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	37
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage40"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Changes
	in or different interpretations of patent laws in the United States and foreign countries may permit others to use our discoveries
	or to develop and commercialize our technology and products without providing any compensation to us or may limit the number of
	patents or claims we can obtain. In particular, there have been proposals to shorten the exclusivity periods available under U.S.
	patent law that, if adopted, could substantially harm our business. The product candidates that we are developing are protected
	by intellectual property rights, including patents and patent applications. If any of our product candidates becomes a marketable
	product, we will rely on our exclusivity under patents to sell the compound and recoup our investments in the research and development
	of the compound. If the exclusivity period for patents is shortened, then our ability to generate revenues without competition
	will be reduced and our business could be materially adversely impacted. The laws of some countries do not protect intellectual
	property rights to the same extent as U.S. laws, and those countries may lack adequate rules and procedures for defending our
	intellectual property rights. For example, some countries, including many in Europe, do not grant patent claims directed to methods
	of treating humans and, in these countries, patent protection may not be available at all to protect our product candidates. In
	addition, U.S. patent laws may change, which could prevent or limit us from filing patent applications or patent claims to protect
	our products or technologies or limit the exclusivity periods that are available to patent holders. For example, the Leahy-Smith
	America Invents Act, or the Leahy-Smith Act, was recently signed into law and includes a number of significant changes to U.S.
	patent law. These include changes to transition from a &ldquo;first-to-invent&rdquo; system to a &ldquo;first-to-file&rdquo; system
	and to the way issued patents are challenged. These changes may favor larger and more established companies that have more resources
	to devote to patent application filing and prosecution. The U.S. Patent and Trademark Office has been in the process of implementing
	regulations and procedures to administer the Leahy-Smith Act, and many of the substantive changes to patent law associated with
	the Leahy-Smith Act may affect our ability to obtain, enforce or defend our patents. Accordingly, it is not clear what, if any,
	impact the Leahy-Smith Act will ultimately have on the cost of prosecuting our patent applications, our ability to obtain patents
	based on our discoveries and our ability to enforce or defend our issued patents.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	we fail to obtain and maintain patent protection and trade secret protection of our product candidates, proprietary technologies
	and their uses, we could lose our competitive advantage and competition we face would increase, reducing our potential revenues
	and adversely affecting our ability to attain profitability.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Risks
	Related to our Common Stock
</U>
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	market price and volume of our common stock fluctuate significantly and could result in substantial losses for individual investors.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	stock market from time to time experiences significant price and volume fluctuations that are unrelated to the operating performance
	of particular companies. These broad market fluctuations may cause the market price and volume of our common stock to decrease.
	In addition, the market price and volume of our common stock is highly volatile.&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Factors
	that may cause the market price and volume of our common stock to decrease include:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	adverse
	results or delays in our clinical trials;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	fluctuations
	in our results of operations, timing and announcements of our bio-technological innovations
	or new products or those of our competitors;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 40; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	38
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage41"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	developments concerning
	any strategic alliances or acquisitions we are in discussion regarding or we may enter into;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	announcements
	of FDA non-approval of our drug products, or delays in the FDA or other foreign regulatory
	review process or actions;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	adverse
	actions taken by regulatory agencies with respect to our drug products, clinical trials,
	manufacturing processes or sales and marketing activities;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	any
	lawsuit involving us or our drug products;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	developments
	with respect to our patents and proprietary rights;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	announcements
	of technological innovations or new products by our competitors;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	public
	concern as to the safety of products developed by us or others;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	regulatory
	developments in the United States and in foreign countries;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD STYLE="COLOR: BLACK">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; COLOR: BLACK">
	our
	shares of common stock trading in five- rather than one-cent increments&nbsp;under the
	SEC&rsquo;s Tick Size Pilot program;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	changes
	in stock market analyst recommendations regarding our common stock or lack of analyst
	coverage;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the
	pharmaceutical industry conditions generally and general market conditions;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	failure
	of our results of operations to meet the expectations of stock market analysts and investors;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	sales
	of our common stock by our executive officers, directors and five percent stockholders
	or sales of substantial amounts of our common stock;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	changes
	in accounting principles; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	loss
	of any of our key scientific or management personnel.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	market for our common stock is illiquid. Our stockholders may not be able to resell their shares at or above the purchase price
	paid by such stockholders, or at all.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	common stock is quoted on the NASDAQ Capital Market. The market for our securities is illiquid. This illiquidity may be caused
	by a variety of factors including:
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	lower
	trading volume; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	&#9679;
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	market
	conditions.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 41; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	39
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage42"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT ARIAL, HELVETICA, SANS-SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; COLOR: BLACK">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	There
	is limited trading in our common stock and our security holders may experience wide fluctuations in the market price of our securities.
	Such price and volume fluctuations have particularly affected the trading prices of equity securities of many pharmaceutical and
	biotechnology companies. These price and volume fluctuations often appear to have been unrelated to the operating performance
	of the affected companies. These fluctuations may have an extremely negative effect on the market price of our securities and
	may prevent a stockholder from obtaining a market price equal to the purchase price such stockholder paid when the stockholder
	attempts to sell our securities in the open market. In these situations, the stockholder may be required either to sell our securities
	at a market price which is lower than the purchase price the stockholder paid, or to hold our securities for a longer period of
	time than planned. An inactive market may also impair our ability to raise capital by selling shares of capital stock or to recruit
	and retain managers with equity-based incentive plans.
<FONT STYLE="COLOR: BLACK">
	Additionally, under the SEC&rsquo;s Tick Size
	Pilot program, in October 2016, shares of our common stock began trading in five cent rather than one cent increments. The change
	to five cent increments may result in greater fluctuations in the market price of our common stock and could result in higher
	trading costs for investors.
</FONT>
<FONT STYLE="COLOR: #333333">
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If
	we do not raise additional funds, we will not be able to continue operations or complete the necessary clinical and preclinical
	trials to complete development of Squalamine and our sustained release ophthalmological platform or our other products and will
	not be able to sell them anywhere.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	will not be able to sell Squalamine and our sustained release ophthalmological platform or our other products in the United States
	or other territories unless we submit, and the FDA or foreign regulatory authority approves, an application for approval for each
	such product. We must conduct clinical trials of each of our products in humans before we submit such application. We currently
	do not have sufficient capital to complete the necessary trials to complete the development of Squalamine and our sustained release
	ophthalmological platform or any of our other therapeutic drug products.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	It
	is possible that the results of clinical and preclinical studies of Squalamine and our sustained release ophthalmological platform
	or our other products will not prove that they are safe and effective. It is also possible that the FDA or foreign regulatory
	authority will not approve the sale of any of our products if we submit an application for such product. Even if the data show
	that any of our products are safe and effective, obtaining approval of the application could take years and require financing
	of amounts not presently available to us.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Conducting
	the clinical and preclinical studies of each of our products will require significant cash expenditures and we do not have the
	funds necessary to complete the clinical trials for Squalamine and our sustained release ophthalmological platform or any other
	products. Our products may never be approved for commercial distribution by any country. Because our research and development
	expenses and clinical and preclinical study expenses will be charged against earnings for financial reporting purposes, we expect
	that losses from operations will continue to be incurred for the near future.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 42; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	40
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage43"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	will not pay cash dividends and investors may have to sell their shares in order to realize their investment.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	have not paid any cash dividends on our common stock and do not intend to pay cash dividends in the foreseeable future. We intend
	to use our cash for reinvestment in the development and marketing of our products and services. As a result, investors may have
	to sell their shares of common stock to realize their investment.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	internal controls over financial reporting may not be effective, and our independent auditors may not be able to certify as to
	their effectiveness, which could have a significant and adverse effect on our business and reputation.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	are subject to the requirements of Section 404 of the Sarbanes-Oxley Act of 2002 and the rules and regulations of the SEC thereunder
	(&ldquo;Section 404&rdquo;). Section 404 requires us to report on the design and effectiveness of our internal controls over financial
	reporting. In the past, our management has identified certain &ldquo;material weaknesses&rdquo; in our internal controls over
	financial reporting which we believe have been remediated. However, any failure to maintain effective controls could result in
	significant deficiencies or material weaknesses, and cause us to fail to meet our periodic reporting obligations, or result in
	material misstatements in our financial statements. We may also be required to incur costs to improve our internal control system
	and hire additional personnel. This could negatively impact our results of operations.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Section
	404 also requires an independent registered public accounting firm to test our internal controls over financial reporting and
	report on the effectiveness of such controls. For future reporting periods, there can be no assurance that our auditors will issue
	an unqualified report attesting to our internal controls over financial reporting at that time. As a result, there could be a
	negative reaction in the financial markets due to a loss of confidence in the reliability of our financial statements or our financial
	statements could change.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Compliance
	with changing regulation of corporate governance and public disclosure may result in additional expenses and divert management&rsquo;s
	attention from operating our business, which could have a material adverse effect on our business.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	There
	have been other changing laws, regulations and standards relating to corporate governance and public disclosure in addition to
	the Sarbanes-Oxley Act, as well as new regulations promulgated by the Commission and rules promulgated by the national securities
	exchanges. These new or changed laws, regulations and standards are subject to varying interpretations in many cases due to their
	lack of specificity, and as a result, their application in practice may evolve over time as new guidance is provided by regulatory
	and governing bodies, which could result in continuing uncertainty regarding compliance matters and higher costs necessitated
	by ongoing revisions to disclosure and governance practices. As a result, our efforts to comply with evolving laws, regulations
	and standards are likely to continue to result in increased general and administrative expenses and a diversion of management
	time and attention from revenue-generating activities to compliance activities. Our board members, Chief Executive Officer and
	Chief Financial Officer could face an increased risk of personal liability in connection with the performance of their duties.
	As a result, we may have difficulty attracting and retaining qualified board members and executive officers, which could have
	a material adverse effect on our business. If our efforts to comply with new or changed laws, regulations and standards differ
	from the activities intended by regulatory or governing bodies, we may incur additional expenses to comply with standards set
	by regulatory authorities or governing bodies which would have a material adverse effect on our business and results of operations.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 43; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	41
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage44"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Delaware
	law could discourage a change in control, or an acquisition of the Company by a third party, even if the acquisition would be
	favorable to stockholders.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Delaware General Corporation Law contains provisions that may have the effect of making more difficult or delaying attempts by
	others to obtain control of the Company, even when these attempts may be in the best interests of stockholders. Delaware law imposes
	conditions on certain business combination transactions with &ldquo;interested stockholders.&rdquo; These provisions and others
	that could be adopted in the future could deter unsolicited takeovers or delay or prevent changes in our control or management,
	including transactions in which stockholders might otherwise receive a premium for their shares of common stock over then current
	market prices. These provisions may also limit the ability of stockholders to approve transactions that they may deem to be in
	their best interests.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our
	Board of Directors has the authority to issue Serial Preferred Stock, which could affect the rights of holders of our common stock
	and may delay or prevent a takeover that could be in the best interests of our stockholders.
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Board of Directors has the authority to issue up to 9,416,664 shares of Serial Preferred Stock, $.0001 par value per share (the
	&ldquo;Serial Preferred Stock&rdquo;) (after giving effect to the conversion and cancellation of a previous issue of 5,583,336
	shares of Series B Preferred), in one or more series and to fix the number of shares constituting any such series, the voting
	powers, designation, preferences and relative participation, optional or other special rights and qualifications, limitations
	or restrictions thereof, including the dividend rights and dividend rate, terms of redemption (including sinking fund provisions),
	redemption price or prices, conversion rights and liquidation preferences of the shares constituting any series, without any further
	vote or action by the stockholders. 6,000,000 shares of the Serial Preferred Stock, designated the Series B Preferred, have been
	authorized, 5,583,336 were issued and, as of the date of this filing, all such shares have been converted and no Series B Preferred
	shares remain issued and outstanding. The issuance of additional Serial Preferred Stock could affect the rights of the holders
	of Common Stock. For example, such issuance could result in a class of securities outstanding that would have preferential voting,
	dividend, and liquidation rights over the Common Stock, and could (upon conversion or otherwise) enjoy all of the rights appurtenant
	to the shares of common stock. The authority possessed by the Board of Directors to issue Serial Preferred Stock could potentially
	be used to discourage attempts by others to obtain control of the Company through merger, tender offer, proxy contest or otherwise
	by making such attempts more difficult or costly to achieve. The Board of Directors may issue the Serial Preferred Stock without
	stockholder approval and with voting and conversion rights which could adversely affect the voting power of holders of common
	stock. There are no agreements or understandings for the issuance of Serial Preferred Stock and the Board of Directors has no
	present intention to issue any Serial Preferred Stock.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 44; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	42
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_RISK_FACTORS>
<A NAME="eolPage45"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A NAME="OHRP-10K_093016_HTM_OHRPA004">
</A>
	ITEM
	2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PROPERTIES
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company&rsquo;s headquarters are located in New York, New York. Our New York offices are being rented to us on a monthly basis.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	currently lease a lab facility in San Diego, where most of our employees operate from and conduct preclinical research on our
	compounds and platform technology.
</FONT>
</P>
</EFX_PROPERTIES>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A NAME="OHRP-10K_093016_HTM_OHRPA005">
</A>
	ITEM
	3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LEGAL PROCEEDINGS
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company is not a party to any material pending legal proceedings.
</FONT>
</P>
</EFX_LEGAL_PROCEEDINGS>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ITEM
	4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MINE SAFETY DISCLOSURES.
</FONT>
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	Not applicable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;&nbsp;
</P>
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 45; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	43
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_I>
<A NAME="eolPage46"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT ARIAL, HELVETICA, SANS-SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<A NAME="OHRP-10K_093016_HTM_OHRPA006">
</A>
	Part II
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<A NAME="OHRP-10K_093016_HTM_OHRPA007">
</A>
	ITEM 5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MARKET FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER
	MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Ohr&rsquo;s shares of common stock are quoted on
	the Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;OHRP.&rdquo; Following is a table of the quotation ranges
	(high and low trading prices) for its shares for the last two years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD">
	FY 2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	High
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Low
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	FY 2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	High
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Low
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	October 1 - December 31, 2015
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.56
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.72
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	October 1 - December 31, 2014
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9.24
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.69
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	January 1 - March 31, 2016
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	6.15
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.65
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	January 1 - March 31, 2015
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	12.31
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.51
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	April 1 - June 30, 2016
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.00
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.57
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	April 1 - June 30, 2015
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3.04
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.35
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="2" STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	July 1 -September 30, 2016
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.93
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.44
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	July 1 - September 30, 2015
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	4.34
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2.02
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 25%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; WIDTH: 7%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; WIDTH: 7%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 26%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; WIDTH: 7%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; WIDTH: 7%">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 1%">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<B>
	Performance Graph
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	The following graph compares our cumulative total
	stockholder return from October 1, 2011, with those of the NASDAQ Capital Market Composite Index (RCMP) and the NASDAQ Biotechnology
	Index (NBI). The graph assumes that U.S. $100 was invested on October 1, 2011 in (1) our common stock, (2) the NASDAQ Capital Market
	Composite Index and (3) the NASDAQ Biotechnology Index. The measurement points utilized in the graph closely approximates the last
	day of the respective fiscal year of the Company. The historical stock performance presented below is not intended to and may not
	be indicative of future stock performance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	9/30/2011
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	9/30/2012
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	9/30/2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	9/30/2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	9/30/2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	9/30/2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 22%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	OHRP
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	100
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	135
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	360
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	322
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	200
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	140
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Nasdaq Capital Market Composite Index
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	100
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	129
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	159
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	152
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	131
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	133
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Nasdaq Biotech Index
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	100
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	153
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	226
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	295
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	352
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	277
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT SANS-SERIF; MARGIN: 0PT 0; COLOR: RED">
	&nbsp;
</P>
<P STYLE="FONT: 10PT SANS-SERIF; MARGIN: 0PT 0; COLOR: RED">
</P>
<!-- FIELD: PAGE; SEQUENCE: 46; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	44
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage47"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT SANS-SERIF; MARGIN: 0PT 0; COLOR: RED">
	&nbsp;
</P>
<P STYLE="FONT: 10PT SANS-SERIF; MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; COLOR: RED">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/12/22/0001387131-16-008696_OHRP001.JPG" ALT="(LINE GRAPH)">
	&nbsp;
</P>
<P STYLE="FONT: 10PT SANS-SERIF; MARGIN: 0PT 0; COLOR: RED">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	Holders
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	As of December 14, 2016 there were 182 stockholders
	of record, which excludes stockholders whose shares were held in nominee or street name by brokers.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	Dividends
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	We have never declared or paid cash dividends on
	our common stock. We currently expect to retain future earnings, if any, for use in the operation and expansion of the business
	and do not anticipate paying any cash dividends in the foreseeable future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<B>
	Securities authorized for issuance under equity compensation plans
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Information regarding our equity compensation plans
	is presented below as of September 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; BORDER-BOTTOM: BLACK 1PT SOLID">
	Plan Category
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Number of Securities
<BR>
	to&nbsp;Be Issued Upon
<BR>
	Exercise of
<BR>
	Outstanding&nbsp;Options,
<BR>
	Warrants&nbsp;and Rights
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Weighted Average
<BR>
	Exercise Price of
<BR>
	Outstanding Options,
<BR>
	Warrants and Rights
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
<TD COLSPAN="2" NOWRAP STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
<B>
	&nbsp;Number of
<BR>
	Securities Remaining
<BR>
	Available for&nbsp;Future
<BR>
	Issuance&nbsp;Under
<BR>
	Equity
<BR>
	Compensation Plans
</B>
</FONT>
</TD>
<TD NOWRAP>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 52%; TEXT-ALIGN: LEFT; TEXT-INDENT: -0.125IN; PADDING-LEFT: 0.125IN">
	Equity Compensation Plans Approved by Stockholders
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,411,350
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	7.59
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	2,649,475
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-INDENT: -4.4PT; PADDING-LEFT: 4.4PT">
	Total
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,411,350
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	7.59
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	2,649,475
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 47; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	45
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_MARKET>
<A NAME="eolPage48"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<A NAME="OHRP-10K_093016_HTM_OHRPA008">
</A>
	ITEM 6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SELECTED FINANCIAL DATA
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 34PT">
	The tables below set
	forth selected historical financial information of the Company that has been derived from the audited financial statements as of
	September 30, 2012, 2013, 2014, 2015 and 2016, and for the five years in the period ended September 30, 2016. The selected historical
	financial data should be read in conjunction with the consolidated financial statements and related notes and &ldquo;Management&rsquo;s
	Discussion and Analysis of Financial Condition and Results of Operations&rdquo;, included elsewhere in this Annual Report on Form
	10-K.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 34PT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="9" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	Consolidated Statements of Operations Data:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="5" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
	Year Ended September 30,
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2012
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2013
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="5" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	Operating expenses
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	General and administrative
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	989,571
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,775,857
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	4,287,205
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	7,509,601
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	7,656,327
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Research and development
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,209,108
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,753,914
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	4,369,413
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	8,777,519
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	16,460,714
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Depreciation and amortization
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	87,729
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	91,145
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	466,306
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,179,254
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,189,276
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Gain on settlement of accounts payable
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(710,264
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	Impairment of intangibles
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	338,906
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	Total Operating Expenses
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,286,408
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	4,620,916
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	9,122,924
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	17,805,280
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	24,596,053
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Operating Loss
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(3,286,408
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(4,620,916
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(9,122,924
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(17,805,280
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(24,596,053
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Change in derivative liability
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,812,224
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(1,117,642
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Change in fair value of contingent consideration
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,637,756
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(1,185,667
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Share in losses on investment in joint venture
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(10,643
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(103,143
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other income and expense
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	19,300
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	86,070
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,903
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	72,802
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	15,522
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	Total other income (expense)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,831,524
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(1,031,572
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(7,740
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,607,415
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(1,170,145
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Loss from operations
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(1,454,884
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(5,652,488
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(9,130,664
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(15,197,865
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(25,766,198
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Provision for income taxes
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PT">
	Net loss
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(1,454,884
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(5,652,488
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(9,130,664
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(15,197,865
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(25,766,198
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Net loss per basic and diluted share
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(0.10
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(0.30
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(0.41
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(0.54
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(0.82
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Weighted-average shares used to compute net loss per basic and
	diluted share:
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	14,242,792
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	18,707,759
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	22,141,538
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	28,404,405
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	31,349,223
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Consolidated Balance Sheet Data:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Total assets
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,517,420
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	5,743,865
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	32,025,144
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	46,370,807
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	29,445,013
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Total liabilities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,091,195
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	479,737
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	5,273,122
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,880,014
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	4,481,866
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Total stockholders&rsquo; equity
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,426,225
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	5,264,128
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	26,752,022
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	42,490,793
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	24,963,147
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 48; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	46
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_FINANCIAL_DATA>
<A NAME="eolPage49"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<A NAME="OHRP-10K_093016_HTM_OHRPA009">
</A>
	ITEM 7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
	AND RESULTS OF OPERATIONS
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<B>
	General
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Ohr Pharmaceutical, Inc. (&ldquo;we,&rdquo; &ldquo;us,&rdquo;
	&ldquo;our,&rdquo; &ldquo;Ohr&rdquo; or the &ldquo;Company&rdquo;) is a pharmaceutical company focused on the development of novel
	therapeutics and delivery technologies for the treatment of ocular disease. Our development pipeline consists of several programs
	and indications at various stages of development. Our lead clinical asset, topical Squalamine (also known as squalamine lactate
	ophthalmic solution, 0.2%, or OHR-102), is a novel therapeutic product which could provide a non-invasive therapy to improve vision
	outcomes beyond that achieved with current standard of care, without requiring multiple injections per office visit. We are conducting
	a Phase 3 registration program evaluating Squalamine in combination with Lucentis&reg; injections for the treatment of wet-AMD.
	This clinical program is proceeding based on the data from a Phase 2 clinical trial in wet-AMD which demonstrated a positive and
	clinically meaningful treatment effect of Squalamine combination therapy in classic containing choroidal neovascularization (classic
	CNV) as well as those with occult neovascularization (occult CNV) less than 10mm
<SUP>
	2
</SUP>
	in area.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Our preclinical stage pipeline is focused on the
	development of sustained release therapeutics utilizing the platform technology we acquired in May 2014. There are several active
	programs evaluating molecules and approaches for the treatment of glaucoma, steroid induced glaucoma, ocular allergy, and retinal
	disease. These programs have been identified by Ohr as large markets with unmet medical needs or where sustained release therapeutics
	can greatly improve upon the way ocular disease is currently being treated, including increasing compliance rates and reducing
	treatment burden.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Company will continue to incur ongoing operating
	losses, which are expected to increase substantially as it funds development and clinical testing of its pharmaceutical compounds.
	In addition, losses will be incurred in paying ongoing reporting expenses, including legal and accounting expenses, as necessary
	to maintain the Company as a public entity. No projected date for potential revenues can be made, and the Company is undercapitalized
	at present to completely develop, test and market any pharmaceutical product.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	Until the Company is able to generate significant
	revenue from its principal operations, it will remain classified as a development stage company. The Company can give no assurance
	that it will be successful in such efforts or that its limited operating funds will be adequate to support the Company&rsquo;s
	operations, nor can there be any assurance of any additional funding being available to the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<B>
	Recent Developments
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On December 7, 2016, we entered into a securities purchase agreement (the "Purchase Agreement") with various purchasers set forth on the signatures pages thereto (the "Purchasers"). Pursuant to the Purchase Agreement, we issued and sold to the Purchasers in a registered offering an aggregate of 3,885,000 shares of our common stock, together with Series A common stock purchase warrants ("Series A Warrants") exercisable for up to an aggregate of 1,942,500 shares of common stock and Series B common stock purchase warrants ("Series B Warrants") exercisable for up to an aggregate of 3,885,000 shares of common stock. The offering closed on December 13, 2016 and we received net proceeds of approximately $6.9 million, after deducting placement agent fees and estimated offering expenses payable by us, but excluding the proceeds, if any, from the exercise of the Series A Warrants and Series B Warrants issued in the offering.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Series A Warrant has an exercise price of $2.75 per share and the Series B Warrant has an exercise price
	of $3.00 per share. The Series A Warrants will be immediately exercisable and will expire on the five year anniversary of the date
	of issuance. The Series B Warrants will be immediately exercisable and will expire on the six month anniversary of the date of
	issuance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
<B>
	Liquidity and Capital Resources
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	The Company
	has limited working capital reserves with which to continue development of its pharmaceutical products and continuing operations.
	The Company is reliant, at present, upon its capital reserves for ongoing operations and has no revenues.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Net working
	capital reserves decreased from the beginning of the 2016 fiscal year to the end by $16,352,880 (to $8,803,142 from $25,156,022)
	and increased from the beginning of 2015 fiscal year to the end by $17,075,123 (to $25,156,022 from $8,080,899) primarily due
	to capital raised through the sale of common stock. At the end of fiscal 2016, our quarterly cash burn increased to approximately
	$5,000,000, which was higher than in fiscal 2015. We expect our cash burn to increase in fiscal 2017 with the full
	phase 3 clinical program underway and the ongoing development of our sustained release platform technology. At present, the Company
	has no bank line of credit or other fixed source of capital reserves. Should the Company need additional capital in the future,
	it will be primarily reliant upon private or public placement of its equities, or a transaction with a pharmaceutical partner,
	for which there can be no warranty or assurance that the Company may be successful in such efforts. Management believes the Company
	has sufficient capital to meet its planned operating needs into June 2017.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 49; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	47
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_LIQUIDITY_CAPITAL>
<A NAME="eolPage50"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<U>
	Results of Operations
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 34PT">
	For the fiscal year ended September
	30, 2016, the Company had no revenues and operating expenses of approximately $24,596,053. The loss from operations was comprised
	of $16,460,714 in research and development costs, $7,656,327 in general and administrative expenses, and $1,189,276 in depreciation
	and amortization. During the same period, the Company recorded a gain on settlement of accounts payable of $710,264, a decrease
	in fair value of contingent consideration of $1,185,667 and had other income and expense, net items totaling $15,522. The net loss
	for the year ended September 30, 2016 was $25,766,198.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 34PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 34PT">
	For the fiscal year ended September
	30, 2015, the Company had no revenues and operating expenses of approximately $17,805,280. The loss from operations was comprised
	of $8,777,519 in research and development costs, $7,509,601 in general and administrative expenses, $1,179,254 in depreciation
	and amortization and $338,906 in impairment of intangibles. During the same period, the Company recorded a loss on investment of
	subsidiary of $103,143, a change in fair value of contingent consideration of $2,637,756 and had other income and expense, net
	items totaling $72,802. The net loss for the year ended September 30, 2015 was $15,197,865.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 34PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 34PT">
	For the fiscal year ended September
	30, 2014, the Company had zero revenues and operating expenses of approximately $9,122,924. The loss from operations was comprised
	of $4,369,413 in research and development costs, $4,287,205 in general and administrative expenses and $466,306 in depreciation
	and amortization. During the same period, the Company recorded a loss on investment of subsidiary of $10,643 and had other income
	and expense, net items totaling $2,903. The net loss for the year ended September 30, 2014 was $9,130,664.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 34PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 34PT">
	As noted above, the Company
	had no revenues for fiscal year 2016, and does not anticipate that it will have any revenues in fiscal year 2017. The operating
	expenses of the Company increased from fiscal year 2015 to fiscal year 2016 by $6,790,773. The Company had increases in all expense
	categories as ongoing development costs and testing efforts for its pharmaceutical products continue. The Company anticipates it
	will have higher expenditures in fiscal year 2017, including clinical development costs, again with no offsetting revenues.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 34PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 34PT; TEXT-ALIGN: LEFT">
	Results of operations for the year ended September
	30, 2016 reflect the following changes from the prior year period:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 34PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 2%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Change
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	General and administrative
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	7,656,327
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	7,509,601
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	146,726
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Research and development
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	16,460,714
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	8,777,519
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	7,683,195
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Depreciation and amortization
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,189,276
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,179,254
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	10,022
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Gain on settlement of accounts payable
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(710,264
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(710,264
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	Impairment of intangibles
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	338,906
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(338,906
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	Total Operating Expenses
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	24,596,053
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	17,805,280
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	6,790,773
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Operating Loss
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(24,596,053
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(17,805,280
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(6,790,773
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Change in fair value of contingent consideration
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(1,185,667
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,637,756
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(3,823,423
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Share in losses on investment in joint venture
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(103,143
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	103,143
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	Other income and expense, net
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	15,522
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	72,802
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(57,280
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PT">
	Net Loss
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(25,766,198
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(15,197,865
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(10,568,333
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 50; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	48
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage51"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	Results of continuing operations for the year ended September 30, 2015
	reflect the following changes from the prior year period:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 90%; MARGIN-LEFT: 2%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Change
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="5" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 61%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	General and administrative
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	7,509,601
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	4,287,205
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,222,396
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Research and development
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	8,777,519
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	4,369,413
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	4,408,106
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Depreciation and amortization
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,179,254
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	466,306
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	712,948
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	Impairment of Intangibles
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	338,906
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	338,906
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	Total Operating Expenses
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	17,805,280
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	9,122,924
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	8,682,356
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Operating Loss
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(17,805,280
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(9,122,924
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(8,682,356
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Change in fair value of contingent consideration
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,637,756
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,637,756
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Share in losses on investment in joint venture
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(103,143
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(10,643
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(92,500
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Other income and expense, net
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	72,802
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,903
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	69,899
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PT">
	Net Loss
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(15,197,865
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(9,130,664
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(6,067,201
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Until the Company experiences an increase in revenues
	as it continues to implement its business plan, significant losses are expected to continue as the trend is reflected in the chart
	above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	Critical Accounting Estimates
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<U>
	Fair Value of Financial Instruments&nbsp;
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	In accordance with ASC 820, the carrying value
	of cash and cash equivalents, accounts receivable, accounts payable, and notes payable approximates fair value due to the short-term
	maturity of these instruments. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and
	establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Level 1 - Inputs are unadjusted quoted prices in
	active markets for identical assets or liabilities available at the measurement date.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Level 2 - Inputs are unadjusted quoted prices for
	similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that
	are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market
	data.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Level 3 - Unobservable inputs, where there is little
	or no market activity for the asset or liability. These inputs reflect the reporting entity&rsquo;s own beliefs about the assumptions
	that market participants would use in pricing the asset or liability, based on the best information available in the circumstances.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<U>
	Research and Development
</U>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The Company follows the policy of expensing its
	research and development costs in the period in which they are incurred in accordance with ASC 730. The Company incurred net research
	and development expenses of $16,460,714, $8,777,519, and $4,369,413 during the years ended September 30, 2016, 2015, and 2014,
	respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<U>
	Share-based Compensation
</U>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The Company follows the provisions of ASC 718,
	&ldquo;Share-Based Payments&rdquo; which requires all share-based payments to employees, including grants of employee stock options,
	be recognized in the income statement based on their fair values. The Company uses the Black- Scholes pricing model for determining
	the fair value of stock options and the stock price on the date of the grant for the fair value of restricted stock awards.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	In accordance with ASC 505, equity instruments
	issued to non-employees for goods or services are accounted for at fair value and are marked to market until service is complete
	or a performance commitment date is reached, whichever is earlier.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 51; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	49
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage52"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<U>
	Goodwill and Intangibles
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The Company evaluates goodwill and other finite-lived
	intangible assets in accordance with FASB ASC Topic 350,
<I>
	&ldquo;Intangibles
</I>
	&mdash;
<I>
	Goodwill and Other.
</I>
	&rdquo; Goodwill
	is recorded at the time of an acquisition and is calculated as the difference between the total consideration paid for an acquisition
	and the fair value of the net tangible and intangible assets acquired. Accounting for acquisitions requires extensive use of accounting
	estimates and judgments to allocate the purchase price to the fair value of the net tangible and intangible assets acquired, including
	in-process research and development (&ldquo;IPR&amp;D&rdquo;). Goodwill is deemed to have an indefinite life and is not amortized,
	but is subject to annual impairment tests. If the assumptions and estimates used to allocate the purchase price are not correct,
	or if business conditions change, purchase price adjustments or future asset impairment charges could be required. The value of
	our goodwill could be impacted by future adverse changes such as: (I) any future declines in our operating results, (ii) a decline
	in the valuation of technology, including the valuation of our common stock, (iii) a significant slowdown in the worldwide economy
	or (iv) any failure to meet the performance projections included in our forecasts of future operating results. In accordance with
	FASB ASC Topic 350, the Company tests goodwill for impairment on an annual basis or more frequently if the Company believes indicators
	of impairment exist. Impairment evaluations involve management estimates of asset useful lives and future cash flows. Significant
	management judgment is required in the forecasts of future operating results that are used in the evaluations. It is possible,
	however, that the plans and estimates used may be incorrect. If our actual results, or the plans and estimates used in future impairment
	analysis, are lower than the original estimates used to assess the recoverability of these assets, we could incur additional impairment
	charges in a future period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The Company performs its annual impairment review
	of goodwill in September, and when a triggering event occurs between annual impairment tests for both goodwill and other finite-lived
	intangible assets. The Company recorded no impairment loss for the years ended September 30, 2016, 2015, and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The Company&rsquo;s other finite-lived intangible
	assets consist of license rights and patents. The Company amortizes its patents over the life of each patent and license rights
	over the remaining life of the patents that it has rights for. The current license rights have a remaining life of 14 years. During
	the years ended September 30, 2016, 2015, and 2014 the Company recognized $1,124,644, $1,138,631, and $448,456 in amortization
	expense on the patents and license rights, respectively. The amortization expense has been included in depreciation
	and amortization expense.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	In January 2015, the Company discontinued development
	of the OHR/AVR118 program. In connection with this decision, the patent portfolio is no longer being maintained and the remaining
	$338,906 in unamortized patent costs have been impaired (Patent cost of $600,000 less $261,094 previously amortized).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Off-Balance Sheet Arrangements
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 34PT; TEXT-ALIGN: LEFT">
	The Company has not entered into any off-balance
	sheet arrangements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 34PT; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Tabular Description of Principal Contracts
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 34PT">
	The Company is not engaged in
	any contract for sale or distribution of its product to date and, therefore, does not have any specific disclosure under this heading.
</P>
</EFX_RESULTS_OF_OPERATIONS>
</EFX_MANAGEMENTS_DISCUSSION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 34PT">
	&nbsp;
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A NAME="OHRP-10K_093016_HTM_OHRPA010">
</A>
	ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES
	ABOUT MARKET RISK
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 34PT">
	Market risk represents the risk
	of loss arising from adverse changes in interest rates and foreign exchange rates. Due to its limited operations, the Company does
	not have any material exposure to interest rate or exchange rate risk.
</P>
</EFX_MARKET_RISK>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 34PT">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A NAME="OHRP-10K_093016_HTM_OHRPA011">
</A>
	ITEM 8 FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	Following are the financial
	statements prepared by Ohr and audited by its independent auditors. These financial statements constitute the formal presentation
	of financial information by the Company, such that all other financial information contained in this Annual Report on Form 10-K
	should be read and reviewed in light of the following financial statements and notes thereto. Should there exist any conflict between
	information appearing elsewhere in this Annual Report on Form 10-K and the following financial statements, the financial statements
	should be given primary definition and control. The notes attached to the financial statements constitute an integral part of the
	financial disclosure and should be read and reviewed in connection with the financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 52; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	50
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage53"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	MANAGEMENT&rsquo;S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
	To the Stockholders of OHR Pharmaceutical, Inc.:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Our management is responsible for establishing and
	maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our
	financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles
	generally accepted in the United States. Internal control over financial reporting includes those policies and procedures that
	(1) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions
	of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation
	of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures of the company
	are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance
	regarding prevention or timely detection of the unauthorized acquisition, use or disposition of our assets that could have a material
	effect on the financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Because of its inherent limitations, internal control
	over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future
	periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance
	with the policies or procedures may deteriorate. Accordingly, even an effective system of internal control over financial reporting
	will provide only reasonable assurance with respect to the reliability of financial reporting and financial statement preparation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Management assessed our internal control over financial
	reporting as of September 30, 2016, the end of our fiscal year. Management based its assessment on the framework in Internal Control
	- Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Management&rsquo;s
	assessment included the evaluation of such elements as the design and operating effectiveness of key financial reporting controls,
	process documentation, accounting policies and our overall control environment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Based on its assessment, management concluded that
	our internal control over financial reporting was effective as of the end of the period covered by this Annual Report on Form 10-K.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	We reviewed the results of management&rsquo;s assessment
	with the Audit Committee of our Board of Directors. Additionally, our independent registered public accounting firm, MaloneBailey,
	LLP, independently assessed our internal control over financial reporting. MaloneBailey, LLP has issued a report on our internal
	control over financial reporting, which is included in this annual report.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 49%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;/s/ JASON S. SLAKTER
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 49%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF">
	/s/ SAM BACKENROTH
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	Jason S. Slakter
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	Sam Backenroth
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	Chief Executive Officer (Principal Executive Officer)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	Chief Financial Officer (Principal Financial and Accounting Officer)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	December 22, 2016
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	December 22, 2016
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 53; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	51
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage54"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
	FIRM
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	To the Board of Directors and Stockholders of
<BR>
	OHR Pharmaceutical, Inc.
<BR>
	New York, NY
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We have audited the accompanying consolidated balance
	sheets of OHR Pharmaceutical, Inc. and its subsidiaries (collectively, the &ldquo;Company&rdquo;) as of September 30, 2016 and
	2015 and the related consolidated statements of operations, stockholders&rsquo; equity and cash flows for each of the three years
	in the period ended September 30, 2016. We also have audited the Company&rsquo;s internal control over financial reporting as of
	September 30, 2016, based on criteria established in Internal Control&mdash;Integrated Framework (2013) issued by the Committee
	of Sponsoring Organizations of the Treadway Commission. The Company&rsquo;s management is responsible for these consolidated financial
	statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of
	internal control over financial reporting, included in the accompanying Management&rsquo;s Report on Internal Control Over Financial
	Reporting. Our responsibility is to express an opinion on these consolidated financial statements and an opinion on the Company&rsquo;s
	internal control over financial reporting based on our audits.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	We conducted our audits in accordance with the
	standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the
	audit to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective
	internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included
	examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting
	principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our
	audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting,
	assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal
	control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the
	circumstances. We believe that our audits provide a reasonable basis for our opinions.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	A company&rsquo;s internal control
	over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting
	and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
	A company&rsquo;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance
	of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
	(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance
	with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance
	with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely
	detection of unauthorized acquisition, use, or disposition of the company&rsquo;s assets that could have a material effect on the
	financial statements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	Because of its inherent limitations,
	internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness
	to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree
	of compliance with the policies or procedures may deteriorate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	In our opinion, the
	consolidated financial statements referred to above present fairly, in all material respects, the financial position of OHR Pharmaceutical,
	Inc. and its subsidiaries as of September 30, 2016 and 2015, and the results of their operations and their cash flows for each
	of the three years in the period ended September 30, 2016, in conformity with accounting principles generally accepted in the United
	States of America. Also, in our opinion, the Company maintained, in all material respects, effective internal control over financial
	reporting as of September 30, 2016, based on the criteria established in Internal Control &mdash; Integrated Framework issued by
	the Committee of Sponsoring Organizations of the Treadway Commission.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<U>
	/s/ MaloneBailey, LLP
</U>
<BR>
	www.malone-bailey.com
<BR>
	Houston, Texas
<BR>
	December 22, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 54; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	52
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_AUDITORS_OPINION>
<A NAME="eolPage55"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<EFX_BALANCE_SHEET>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="9" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<A NAME="FIS_BALANCE_SHEET"></A>
	OHR PHARMACEUTICAL, INC.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="9" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<B>
	Consolidated Balance Sheets
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	September
	30,
<SUP>
</SUP>
</B>
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
	September 30,
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="9" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
	ASSETS
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="9" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	CURRENT ASSETS
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 72%; FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 10PT">
	Cash and cash equivalents
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	12,546,890
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	28,697,323
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Prepaid expenses and other current assets
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	738,118
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	338,713
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 20PT">
	Total Current Assets
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	13,285,008
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	29,036,036
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	EQUIPMENT, net
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	198,631
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	248,753
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	OTHER ASSETS
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Security deposit
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	12,243
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	12,243
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Intangible assets, net
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	15,208,219
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	16,332,863
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Goodwill
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	740,912
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	740,912
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PT; PADDING-LEFT: 20PT">
	TOTAL ASSETS
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	29,445,013
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	46,370,807
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_BALANCE_SHEET>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<EFX_BALANCE_SHEET>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD COLSPAN="8" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; PADDING-LEFT: 5.4PT">
<A NAME="FIS_BALANCE_SHEET_2"></A>
	LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	CURRENT LIABILITIES
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Accounts payable and accrued expenses
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	4,394,068
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,592,348
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Notes payable
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	87,798
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	48,063
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Contingent consideration
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,239,603
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 20PT">
	Total Current Liabilities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	4,481,866
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,880,014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 20PT">
	TOTAL LIABILITIES
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	4,481,866
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,880,014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_BALANCE_SHEET>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<EFX_BALANCE_SHEET>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
<A NAME="FIS_BALANCE_SHEET_3"></A>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	COMMITMENTS AND
	CONTINGENCIES&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT;">
	STOCKHOLDERS&rsquo; EQUITY
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Preferred stock, Series B; 6,000,000 shares authorized, $0.0001 par value, 0 shares issued and outstanding, respectively
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT; TEXT-INDENT: -10PT">
	Common stock; 180,000,000 shares authorized, $0.0001 par value, 32,076,396 and 30,331,309 shares issued and outstanding, respectively
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,207
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,033
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Additional paid-in capital
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	109,237,551
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	100,999,173
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Accumulated deficit
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(84,277,611
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(58,511,413
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 20PT">
	Total Stockholders&rsquo; Equity
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	24,963,147
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	42,490,793
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PT; PADDING-LEFT: 20PT">
	&nbsp;&nbsp;TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	29,445,013
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	46,370,807
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</EFX_BALANCE_SHEET>
</TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part of these consolidated financial statements.
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 55; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	53
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage56"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="13" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
	OHR PHARMACEUTICAL, INC.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="13" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
	Consolidated Statements of Operations
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="13" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
	For the Year Ended September 30,
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="9" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	OPERATING EXPENSES
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 58%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 8.1PT">
	General and administrative
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	7,656,327
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	7,509,601
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	4,287,205
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 8.1PT">
	Research and development
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	16,460,714
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	8,777,519
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	4,369,413
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 8.1PT">
	Depreciation and amortization
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,189,276
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,179,254
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	466,306
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 8.1PT">
	Gain on settlement of accounts payable
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(710,264
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT; PADDING-LEFT: 8.1PT">
	Impairment of Intangibles
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	338,906
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	OPERATING LOSS
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	24,596,053
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	17,805,280
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	9,122,924
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	OTHER INCOME (EXPENSE)
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Change in fair value of contingent consideration
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(1,185,667
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,637,756
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Share in losses on investment in joint venture
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(103,143
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(10,643
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Other income and expense
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,419
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	42,966
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	8,479
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Interest income (expense), net
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	12,103
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(5,977
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(5,576
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Royalty income
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	35,813
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 20PT">
	Total Other Income (Expense)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(1,170,145
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,607,415
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(7,740
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	LOSS FROM OPERATIONS BEFORE INCOME
	TAXES
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(25,766,198
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(15,197,865
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(9,130,664
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0IN">
	PROVISION FOR INCOME TAXES
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PT; PADDING-LEFT: 0IN">
	NET LOSS
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(25,766,198
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(15,197,865
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(9,130,664
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0IN">
	BASIC AND DILUTED LOSS PER SHARE
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(0.82
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(0.54
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(0.41
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 0IN">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	WEIGHTED AVERAGE&nbsp;&nbsp;NUMBER OF SHARES
	OUTSTANDING:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	BASIC AND DILUTED
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	31,349,223
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	28,404,405
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	22,141,538
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	The accompanying notes are an integral part of these consolidated financial statements.
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 56; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	54
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage57"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="28" STYLE="FONT: BOLD 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	OHR PHARMACEUTICAL,
	INC.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="28" STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	Consolidated Statements
	of Stockholders&rsquo; Equity
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="6" STYLE="FONT-SIZE: 8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 8PT">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="6" STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<B>
	Series B
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-SIZE: 8PT">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<B>
	Additional
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<B>
	Total
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="6" STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<B>
	Preferred Stock
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="6" STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<B>
	Common Stock
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<B>
	Paid-in
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<B>
	Accumulated
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<B>
	Stockholders&rsquo;
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 8PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Shares
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Amount
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Shares
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Amount
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Capital
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Deficit
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Equity
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 33%; FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Balance, September 30, 2013
</TD>
<TD STYLE="WIDTH: 2%; FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	500,000
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	50
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	19,741,541
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 6%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,974
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	39,444,988
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(34,182,884
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 7%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	5,264,128
</TD>
<TD STYLE="WIDTH: 1%; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Conversion of preferred series B to common stock
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(500,000
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(50
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	166,667
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	17
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	33
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Exercise of warrants for cash
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	106,056
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	11
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	260,741
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	260,752
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Cashless exercise of warrants
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,238,782
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	223
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(223
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Common stock issued for settlement of accounts payable
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	6,282
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	49,999
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	50,000
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Common stock issued for cash
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,800,000
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	180
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	16,875,820
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	16,876,000
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Common stock issued for acquisition of Assets
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,194,862
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	119
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	10,180,105
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	10,180,224
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Warrants issued for services
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,177,095
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,177,095
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Fair value of employee stock options
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,074,487
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,074,487
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Net loss for the year ended September 30, 2014
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(9,130,664
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(9,130,664
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Balance, September 30, 2014
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	25,254,190
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,525
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	70,063,045
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(43,313,548
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	26,752,022
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 8PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Exercise of warrants for cash
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	36,548
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	4
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	79,999
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	80,003
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Cashless exercise of warrants
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	663,608
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	66
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(66
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Common stock issued for settlement of accounts payable
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	5,952
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	49,999
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	50,000
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Common stock issued for cash, net of stock issuance costs
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	4,259,259
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	426
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	26,582,572
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	26,582,998
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Common stock issued for services
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	111,752
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	11
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	635,277
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	635,288
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Warrants issued for services
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	8,559
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	8,559
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Fair value of employee stock options and warrants issued for
	services
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,579,788
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,579,788
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Net loss for the year ended September 30, 2015
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(15,197,865
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(15,197,865
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Balance, September 30, 2015
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	30,331,309
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,033
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	100,999,173
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(58,511,413
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	42,490,793
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 8PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 8PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Exercise of warrants for cash
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	88,612
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	8
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	144,834
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	144,842
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Common stock issued for achievement of milestones set in asset
	acquisition
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	995,718
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	100
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,425,170
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,425,270
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Common stock issued for services
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	660,757
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	66
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,754,748
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,754,814
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Fair value of employee stock options and
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,913,626
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,913,626
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Net loss for the year ended September 30, 2016
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(25,766,198
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(25,766,198
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	Balance, September 30, 2016
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	32,076,396
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,207
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	109,237,551
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(84,277,611
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 8PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	24,963,147
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 8PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	The accompanying
	notes are an integral part of these consolidated financial statements.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 8PT">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 57; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	55
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage58"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="13" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
	OHR PHARMACEUTICAL, INC.
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="13" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
	Consolidated Statements of Cash Flows
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="10" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<B>
	For the Year Ended September 30,
</B>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	OPERATING ACTIVITIES
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 58%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Net loss
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(25,766,198
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(15,197,865
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(9,130,664
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN; TEXT-INDENT: -0.125IN">
	Adjustments to reconcile net loss to net cash&nbsp;used by operating activities:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Common stock issued for services
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,754,814
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	635,288
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Warrants issued for services
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	8,559
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,177,095
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Stock option expense
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,913,626
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,579,788
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,074,487
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Change in fair value of contingent consideration
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,185,667
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(2,637,756
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Share in losses on investment in joint venture
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	103,143
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	10,643
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 20PT">
	Depreciation
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	64,632
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	40,623
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	17,850
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Amortization of intangible assets
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,124,644
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,138,631
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	448,456
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 20PT">
	Impairment of intangibles
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	338,906
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Gain on settlement of accounts payable
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(710,264
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(40,636
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Changes in operating assets and liabilities
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Prepaid expenses and deposits
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(64,794
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	7,214
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	105,823
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 20PT">
	Accounts payable and accrued expenses
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,511,984
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,331,120
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(63,822
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 30PT">
	Net Cash Used in Operating Activities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(15,985,889
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(10,692,985
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(5,360,132
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	INVESTING ACTIVITIES
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Acquisition of SKS Ocular&rsquo;s assets
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(3,500,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 20PT">
	Investment in joint venture
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(100,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(13,786
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 20PT">
	Purchase of property and equipment
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(14,510
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(184,951
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(1,083
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 30PT">
	Net Cash Used in Investing Activities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(14,510
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(284,951
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(3,514,869
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	FINANCING ACTIVITIES
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Proceeds for issuance of common stock for cash
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	26,582,998
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	16,876,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 10PT">
	Proceeds from warrants exercised for cash
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	26,041
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	80,003
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	260,752
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 10PT">
	Repayments of short-term notes payable
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(176,075
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(208,236
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(164,152
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 20PT">
	Net Cash Provided by/(Used in) Financing Activities
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(150,034
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	26,454,765
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	16,972,600
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	NET CHANGE IN CASH AND CASH EQUIVALENTS
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(16,150,433
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	15,476,829
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	8,097,599
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	28,697,323
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	13,220,494
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	5,122,895
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	CASH AND CASH EQUIVALENTS AT END OF PERIOD
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	12,546,890
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	28,697,323
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2PT DOUBLE; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	13,220,494
</TD>
<TD STYLE="PADDING-BOTTOM: 2PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 0.125IN">
	CASH PAID FOR:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 20PT">
	Interest
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	6,071
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	5,977
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	5,576
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 20PT">
	Income Taxes
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0IN">
	NON CASH FINANCING ACTIVITIES:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Settlement of contingent consideration
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3,425,270
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Financing of insurance premiums through issuance of short term notes
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	215,810
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	212,400
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	194,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Subscription receivable from exercise of warrants
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	118,801
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Conversion of preferred for common stock
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	50
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Noncash exercise of options and warrants
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	223
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Common stock issued to acquire intangible assets
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	10,180,224
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
	Common stock issued to settle accounts payable
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	50,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	50,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	The accompanying notes are
	an integral part of these consolidated financial statements.
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 58; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	56
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage59"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0 0PT 1PT; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0 0PT 1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	OHR
	PHARMACEUTICAL, INC.
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0 0PT 1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0 0PT 1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Notes
	to the Consolidated Financial Statements
<BR>
	September 30, 2016
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0 0PT 1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	NOTE
	1 &ndash; DESCRIPTION OF BUSINESS
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	OHR
	Pharmaceutical, Inc. (&ldquo;we&rdquo;, &ldquo;our,&rdquo; or the &ldquo;Company&rdquo;) is a pharmaceutical company
	focused on the development of the Company&rsquo;s previously acquired compounds and technologies with a focus on the clinical
	and preclinical development of ophthalmology products. Our lead clinical program, topical Squalamine (also known as
	Squalamine Lactate Ophthalmic Solution, 0.2% or OHR-102), is being evaluated in a phase 3 clinical
	program for the treatment of the wet form of age-related macular degeneration (&ldquo;wet-AMD&rdquo;). We are
	also developing a sustained release ocular drug delivery platform technology.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	On
	May 30, 2014, the Company completed the acquisition of certain assets of SKS Ocular, LLC (&ldquo;SKS Parent&rdquo;), and
	SKS Ocular 1, LLC (&ldquo;SKS 1&rdquo; and SKS Parent referred to herein as &ldquo;SKS&rdquo;), including licenses, patents
	and contracts relating to a micro-fabrication polymer- based sustained delivery platform related to ocular therapeutics and a
	dry age-related macular degeneration animal model, together with biomarkers to support such model.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	NOTE
	2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Use
	of Estimates
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	preparation of financial statements in conformity with accounting principles generally accepted in the United States of America
	requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of
	the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ
	from those estimates. Estimates subject to change in the near term include impairment (if any) of long-lived assets and fair value
	of liabilities.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Accounting
	Basis and Principles of Consolidation
</U>
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted
	in the United States of America, or GAAP, and they include the accounts of Ohr Pharmaceutical, Inc. and its subsidiaries. The
	Company has elected a September 30 fiscal year end. All intercompany balances and transactions have been eliminated in consolidation.
	The Company also uses the equity method to account for its joint venture. This method is used because the joint venture does not
	meet the variable interest entity requirements for consolidation and the Company does not have control of the entity.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Cash
	and Cash Equivalents
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company considers all highly-liquid investments purchased with an original maturity date of three months or less to be cash equivalents.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 46PT 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Concentration
	of Credit Risk
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Financial
	instruments, which potentially subject us to concentrations of credit risk, consist principally of cash. Our cash balances are
	maintained in accounts held by major banks and financial institutions located in the United States. The Company occasionally maintains
	amounts on deposit with a financial institution that are in excess of the federally insured limit of $250,000. The risk is managed
	by maintaining all deposits in high quality financial institutions. The Company had approximately $12,046,890 and $27,947,323
	of cash balances in excess of federally insured limits at September 30, 2016 and 2015, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Property
	and Equipment
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Property
	and equipment is recorded at cost less accumulated depreciation. Depreciation and amortization is calculated using the straight-
	line method over the expected useful life of the asset, after the asset is placed in service. The Company generally uses the following
	depreciable lives for its major classifications of property and equipment:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="WIDTH: 80%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 65%; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Description
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 15%; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Useful
	Lives
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CEEEFE">
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Equipment
</FONT>
</TD>
<TD STYLE="BORDER-TOP: BLACK 1PT SOLID; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3
	to 5 years
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Lab
	Equipment
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5
	years
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CEEEFE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Leasehold
	Improvements
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	7
	years
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Office
	Furniture and Fixtures
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3
	years
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Expenditures
	associated with upgrades and enhancements that improve, add functionality, or otherwise extend the life of property and equipment
	that exceed $1,000 are capitalized, while expenditures that do not, such as repairs and maintenance, are expensed as incurred.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Valuation
	of Long-Lived Assets
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Long-lived
	tangible assets and definite-lived intangible assets are reviewed for possible impairment whenever events or changes in circumstances
	indicate that the carrying amount of such assets may not be recoverable. The Company uses an estimate of undiscounted future net
	cash flows of the assets over the remaining useful lives in determining whether the carrying value of the assets is recoverable.
	If the carrying values of the assets exceed the expected future cash flows of the assets, the Company recognizes an impairment
	loss equal to the difference between the carrying values of the assets and their estimated fair values. Impairment of long-lived
	assets is assessed at the lowest levels for which there are identifiable cash flows that are independent from other groups of
	assets. The evaluation of long-lived assets requires the Company to use estimates of future cash flows. However, actual cash flows
	may differ from the estimated future cash flows used in these impairment tests. In fiscal 2015, management discontinued development
	of the OHR/AVR118 program. In connection with this decision, the OHR/AVR118 patent portfolio is no longer being maintained and the remaining
	$338,906 in unamortized patent costs have been impaired. As of September 2016, management does not believe any of the Company&rsquo;s
	long-lived assets were impaired.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 59; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	57
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage60"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Fair
	Value of Financial Instruments
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	accordance with ASC 820, the carrying value of cash and cash equivalents, accounts receivable, accounts payable and notes payable
	approximates fair value due to the short-term maturity of these instruments. ASC 820 clarifies the definition of fair value, prescribes
	methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as
	follows:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Level
	1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Level
	2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar
	assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived
	from or corroborated by observable market data.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Level
	3 - Unobservable inputs, where there is little or no market activity for the asset or liability. These inputs reflect the reporting
	entity&rsquo;s own beliefs about the assumptions that market participants would use in pricing the asset or liability, based on
	the best information available in the circumstances.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	following table presents assets and liabilities that are measured and recognized at fair value as of September 30, 2016 and 2015,
	on a recurring basis:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; WIDTH: 44%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; WIDTH: 10%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; WIDTH: 10%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; WIDTH: 10%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; WIDTH: 10%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Assets
	and liabilities measured at fair value on a recurring basis at September 30, 2016
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Level 1
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Level 2
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Level 3
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total
<BR>
	Carrying Value
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Contingent
	stock consideration
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0; TEXT-INDENT: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Assets
	and liabilities measured at fair value on a recurring basis at September 30, 2015
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Level 1
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Level 2
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Level 3
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Total
<BR>
	Carrying Value
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 44%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Contingent
	stock consideration
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2,239,603
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2,239,603
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2,239,603
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2,239,603
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0; TEXT-INDENT: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	A
	financial instrument&rsquo;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant
	to the fair value measurement. The fair value of the contingent stock consideration was based on the decision tree analysis method
	that considers the impact on project value of different scenarios at nominated decision points along the development path.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	following table provides a summary of the changes in fair value, including net transfers in and/or out, of the financial instruments,
	measured at fair value on a recurring basis using significant unobservable inputs:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Level
	3 Reconciliation:
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Contingent
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Stock
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Consideration
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Level
	3 assets and liabilities at September 30, 2013
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 66%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Purchases,
	sales, issuances and settlements (net)
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4,877,359
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Mark
	to market adjustments
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Level
	3 assets and liabilities at September 30, 2014
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4,877,359
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Purchases,
	sales, issuances and settlements (net)
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Mark
	to market adjustments
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(2,637,756
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Total
	Level 3 assets and liabilities at September 30, 2015
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2,239,603
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Purchases,
	sales, issuances and settlements (net)
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(3,425,270
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Mark
	to market adjustments
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1,185,667
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Total
	Level 3 assets and liabilities at September 30, 2016
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 60; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	58
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage61"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Goodwill
	and Intangibles
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company evaluates goodwill and other finite-lived intangible assets in accordance with FASB ASC Topic 350,
<I>
	&ldquo;Intangibles
</I>
	&mdash;
<I>
	Goodwill and Other.
</I>
	&rdquo; Goodwill is recorded at the time of an acquisition and is calculated as the difference
	between the total consideration paid for an acquisition and the fair value of the net tangible and intangible assets acquired.
	Accounting for acquisitions requires extensive use of accounting estimates and judgments to allocate the purchase price to the
	fair value of the net tangible and intangible assets acquired, including in-process research and development (&ldquo;IPR&amp;D&rdquo;).
	Goodwill is deemed to have an indefinite life and is not amortized, but is subject to annual impairment tests. If the assumptions
	and estimates used to allocate the purchase price are not correct, or if business conditions change, purchase price adjustments
	or future asset impairment charges could be required. The value of our goodwill could be impacted by future adverse changes such
	as: (i) any future declines in our operating results, (ii) a decline in the valuation of technology, including the valuation of
	our common stock, (hi) a significant slowdown in the worldwide economy or (iv) any failure to meet the performance projections
	included in our forecasts of future operating results. In accordance with FASB ASC Topic 350, the Company tests goodwill for impairment
	on an annual basis or more frequently if the Company believes indicators of impairment exist. Impairment evaluations involve management
	estimates of asset useful lives and future cash flows. Significant management judgment is required in the forecasts of future
	operating results that are used in the evaluations. It is possible, however, that the plans and estimates used may be incorrect.
	If our actual results, or the plans and estimates used in future impairment analysis, are lower than the original estimates used
	to assess the recoverability of these assets, we could incur additional impairment charges in a future period.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company performs its annual impairment review of goodwill in September, and when a triggering event occurs between annual impairment
	tests for both goodwill and other finite-lived intangible assets. The Company recorded no impairment loss for the years ended
	September 30, 2016, 2015 and 2014.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company&rsquo;s other finite-lived intangible assets consist of license rights and patents. The Company amortizes its patents
	over the life of each patent and license rights over the remaining life of the patents that it has rights for. The current license
	rights have a remaining life of 15 years. During the years ended September 30, 2016, 2015, and 2014 the Company recognized $1,124,644,
	$1,138,631, and $448,456 in amortization expense on the patents and license rights, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Research
	and Development
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Research
	and development expenses are expensed in the consolidated statements of operations as incurred in accordance with FASB
	ASC 730,
<I>
	Research and Development.
</I>
	Research and development expenses include salaries, related employee expenses,
	clinical trial expenses, research expenses, manufacturing expenses, consulting fees, and laboratory costs. The Company
	incurred net research and development expenses of $16,460,714, $8,777,519, and $4,369,413 during the years ended September
	30, 2016, 2015, and 2014 respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Share-based
	Compensation
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company follows the provisions of ASC 718, &ldquo;Share-Based Payments&rdquo; which requires all share-based payments to employees,
	including grants of employee stock options, be recognized in the income statement based on their fair values. The Company uses
	the Black- Scholes pricing model for determining the fair value of stock options and the stock price on the date of issuance to
	determine the fair value of restricted stock awards.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 61; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	59
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage62"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	accordance with ASC 505, equity instruments issued to non-employees for goods or services are accounted for at fair value and
	are marked to market until service is complete or a performance commitment date is reached, whichever is earlier.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Stock-based
	compensation expense is recognized in the Company&rsquo;s financial statements on a straight-line basis over the awards&rsquo;
	vesting periods. The stock-based compensation awards generally vest over a period of up to five years.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Income
	Taxes
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined
	based on differences between the financial reporting and tax bases of assets and are measured using the enacted tax rates and
	laws that will be in effect when the differences are expected to reverse. This method requires the reduction of deferred tax
	assets by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of
	the deferred tax assets will not be realized. The charge for taxation is based on the results for the year as adjusted for
	items which are nonassessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted
	by the balance sheet date.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	As
	of September 30, 2016 and 2015, the Company&rsquo;s deferred tax assets relate to net operating loss
	(&ldquo;NOL&rdquo;) carryforwards that were derived from operating losses from prior years amounting to $40,779,002 and
	$20,746,188, respectively. A full valuation allowance has been applied to the Company&rsquo;s deferred tax assets. The
	valuation allowance will be reduced when and if the Company determines it is more likely than not that the related deferred
	income tax assets will be realized.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	July, 2006, the FASB issued ASC 740,
<I>
	Accounting for Uncertainty in Income Taxes,
</I>
	which clarifies the accounting for uncertainty
	in tax positions taken or expected to be taken in a return. ASC 740 provides guidance on the measurement, recognition, classification
	and disclosure of tax positions, along with accounting for the related interest and penalties. Under this pronouncement, the Company
	recognizes the financial statement benefit of a tax position only after determining that a position would more likely than not
	be sustained based upon its technical merit if challenged by the relevant taxing authority and taken by management to the court
	of the last resort. For tax positions meeting the more- likely-than-not threshold, the amount recognized in the consolidated financial
	statements is the largest benefit that has a greater than 50% likelihood of being realized upon settlement with the relevant tax
	authority. ASC 740 became effective for the Company as of July 1, 2008, and had no material impact on the Company&rsquo;s financial
	statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company&rsquo;s policy is to recognize both interest and penalties related to unrecognized tax benefits in income tax expense.
	Interest and penalties on unrecognized tax benefits expected to result in payment of cash within one year are classified as accrued
	liabilities, while those expected beyond one year are classified as other liabilities. The Company has not recorded any interest
	and penalties since its inception.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Company files income tax returns in the U.S. federal tax jurisdiction and various state tax jurisdictions. The tax years for 2013
	to 2015 remain open for examination by federal and/or state tax jurisdictions. The Company is currently not under examination
	by any other tax jurisdictions for any tax years.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Loss
	Per Share
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Basic
	loss per common share is computed by dividing losses attributable to common shareholders by the weighted-average number of shares
	of common stock outstanding during the period.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Diluted
	loss per common share is computed by dividing losses attributable to common shareholders by the weighted-average number of shares
	of common stock outstanding during the period increased to include the number of additional shares of common stock that would
	have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include outstanding
	stock options, and warrants.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	For
	the years ended September 30, 2016, 2015 and 2014, all of the Company&rsquo;s potentially dilutive securities (warrants and options)
	were excluded from the computation of diluted loss per share as they were anti-dilutive. The total numbers of potentially dilutive
	shares that were excluded were 440,449, 1,313,536 and 3,995,343 at September 30, 2016, 2015 and 2014, respectively.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Reclassification
	of Financial Statement Accounts
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Certain
	amounts in the September 30, 2015 and 2014 financial statements have been reclassified to conform to the presentation in the September
	30, 2016 financial statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<U>
	Recent
	Accounting Pronouncements
</U>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Management
	has considered all recent accounting pronouncements issued since the last audit of the Company&rsquo;s financial statements. The
	Company&rsquo;s management believes that these recent pronouncements will not have a material effect on the Company&rsquo;s financial
	statements.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 46PT 0PT 31.5PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 46PT 0PT 31.5PT; TEXT-ALIGN: JUSTIFY">
</P>
<!-- FIELD: PAGE; SEQUENCE: 62; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	60
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage63"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 46PT 0PT 31.5PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	NOTE
	3 &ndash; ASSET ACQUISITION
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 46PT 0PT 31.5PT; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL; FONT-VARIANT: NORMAL">
	On
	May 30, 2014, the Company completed the acquisition of certain assets of SKS, including licenses, patents and
	contracts relating to a micro-fabrication polymer-based sustained delivery platform related to ocular therapeutics and a dry
	age-related macular degeneration animal model, together with biomarkers to support such model.
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL; FONT-VARIANT: NORMAL">
	The
	purchase price consisted of: (a) Cash in the amount of $3,500,000; (b) 1,194,862 shares of the Company&rsquo;s common stock (valued
	at $10,180,224 based on the trading price on May 30, 2014 of the Company&rsquo;s common stock) and (c) an additional 1,493,577
	shares (the &ldquo;contingent shares&rdquo;) that will be issued contingent to achievement of certain milestones.
</FONT>
</P>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; MARGIN-LEFT: 5%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Purchase Price
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 46%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Cash
	at closing
</FONT>
</TD>
<TD STYLE="WIDTH: 2%; FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3,500,000
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Stock
	Issued
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10,180,224
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Contingent
	Consideration Stock
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4,877,359
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Total
	Purchase Price
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PX SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	18,557,583
</FONT>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	acquisition of the assets of SKS has been accounted for as an acquisition of a business whereby the purchase price was allocated
	to tangible and intangible assets acquired based on their fair values as of the acquisition date.
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL; FONT-VARIANT: NORMAL">
	The
	Company evaluated the contingent stock consideration in accordance with ASC 480 and 815, regarding contingent consideration arrangements.
	Based on this evaluation, the Company has determined that the contingent consideration met the liability criteria and should be
	recorded as a liability of the Company.
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT-SIZE: 10PT; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL; FONT-VARIANT: NORMAL">
	A summary of the pro forma purchase price allocation
	as of May 30, 2014 is as follows:
</FONT>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; MARGIN-LEFT: 5%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-STYLE: NORMAL; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Purchase
	Price Allocation
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 46%; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Lab
	equipment
</FONT>
</TD>
<TD STYLE="WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	86,733
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Computer
	and software
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2,523
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Leasehold
	improvements
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2,181
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Security
	deposit
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	12,243
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	License
	rights
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	17,712,991
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; PADDING-LEFT: 0.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Goodwill
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	740,912
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2PX; PADDING-LEFT: 0.5PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Total
	Purchase Price Allocation
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PX SOLID; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	18,557,583
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 2PX; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	following pro forma statement of operations presents the results of operations as if the SKS Acquisition had taken place on October
	1, 2013 and represents the combined revenues and expenses of the Company had the SKS Acquisition existed for the entire year ended
	September 30, 2014:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%; MARGIN-LEFT: 5%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD COLSPAN="5" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: TRANSPARENT">
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-VARIANT: NORMAL">
	Pro
	Forma Consolidated Statement of Operations
</FONT>
<BR>
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-VARIANT: NORMAL">
	For the Year Ended September 30, 2014
</FONT>
<BR>
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-VARIANT: NORMAL">
	(Unaudited)
</FONT>
	&nbsp;
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD COLSPAN="5" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 46%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	REVENUES
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	1,839,000
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	OPERATING EXPENSES
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.175IN">
	General and administrative
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	827,345
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.175IN">
	Professional fees
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	2,335,422
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.175IN">
	Research and development
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	5,948,332
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.175IN">
	Salaries and wages
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2,616,783
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.35IN">
	Total Operating Expenses
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	11,727,882
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.35IN">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	OPERATING LOSS
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(9,888,882
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	OTHER INCOME (EXPENSE)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.175IN">
	Interest expense
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	(62,944
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-LEFT: 0.175IN">
	Other income
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	8,478
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.35IN">
	Total Other Income (Expense)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(54,466
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	NET LOSS
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK MEDIUM DOUBLE">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK MEDIUM DOUBLE">
<FONT STYLE="FONT-SIZE: 10PT">
	(9,943,348
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<SUP>
	)
</SUP>
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 63; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	61
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage64"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	NOTE 4 &ndash;
	PROPERTY AND EQUIPMENT
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Property and equipment at September 30, 2016 and
	2015 consist of:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 74%; FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 5.4PT">
	Equipment
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	93,789
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	91,715
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 5.4PT">
	Lab equipment
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	251,908
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	239,472
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 5.4PT">
	Leasehold improvements
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,181
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,181
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	Office furniture and fixtures
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,523
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,523
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	350,401
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	335,891
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	Accumulated depreciation
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(151,770
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(87,138
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	198,631
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	248,753
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	Depreciation expense for the years ended September 30, 2016, 2015, and 2014 was $64,632, $40,623, and $17,850, respectively.
</FONT>
</P>
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	NOTE 5 &ndash; INTANGIBLE
	ASSETS
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Intangible assets at September 30, 2016 and 2015
	consist of:
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 85%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 74%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 5.4PT">
	License rights
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	17,712,991
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	17,712,991
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	Patent costs
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	200,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	200,000
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	17,912,991
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	17,912,991
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	Accumulated amortization
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(2,704,772
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(1,580,128
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT; PADDING-LEFT: 5.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	15,208,219
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	16,332,863
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	During the years ended September 30, 2016, 2015, and 2014, the Company recognized $1,124,644, $1,138,631, and $448,456, respectively, in amortization expense on the patents.&nbsp;The amortization expense has been included in research and development expense.
</FONT>
</P>
<P STYLE="MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	In January 2015, the Company discontinued
	development of the OHR/AVR118 program. In connection with this decision, the OHR/AVR118 patent portfolio is no longer being
	maintained and the remaining $338,906 in unamortized patent costs have been impaired (Patent cost of $600,000 less $261,094
	previously amortized).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The estimated future amortization of intangibles
	for the next five years is as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 65%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-FAMILY: CALIBRI,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-FAMILY: CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: CALIBRI,SANS-SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Years ending
<BR>
	September 30,
</B>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	&nbsp;
</B>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Estimated
<BR>
	Amortization Expense
</B>
</TD>
<TD>
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 30%; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.625IN">
	2017
</TD>
<TD STYLE="WIDTH: 20%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 15%; TEXT-ALIGN: RIGHT">
	1,120,616
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.625IN">
	2018
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,117,731
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.625IN">
	2019
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,116,449
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.625IN">
	2020
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,119,508
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.625IN">
	2021
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	1,115,577
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.625IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; FONT-SIZE: 10PT">
	Thereafter
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	9,618,338
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-LEFT: 0.625IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; FONT-SIZE: 10PT">
	Total
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT; BORDER-TOP: BLACK 1PT SOLID; BORDER-BOTTOM: BLACK 1PT SOLID">
	15,208,219
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	NOTE 6 &ndash; ACCOUNTS PAYABLE AND ACCRUED
	EXPENSES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	During the year ended September 30, 2016, the Company
	realized a gain of $710,264 related to the settlement of an accounts payable balance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	NOTE 7 &ndash;NOTES PAYABLE
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	On February 28, 2016, the Company entered into a premium financing arrangement
	for its directors&rsquo; and officers&rsquo; insurance policy in the amount of $215,810. The financing arrangement bears interest
	at 7.0% per annum and will be fully paid in ten months from the date of issuance. As of September 30, 2016, the Company had repaid
	$128,012 of principal and had paid interest of $5,664.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 64; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	62
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage65"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	On February 28, 2015, the Company entered into a premium financing arrangement
	for its directors and officers insurance in the amount of $212,400. The financing arrangement bears interest at 6.75% and will
	be fully paid in nine months from the date of issuance. As of September 30, 2016, the Company had repaid $212,400 of principal
	and had paid interest of $5,950.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	NOTE 8 &ndash; EQUITY
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The Company intends to retain cash in order to
	continue to invest in the development and marketing of the business. Therefore, it does not expect to pay any cash dividends in
	the foreseeable future.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	During fiscal 2016, 2015, and 2014, the Company
	issued 1,745,087, 5,077,119 and 5,512,649 shares, respectively, of common stock primarily due to stock option exercises, issuance
	of restricted stock awards for services, acquisition of assets, settlement of accounts payable and capital raised from sale of
	common stock. Refer to Note 9 for further detail on issuances related to common stock warrants and options.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT/107% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	On October 2, 2013, the Company issued 6,282 shares of common
	stock to a legal firm to settle $50,000 in accounts payable. These shares were valued at $7.96 which was the price of the stock
	at the close of business on the previous trading day.
</P>
<P STYLE="FONT: 10PT/107% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/107% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	On November 13, 2013, two holders of its Series B preferred
	shares converted an aggregate of 500,000 preferred shares into 166,667 common shares.
</P>
<P STYLE="FONT: 10PT/107% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/107% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	On April 28, 2014, the Company received subscription notices
	to purchase 1,800,000 shares of common stock with a price of $10.00 less issuance costs. Accordingly, the Company issued 1,800,000
	common shares and received net proceeds of approximately $16.9 million.
</P>
<P STYLE="FONT: 10PT/107% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/107% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	On May 30, 2014, the Company issued 1,194,862 common shares
	to acquire certain assets of SKS pursuant to a contribution agreement (see Note 3). The shares were valued at $8.52 per share for
	a fair value of $10,180,224.
</P>
<P STYLE="FONT: 10PT/107% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/107% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	On December 23, 2014, the Company issued 5,952 common shares
	as settlement of accounts payable in the amount of $50,000.
</P>
<P STYLE="FONT: 10PT/107% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT/107% TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT">
	On February 11, 2015, the Company issued 4,259,259 shares of
	common stock at a price of $6.75 per share. Accordingly, the Company received net proceeds of approximately $26,582,998 which were
	net of stock issuance costs amounting to $2,167,000.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	On December 11, 2015, the Board approved the achievement
	of Milestone 1 in connection with the SKS ophthalmology assets acquisition by the Company. As a result, the Company issued 497,859
	shares of its common stock to SKS. The value of the stock issued was $2,061,136 as determined by the $4.14 per share closing sale
	price of the Company&rsquo;s common stock on the date of Board approval. On July 12, 2016, the Board approved the achievement of
	Milestone 2, and as result, the Company issued an additional 497,859 shares of its common stock to SKS. The value of the stock
	issued was $1,364,134 as determined by the $2.74 per share closing sale price of the Company&rsquo;s stock on the date of Board
	approval.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	NOTE 9 &ndash; STOCK BASED COMPENSATION
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	The Company&rsquo;s Consolidated
	2016 Stock Plan (the &ldquo;Plan&rdquo;) provides for granting stock options and restricted stock awards to employees, directors
	and consultants of the Company. A total of 5,833,334 shares have been authorized for issuance under the Plan. At September 30,
	2016, the Company had 2,649,475 shares available for future grant. Upon share option exercise or issuance of restricted stock,
	the Company issues new shares to fulfill these grants
</FONT>
	.
<FONT STYLE="FONT-SIZE: 10PT">
	The Company previously maintained a
	2014 Stock Incentive Plan and the 2009 Stock Incentive Plan. The 2016 Plan consolidated the 2014 Plan and the 2009 Plan into a
	new plan.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<U>
	Common Stock Warrants
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	For all warrants included within permanent equity,
	the Company has determined the estimated value of the warrants granted to nonemployees in exchange for services and financing expenses
	using the Black-Scholes pricing model and the following assumptions: stock price at valuation, $7.85-$7.96; expected term of 2-5
	years, exercise price of $7.88-$7.96, a risk free interest rate of 0.38-1.72 percent, a dividend yield of 0 percent and volatility
	of 98-163 percent.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	On October 1, 2013, the Company issued a total
	of 100,000 warrants with a fair market value of $481,724 for services rendered to the Company. The warrants vested immediately,
	have an exercise price of $7.96 per share and a term of 3 years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	On December 30, 2013, the Company issued a total
	of 26,667 warrants with a fair market value of $65,748 for services rendered to the Company. The warrants vested immediately, have
	an exercise price of $7.94 per share and a term of 2 years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	On January 2, 2014, the Company issued 20,550 warrants
	with a fair market value of $150,665 to a consultant for services rendered to the Company. The warrants vested immediately, have
	an exercise price of $7.88 per common share and a term of 5 years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	On January 7, 2014, the Company issued 100,000
	warrants with a fair market value of $390,852 to a consultant for services to be rendered to the Company. 25,000 warrants vested
	immediately, with the remainder vesting over the next three quarterly periods, have an exercise price of $7.94 per common share
	and a term of 3 years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	During the year ended September 30, 2015, an aggregate of 979,090 warrants
	at an exercise price per share of $1.65 through $3.60 were exercised by cashless exercise. In addition, 36,548 warrants were exercised
	at prices ranging from $1.50 through $2.85 for which $80,003 in cash was received by the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 65; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	63
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage66"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	During the year ended September 30, 2016,
	15,278 shares of common stock were issued in connection with the exercise of warrants to purchase the Company&rsquo;s common
	stock. The warrants were exercised at prices ranging from $1.50 through $1.95 per share for which $26,041 in cash was
	received by the Company. An additional 73,334 shares of common stock were also issued in connection with the exercise of
	warrants to purchase common stock. These warrants were exercised at a price of $1.62 per share and a receivable for $118,801
	was recorded as September 30, 2016 to account for cash proceeds not yet received at September 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Below is a table summarizing the warrants issued
	and outstanding as of September 30, 2016:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 80%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Number
</B>
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	&nbsp;Weighted-Average
</B>
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Outstanding
</B>
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	&nbsp;Exercise Price
</B>
</FONT>
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 48%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Outstanding at September 30, 2013
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	5,860,934
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 13%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2.78
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Granted
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	247,217
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	7.94
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Exercised
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(4,135,989
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	4.41
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Forfeited
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(25,154
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1.20
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Outstanding at September 30, 2014
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,947,008
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3.64
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Granted
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Exercised
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(1,015,638
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	3.03
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Forfeited
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(184,501
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2.39
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Outstanding at September 30, 2015
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	746,869
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	4.75
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Granted
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Exercised
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(88,612
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1.63
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Forfeited
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(43,334
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	6.55
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Outstanding at September 30, 2016
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	614,923
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	5.08
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Exercisable at September 30, 2016
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	614,923
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	5.08
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The outstanding warrants as of September 30, 2016
	have an intrinsic value of approximately $33,671. For the years ended September 30, 2016, 2015, and 2014, the Company has expensed
	$0, $8,559, and $1,177,095, respectively, related to the fair value of warrants issued for services.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<U>
	Stock Options
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Stock Options are granted for a term not exceeding
	five years and the nonvested options are generally forfeited in the event the employee, director or consultant terminates his or
	her employment or relationship with the Company. Any options that have vested at the time of termination are forfeited to the extent
	they are not exercised within the applicable post-employment exercise period provided in the option agreements. These options vest
	over one to five years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The following assumptions were used to calculate
	the fair value of the Company&rsquo;s options on the date of grant:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 90%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD COLSPAN="5" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Year Ended September 30,
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 40%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 16%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2016
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 16%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2015
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 16%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	2014
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Expected term
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	3 to 3.5 years
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	3 to 3.5 years
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	2.25 to 3.25 years
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Expected volatility
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	103% - 105%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	69% - 73%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	56% - 83%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Expected dividends
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	0%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	0%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	0%
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-SIZE: 10PT">
	Risk-free rates
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	1.04% - 1.22%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	1.02% - 1.10%
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
	0.30% - 1%
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 66; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	64
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage67"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	Below is a table summarizing the options issued
	and outstanding as of September 30, 2016 (&ldquo;Price&rdquo; reflects the weighted average exercise price per share):
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="22" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Year Ended September 30,
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2016
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2015
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="6" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	2014
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Options
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Price
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Options
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Price
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Options
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Price
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 28%; FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 0.125IN">
	Outstanding October 1
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,761,001
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	7.27
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,048,335
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	5.43
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,133,335
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2.31
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 0.25IN">
	Granted
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	669,275
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	4.11
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,106,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	9.04
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	915,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	9.29
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 0.25IN">
	Exercised
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN; PADDING-BOTTOM: 1PT">
	Forfeited or expired
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(572,808
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	6.61
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	(393,334
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2.54
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 0.125IN; PADDING-BOTTOM: 1PT">
	Outstanding September 30
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2,857,468
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	6.66
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2,761,001
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	7.27
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	2,048,335
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	5.43
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 0.125IN; PADDING-BOTTOM: 2.5PT">
	Exercisable September 30
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	1,833,712
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	6.49
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	1,450,667
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	5.74
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	1,103,750
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 2.5PT DOUBLE">
	3.53
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 0.25IN; TEXT-INDENT: -0.125IN">
	Weighted average fair value per option granted
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK MEDIUM DOUBLE">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK MEDIUM DOUBLE">
	2.68
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK MEDIUM DOUBLE">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK MEDIUM DOUBLE">
	4.77
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK MEDIUM DOUBLE">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK MEDIUM DOUBLE">
	4.08
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	As of September 30, 2016, the intrinsic value of
	both outstanding options and exercisable options was $373,334. There were no options exercised during the years ended September
	30, 2016, 2015, and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The Company recognized stock-based compensation
	expense from stock options of $2,913,626, $3,579,788, and $2,074,487 during the years ended September 30, 2016, 2015, and 2014,
	respectively. As of September 30, 2016, there was $2,517,203 of stock-based compensation cost related to unvested shares of stock
	options which had not yet been recognized. The Company expects to recognize this compensation cost over a weighted-average period
	of 1.1 years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<U>
	Restricted Stock
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The Company has granted restricted stock awards
	to its employees, directors and consultants under the 2016 Plan and related restricted stock agreements. The restricted stock-based
	compensation awards generally vest over a period ranging from zero to three years. These common shares are forfeited in the event
	the recipient&rsquo;s employment or relationship with the Company is terminated prior to the lapse of the restriction.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Below is a table summarizing nonvested restricted
	stock shares as of September 30, 2016, and changes during the year ended September 30, 2016:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 60%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	&nbsp;Shares
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Weighted
	Average Grant Date Fair Value
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Nonvested at September 30, 2013
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Granted
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Vested
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Forfeited
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Nonvested at September 30, 2014
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 30%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Granted
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	111,752
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 12%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	8.89
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Vested
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(49,072
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	7.91
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Forfeited
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Nonvested at September 30, 2015
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	62,680
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PT">
	9.66
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Granted
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	660,757
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	4.46
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Vested
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(123,079
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PT">
	5.45
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-SIZE: 10PT">
	Forfeited
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; PADDING-BOTTOM: 1PT; BORDER-BOTTOM: BLACK 1PT SOLID">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-SIZE: 10PT">
	Nonvested at September 30, 2016
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK MEDIUM DOUBLE">
	600,358
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; BORDER-BOTTOM: BLACK MEDIUM DOUBLE">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT; BORDER-BOTTOM: BLACK MEDIUM DOUBLE">
	4.80
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 67; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	65
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage68"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The Company recognized stock-based compensation
	expense from restricted stock awards of $1,754,814, $635,288, and $0 during the years ended September 30, 2016, 2015, and 2014,
	respectively. As of September 30, 2016, there was $1,289,333 of stock-based compensation cost related to unvested shares of restricted
	stock which had not yet been recognized. The Company expects to recognize this compensation cost over a weighted-average period
	of 1.27 years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	NOTE 10 &ndash; RELATED PARTY
	TRANSACTIONS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Our Contract Research Organization running our phase 3 trial has contracted with Jason S. Slakter, M.D., P.C., d/b/a Digital Angiography
	Reading Center (&ldquo;DARC&rdquo;), a well-known digital reading center, which is owned by Dr. Jason Slakter, Ohr's CEO, pursuant
	to our related party transactions policy, with the review and approval of the Audit Committee, to provide digital reading and imaging
	services in connection with the Phase 3 study. During the years ended September 30, 2016 and 2015, the Company has been invoiced
	$267,680 and $91,280, respectively, from DARC.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<B>
	NOTE 11 &ndash; COMMITMENTS AND
	CONTINGENCIES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<U>
	Legal Proceedings
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The Company may become involved in certain legal
	proceedings and claims which arise in the normal course of business. If an unfavorable ruling were to occur, there exists the possibility
	of a material adverse impact on the Company&rsquo;s results of operations, prospects, cash flows, financial position and brand.
	To the best knowledge of the Company&rsquo;s management, at September 30, 2016 and 2015, there are no legal proceedings which the
	Company believes will have a material adverse effect on its business, results of operations, cash flows or financial condition.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<U>
	Lease Obligation
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	The Company is currently obligated under
	an operating lease for office and laboratory space and associated building expenses. The lease expires in December 2017. As
	of September 30, 2016, future minimum payments for all lease obligations are as follows:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 70%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Year
</B>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Amount
</B>
</FONT>
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 46%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Fiscal 2017
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 18%; TEXT-ALIGN: RIGHT">
	283,524
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 10PT">
	Fiscal 2018
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	70,887
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	354,411
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0PT 0PT 0; TEXT-ALIGN: LEFT">
	Rental expense related to the operating
	lease has been recorded in the consolidated statements of operations in the amounts of $340,064, $305,638, and $83,556 for each
	of the years ended September 30, 2016, 2015, and 2014, respectively.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0PT 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<U>
	Contingent Stock Consideration
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0PT 0PT 0; TEXT-ALIGN: LEFT">
	On May 30, 2014, the Company
	completed the acquisition of certain assets of SKS Ocular, LLC (&ldquo;SKS Parent&rdquo;), and SKS Ocular 1, LLC (&ldquo;SKS
	1&rdquo; and SKS Parent referred to herein as &ldquo;SKS&rdquo;), including licenses, patents and contracts relating to a
	micro-fabrication polymer- based sustained delivery platforms related to ocular therapeutics and a dry age-related macular
	degeneration animal model, together with biomarkers to support such model.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0PT 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0PT 0PT 0; TEXT-ALIGN: LEFT">
	The purchase price consisted of: (a) Cash
	in the amount of $3,500,000; (b) 1,194,862 shares of the Company&rsquo;s common stock (valued at $10,180,224 based on the trading
	price on May 30, 2014 of the Company&rsquo;s common stock) and (c) an additional 1,493,577 shares (the &ldquo;contingent shares&rdquo;)
	that will be issued contingent to achievement of certain milestones. This contingent consideration has been recorded as a liability
	of the Company and is reviewed by management for probability and likelihood of the milestones being achieved at each reporting
	period. The liability is adjusted according to management&rsquo;s assessment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0PT 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0PT 0PT 0; TEXT-ALIGN: LEFT">
	On December 11, 2015 and July 12, 2016,
	the Board approved the achievement of Milestone 1 and Milestone 2, respectively. Consequently, the Company issued 995,718 shares
	of its common stock to SKS. Milestone 3 is contingent upon the approval of an Investigational New Drug Application (&ldquo;IND&rdquo;)
	within three years of the closing date of the SKS acquisition. We do not expect IND approval within this time frame and therefore,
	do not expect to achieve Milestone 3. As such, there is no related contingent stock consideration recorded in association with
	Milestone 3.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 68; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	66
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage69"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0PT 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<B>
	NOTE 12 &ndash; QUARTERLY FINANCIAL DATA
	(Unaudited)
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	First
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Second
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Third
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fourth
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; BORDER-BOTTOM: BLACK 1PT SOLID">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Total
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	2016
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Total revenue
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="WIDTH: 40%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Operating loss
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(3,592,148
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(6,596,035
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(7,598,627
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT ARIAL,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT ARIAL,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(6,809,243
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT ARIAL,SANS-SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 9%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(24,596,053
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(6,145,462
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(5,284,859
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(7,699,741
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT ARIAL,SANS-SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT ARIAL,SANS-SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(6,636,136
</TD>
<TD STYLE="FONT: 10PT ARIAL,SANS-SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(25,766,198
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Net loss per basic and diluted share
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(0.20
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(0.17
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(0.24
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(0.21
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(0.82
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	WEIGHTED AVERAGE&nbsp;NUMBER&nbsp;OF SHARES OUTSTANDING:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	BASIC AND DILUTED
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	30,472,493
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	31,344,424
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	31,501,540
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	32,016,707
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	31,349,223
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	2015
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Total revenue
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Operating loss
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(4,205,513
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(6,806,088
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(3,334,840
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(3,458,839
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(17,805,280
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Net loss
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(4,540,957
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(3,400,548
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(3,345,997
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(3,910,363
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(15,197,865
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	Net loss per basic and diluted share
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(0.18
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(0.12
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(0.11
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(0.13
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	(0.54
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	)
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-LEFT: 0.125IN; TEXT-INDENT: -0.125IN">
	WEIGHTED AVERAGE&nbsp;NUMBER&nbsp;OF SHARES OUTSTANDING:
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.25IN">
	BASIC AND DILUTED
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	25,259,154
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	27,713,410
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	30,323,206
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	30,331,309
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	28,404,405
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 69; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	67
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage70"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_SUBSEQUENT_EVENTS>
<A NAME="FIS_SUBSEQUENT_EVENTS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<B>
	NOTE 13 &ndash; SUBSEQUENT EVENTS
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	In October 2016, $118,801
	in cash proceeds were received related to the receivable recorded in connection with the 73,334 common shares issued for warrants
	exercised in July 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	On December 7, 2016, the
	Company entered into a securities purchase agreement (the &ldquo;Purchase Agreement&rdquo;) with various purchasers pursuant
	to which the Company issued and sold to the purchasers in a registered offering an aggregate of 3,885,000 shares of
	its common stock, together with Series A common stock purchase warrants (&ldquo;Series A Warrants&rdquo;) exercisable for up
	to an aggregate of 1,942,500 shares of common stock and Series B common stock purchase warrants (&ldquo;Series
	B Warrants&rdquo;) exercisable for up to an aggregate of 3,885,000 shares of common stock. The offering closed on December
	13, 2016 and the Company received net proceeds of approximately $6.9 million, after deducting placement agent fees and
	estimated offering expenses payable by the Company, but excluding the proceeds, if any, from the exercise of the Series A
	Warrants and Series B Warrants issued in the offering.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 24.5PT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	The Series A Warrant has
	an exercise price of $2.75 per share and the Series B Warrant has an exercise price of $3.00 per share. The Series A Warrants will
	be immediately exercisable and will expire on the five year anniversary of the date of issuance. The Series B Warrants will be
	immediately exercisable and will expire on the six month anniversary of the date of issuance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 70; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	68
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_SUBSEQUENT_EVENTS>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
</EFX_FINANCIAL_STATEMENTS>
</EFX_PART_II>
<A NAME="eolPage71"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<A NAME="OHRP-10K_093016_HTM_OHRPA012">
</A>
	Part III
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<A NAME="OHRP-10K_093016_HTM_OHRPA013">
</A>
	ITEM 9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
	AND FINANCIAL DISCLOSURE
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	NONE
</P>
</EFX_ACCOUNTING_CHANGES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
<A NAME="OHRP-10K_093016_HTM_OHRPA014">
</A>
	ITEM 9A&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CONTROLS AND PROCEDURES
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	Evaluation of Disclosure Controls and Procedures
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Our management, with the
	participation of our principal executive officer and principal financial officer, conducted an evaluation of the
	effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the
	Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;)) as of the end of the period covered by this Annual Report
	on Form 10-K. Based on this evaluation, our principal executive officer and principal financial officer each concluded that,
	as of the end of the period covered by this Annual Report on Form 10-K, our disclosure controls and procedures were effective
	in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is
	recorded, processed, summarized, and reported on a timely basis, and is accumulated and communicated to our management,
	including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding
	required disclosures.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Management Report on Internal Control over Financial Reporting
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	The report of
	management on our internal control over financial reporting as of September 30, 2016, and the attestation report of our
	independent registered accounting firm on our internal report on financial reporting are set forth in &ldquo;Part II.
	Financial Statements and Supplementary Data&rdquo; in this Annual Report on Form 10-K.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 71; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	69
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage72"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	Changes in Internal Control over Financial Reporting
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	There has been no change in our internal control
	over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended
	September 30, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial
	reporting.
</P>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A NAME="OHRP-10K_093016_HTM_OHRPA015">
</A>
	ITEM 9B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OTHER INFORMATION
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	None.
</P>
</EFX_OTHER_INFORMATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A NAME="OHRP-10K_093016_HTM_OHRPA016">
</A>
	ITEM 10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Following this table is a brief biographical description
	for each of Ohr&rsquo;s executive officers and directors, with a brief description of their business experience and present relationship
	to Ohr as of September 30, 2016, together with all required relevant disclosures for the past five years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_NAME_AND_TITLE>
<A NAME="FIS_NAME_AND_TITLE"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 29%; PADDING-RIGHT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Name
</B>
</P>
</TD>
<TD STYLE="WIDTH: 31%; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Position
</B>
</P>
</TD>
<TD STYLE="WIDTH: 40%; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Current Term of Office
</B>
</P>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT">
	Ira Greenstein
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Chairman
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Director since 2007
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT">
	Jason S. Slakter, M.D.
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Chief Executive Officer, President and Director
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Officer since 2014, Director since 2015
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT">
	Orin Hirschman
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Director
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Director since 2009
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT">
	Thomas Riedhammer
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Director
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Director since 2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT">
	June Almenoff
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Director
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Director since 2013
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT">
	Sam Backenroth
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	CFO and Vice President of Business Development
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Officer since 2010
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT">
	Avner Ingerman, M.D.
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Chief Clinical Officer
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; PADDING-RIGHT: 5.4PT; PADDING-LEFT: 5.4PT">
	Officer since 2015
</TD>
</TR>
</TABLE>
</EFX_NAME_AND_TITLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Ira Greenstein, age 56, has served as a Director
	of Ohr since March 2007. Mr. Greenstein has served as President of Genie Energy Ltd. since December 2011. Mr. Greenstein currently
	also serves as Counsel to the Chairman of IDT Corporation and General Counsel to various companies, including Ohr and Global Risk
	Advisors, LLC, an international strategic consulting firm providing clients with innovative security and risk mitigation strategies.
	Mr. Greenstein had served as the President of IDT from 2001 through 2011 and Counsel to the Chairman of IDT in 2000 and 2001. He
	has served as a Director of IDT and General Counsel and Secretary of IDT&rsquo;s subsidiary, Net2Phone, Inc. Prior to joining IDT,
	Mr. Greenstein was a partner in Morrison &amp; Foerster LLP, where he served as the Chairman of that firm&rsquo;s New York Office&rsquo;s
	Business Department. Mr. Greenstein was an associate in the New York and Toronto offices of Skadden, Arps, Slate, Meagher &amp;
	Flom LLP and served on the Securities Advisory Committee and as secondment counsel to the Ontario Securities Commission. Mr. Greenstein
	serves as Chairman of the Board of NanoVibronix, Inc. and on the Boards of Directors of Document Security Systems, Inc., Enerpulse
	Technologies, Inc. and Regal Bank of New Jersey. Mr. Greenstein received a B.S. from Cornell University and a J.D. from Columbia
	University Law School where he serves as a member of the Dean&rsquo;s Council.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 72; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	70
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage73"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Dr. Jason S. Slakter, age 58, joined Ohr as Chief
	Medical Officer in May 2014 and was appointed Director in January 2015. He was appointed Chief Executive Office in September 2015.
	He was previously Chief Executive Officer and co-founder of SKS Ocular LLC. He is also the Founder and Director of the Digital
	Angiography Reading Center (DARC) in New York, which is the largest center for ocular image evaluation for clinical trials of posterior
	segment disease with over 900 certified clinical sites in over 44 countries worldwide. Dr. Slakter has been involved extensively
	in the design and application of new diagnostic and treatment modalities for ophthalmic diseases. He has played a major role in
	the discovery, development and commercialization of treatments for age-related macular degeneration, diabetic retinopathy, retinal
	vascular disease, central serous chorioretinopathy and other retinal diseases. He has provided critical assistance in the design
	of clinical trials at all stages of development, and has participated in numerous meetings with the FDA. Dr. Slakter served as
	Chief Medical Officer for Potentia Pharmaceuticals from its inception through its acquisition by Alcon Laboratories, Inc. (Novartis).
	Dr. Slakter is a member of The American Ophthalmological Society, The Macula Society, The Retina Society, and The American Society
	of Retina Specialists, and was the founder and first Editor-in-Chief of Retinal Physician journal. He has been the recipient of
	many awards including The Macula Society&rsquo;s Richard and Hinda Rosenthal Award for outstanding contribution to the treatment
	of ocular disease by an individual under the age of 45, the 2003 Helen Keller Manhattan League Award, and Life Achievement Honor
	Award from the American Academy of Ophthalmology. Dr. Slakter is a Clinical Professor of Ophthalmology at New York University School
	of Medicine and has also practiced at the Vitreous-Retina-Macula Consultants of New York for over 28 years.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Orin Hirschman, age 47, has served as a Director
	of Ohr since March 2009. Mr. Hirschman has over 25 years of experience in money management, leveraged buyouts, restructuring and
	venture capital. Mr. Hirshman has been the manager of AIGH Investment Partners, LP since 2011. From 1994 until 2001 Mr. Hirschman
	served as a co-manager of two private investment funds, Adam Smith Investment Partnerships and Adam Smith Investment Partners,
	Ltd (the &ldquo;Adam Smith Funds&rdquo;). In addition to Mr. Hirschman&rsquo;s private placement investments over the last thirteen
	years, the Adam Smith Funds, and AIGH Investment Partners, LP, his experience in the securities industry includes tenures with
	Wesray Capital, the investment firm founded by former U.S. Secretary of the Treasury William E. Simon, and Randall Rose &amp; Company,
	a $100 million money management firm based in New York. Mr. Hirschman has been actively involved in the financing and structuring
	of over 70 companies, including many high technology companies. Mr. Hirschman has served as a Director of Novint Technologies Inc.
	since August 2013. Mr. Hirschman&rsquo;s educational background includes an M.B.A. in Finance from New York University Graduate
	School of Business and a degree in Biology and Finance from Touro College where he graduated Summa Cum Laude.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 73; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	71
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage74"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Dr. Thomas M.
	Riedhammer, age 68, has been a Director of Ohr since April 2013, and has been a Director of DepYmed, a joint venture of Ohr,
	since 2014. He most recently served as Chairman of Sirion Therapeutics Inc, a position he held from 2007 to 2013. Prior to that,
	Dr. Riedhammer served as Chief Operating Officer of Presby Corp., a medical device company engaged in the research and
	development of treatments for eye disorders. Prior to Presby Corp., Dr. Riedhammer served as President and Senior Vice
	President of Worldwide Pharmaceuticals at Bausch and Lomb from 1994 to 2000. He also held various other positions at Bausch
	and Lomb including: Senior Vice President, and Chief Technical Officer from 1998 to 2000, Senior Vice President and President
	for Worldwide Pharmaceutical, Surgical, and Hearing Care Products from 1994 to 1998, and Vice President from 1993 to 1994. He
	was a corporate Vice President of Paco Pharmaceuticals and President of Paco Research Corp from 1984 to 1991. Dr. Riedhammer
	began his career at Bausch &amp; Lomb as a Research Chemist and was its Director, Lens Care Products R&amp;D. He has served
	as Chairman and Director of Prevent Blindness Florida, Director of Prevent Blindness America, Sjogren&rsquo;s Syndrome
	Foundation as secretary and Junior Achievement International. Dr. Riedhammer holds a B.A. in Chemistry and a Ph.D. in
	Electrochemistry from State University of New York at Buffalo.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Dr. June S. Almenoff,
	age 59, has been a Director of Ohr since May 2013. Dr. Almenoff is currently an independent biopharma consultant and Board Director. She is the Executive Chair of RDD Pharma
	and an independent Board Director of Tigenix NV (Nasdaq: TIG). She also serves on the investment advisory board of the Harrington
	Discovery Institute (University Hospitals, Cleveland), the advisory board of Redhill Biopharma (Nasdaq: RDHL) and of several
	private companies. Recently, Dr. Almenoff served as President, Principal Executive Officer and Chief Medical Officer at
	Furiex Pharmaceuticals (Nasdaq). During her four year tenure, the company&rsquo;s valuation increased approximately 10x
	culminating in its acquisition by Forest Labs/Actavis for approximately $1.2B in 2014. Furiex&rsquo;s lead product, eluxadoline, a novel
	gastrointestinal drug, received FDA approval in 2015. Prior to joining Furiex, Dr. Almenoff was at GlaxoSmithKline for 12
	years, where she held positions of increasing responsibility, including Vice President of the clinical safety organization.
	She served on the GSK&rsquo;s senior governing medical boards, managed a diverse therapeutic portfolio supporting numerous
	regulatory approvals, and chaired a Pharma-FDA working group. She led the development of several pioneering systems for
	minimizing risk in early- and late-stage drug development; these have been widely implemented by pharmaceutical companies
	and regulatory agencies and were recognized with numerous awards including the Wall Street Journal Technology Innovation
	Award. Dr. Almenoff also worked in GSK&rsquo;s Scientific Licensing group. Dr. Almenoff received her B.A. cum laude from Smith College and graduated with AOA honors from the M.D.-Ph.D. program at the
	Icahn (Mt. Sinai) School of Medicine. She completed post-graduate medical training at Stanford University Medical Center and
	served on the faculty of Duke University School of Medicine. She is an adjunct Professor at Duke and a Fellow of the American
	College of Physicians.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Sam Backenroth, age 32, has served as Chief Financial
	Officer and Vice President of Business Development since April 2010, and has been a Director of DepYmed, a joint venture of Ohr,
	since 2014. Mr. Backenroth has previously worked as an investment banker
	with The Benchmark Company LLC, an investment banking firm specializing in micro-cap biotech transactions. While at Benchmark,
	he helped fund numerous small biotech companies raise in excess of $75 million of growth equity capital through a variety of structures.
	Mr. Backenroth also acted as an advisor to multiple public and private biotech companies in assisting with business development
	activities, joint ventures, licensing, strategic partnerships, and mergers &amp; acquisitions. He graduated with honors from Touro
	College with a Bachelors degree in finance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 74; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	72
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage75"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Dr. Avner Ingerman, age 53, has served as our Chief
	Clinical Officer since February 2015. Dr. Ingerman is an ophthalmologist, with more than 15 years of pharmaceutical industry product
	development. He served as vice president of ophthalmology at Regeneron Pharmaceuticals, responsible for the Eylea&reg; development
	program, and previously served as the clinical leader of the Lastacaft&reg; development program at Johnson and Johnson. Dr. Ingerman
	has additionally served as an ophthalmology development consultant to numerous companies. Dr. Ingerman received his MD degree from
	the Tel-Aviv University Sackler School of Medicine. He completed his ophthalmology residency at the Rabin Medical Center in Israel.
	He was the R&amp;D director of Johnson &amp; Johnson in Israel and the UK, and the clinical leader of Alcaftadine (Lastacaft&reg;)
	development. He later became the Vice President of Ophthalmology at Regeneron Pharmaceuticals, responsible for the Aflibercept
	(Eylea&reg;) development program, conducted in collaboration with Bayer Healthcare.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Family Relationships
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	No family relationships exist between any of the
	executive officers and directors (or nominees for director) of the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Section 16(a) Beneficial Ownership Reporting Compliance
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Section 16(a) of the Exchange Act requires our directors
	and executive officers and persons who own more than 10% of the issued and outstanding shares of our common stock to file reports
	of initial ownership of common stock and other equity securities and subsequent changes in that ownership with the SEC. To our
	knowledge, during the fiscal year ended September 30, 2016, all Section 16(a) filing requirements applicable to our officers, directors
	and greater than 10% beneficial owners were complied with.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Code of Ethics
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	We have adopted a Code of Business Conduct and Ethics
	(&ldquo;Code of Ethics&rdquo;) that applies to all of our directors and employees, including our Chief Executive Officer, Chief
	Financial Officer and other officers. Our Code of Ethics includes provisions covering conflicts of interest, the reporting of illegal
	or unethical behavior, business gifts and entertainment, compliance with laws and regulations, insider trading practices, antitrust
	laws, bribes or kickbacks, corporate record keeping, and corporate accounting and disclosure. The Code of Ethics is available at
	the Investor Relations section of our website at www.ohrpharmaceutical.com. Our Code of Ethics may also be obtained without charge
	upon written request to Ohr Pharmaceutical, Inc. 800 3rd Avenue, 11th Floor, New York, NY 110022, Attention: Investor Relations.
	We intend to disclose future amendments to certain provisions of the Code, or waivers of such provisions granted to executive officers
	and directors, on the website within four business days following the date of such amendment or waiver.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 75; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	73
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage76"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Change in Procedures for Recommending Directors
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	There have been no material changes to the procedures
	by which our stockholders may recommend nominees to our Board from those procedures set forth in our Proxy Statement for our 2016
	Annual Meeting of Stockholders, filed with the SEC on January 29, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Audit Committee
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	The Audit Committee&rsquo;s function is to evaluate
	the adequacy of the Company&rsquo;s internal accounting controls, review the scope of the audit by MaloneBailey, LLP and related
	matters pertaining to the examination of the financial statements, review the year-end and the quarterly financial statements,
	review the nature and extent of any non-audit services provided by the Company&rsquo;s independent accountants and make recommendations
	to the Board of Directors with respect to the foregoing matters as well as with respect to the appointment of the Company&rsquo;s
	independent accountants. The Audit Committee had four meetings in fiscal 2015, and each member attended all meetings. The members
	of the Audit Committee are independent with the meaning of the rules of the Nasdaq Stock Market and applicable rules and regulations
	of the Securities and Exchange Commission. Members of the Audit Committee are Thomas Riedhammer (Chairman), June Almenoff and Orin
	Hirschman. The Board of Directors has determined that Thomas Riedhammer is a financial expert.
</P>
</EFX_DIRECTORS_AND_OFFICERS>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 1IN; TEXT-ALIGN: LEFT">
<A NAME="OHRP-10K_093016_HTM_OHRPA017">
</A>
	ITEM 11
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
	EXECUTIVE COMPENSATION
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Executive Compensation
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The table below provides information on the compensation
	we paid to the named executive officers in fiscal 2016, 2015 and 2014.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_COMPENSATION_TABLE>
<A NAME="FIS_COMPENSATION_TABLE"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Summary Compensation Table&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="14" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Annual Compensation
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="14" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
<B>
	Long-Term Compensation
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Change in
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Pension Value
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	and Non-
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Qualified
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Name and
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Non- Equity
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Deferred
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Principal
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Stock
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Option
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Incentive Plan
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	Compensation
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	All Other
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Position
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Year
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Salary
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Bonus(2)
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Awards
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Awards(3)
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Compensation
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Earnings
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Compensation (4)
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-SIZE: 8PT">
	Total
</FONT>
</TD>
<TD NOWRAP STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; WIDTH: 28%">
<FONT STYLE="FONT-SIZE: 8PT">
	Jason Slakter
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 4%; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	2016
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 5%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	200,000
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="WIDTH: 5%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	175,000
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 5%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,583,618
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 5%; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 5%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 5%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 7%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	195
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 5%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,958,813
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 17.3PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Chief Executive Officer
	(1)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	2015
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	200,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	163,333
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	247,289
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	610,622
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	2014
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	38,462
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	38,462
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Sam Backenroth
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	2016
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	200,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	107,500
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	587,600
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	16,620
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	911,720
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 17.3PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Chief Financial Officer
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	2015
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	200,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	150,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	296,746
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	17,877
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	664,623
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	2014
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	177,704
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	977,192
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	21,530
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,176,426
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	Avner Ingerman
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	2016
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	244,615
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	120,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	16,620
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	381,235&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -8.65PT; PADDING-LEFT: 17.3PT">
<FONT STYLE="FONT-SIZE: 8PT">
	Chief Clinical Officer
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	2015
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	132,692
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	50,000
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 8PT">
	$&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	586,800
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,128,604
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	12,381
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	1,910,477
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-SIZE: 8PT">
	2014
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-SIZE: 8PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-SIZE: 8PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_COMPENSATION_TABLE>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 76; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	74
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage77"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
</P>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	(1)
</TD>
<TD>
	Dr. Slakter became Chief Executive Officer of the Company on August 7, 2015. Salary for Dr. Slakter includes salary, bonus,
	and consulting fees for fiscal years 2016, 2015 and 2014.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	(2)
</TD>
<TD>
	Cash bonuses for 2014 and 2015 were paid in January of 2015 and 2016, respectively.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN">
	(3)
</TD>
<TD>
	The amounts in this column reflect the aggregate grant date fair value of equity awards granted during the applicable
	fiscal year, calculated in accordance with FASB ASC Topic 718 and using a Black-Scholes valuation model. Assumptions used in
	the calculation of these amounts are included in Note 9 of the audited financial statements included elsewhere in this Annual
	Report on Form 10-K.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(4)
</TD>
<TD>
	Consists of the following for each named executive officer:
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Name
</B>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Year
</B>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	401(k)
<BR>
	Company
</B>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Group
<BR>
	Term
</B>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Health
<BR>
	Benefits
</B>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Paid
<BR>
	Time
<BR>
	Off
<BR>
	buy
<BR>
	Back
</B>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Total Other
<BR>
	Compensation
</B>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	Jason Slakter
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2016
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;&mdash;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	195
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;&mdash;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;&mdash;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	195
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 20PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	Chief Executive Officer
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2014
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 32%; PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	Sam Backenroth
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2016
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	195&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	16,425
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="WIDTH: 8%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	16,620
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 20PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	Chief Financial Officer
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	17,877
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	17,877
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2014
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	21,530
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	21,530
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	Avner Ingerman
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2016
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;&mdash;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	195&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	16,425
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	&nbsp;&mdash;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	16,620
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 20PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	Chief Clinical Officer
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2015
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	12,381
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	12,381
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2014
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Pension Benefit
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Company has established a 401(k) plan but does
	not make contributions to it. The Company provides no other pension benefits.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Option Exercises
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	There were no options exercised by named executive
	officers in the fiscal year ended September 30, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 77; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	75
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage78"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_OPTIONS>
<A NAME="FIS_OPTIONS"></A>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	Grants of Plan-Based Stock and Option
	Awards 2016
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The following table sets forth information concerning
	all grants of stock options, restricted stock and other equity awards made to the named executive officers for service during the
	year ended September 30, 2016:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Name
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Grant Date
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	All other
<BR>
	stock
<BR>
	awards:
<BR>
	Number of
<BR>
	shares of
<BR>
	stock or
<BR>
	units
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	All other
<BR>
	option
<BR>
	awards:
<BR>
	Number of
<BR>
	securities
<BR>
	underlying
<BR>
	options
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Exercise
<BR>
	Price(1)
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="2" STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Grant Date
<BR>
	Fair Value of
<BR>
	Stock and
<BR>
	Option
<BR>
	Awards(2)
</TD>
<TD STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT; PADDING-LEFT: 4.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 27%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -4.4PT; PADDING-LEFT: 4.4PT">
	Jason Slakter
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1/9/2016&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	350,358
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,583,618
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -4.4PT; PADDING-LEFT: 20PT">
	Chief Executive Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT; PADDING-LEFT: 4.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -4.4PT; PADDING-LEFT: 4.4PT">
	Sam Backenroth
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1/9/2016
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	130,000
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	587,600
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -4.4PT; PADDING-LEFT: 20PT">
	Chief Financial Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; TEXT-INDENT: -4.4PT; PADDING-LEFT: 4.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -4.4PT; PADDING-LEFT: 4.4PT">
	Avner Ingerman
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&mdash;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT; TEXT-INDENT: -4.4PT; PADDING-LEFT: 20PT">
	Chief Clinical Officer
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_OPTIONS>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(1)
</TD>
<TD>
	The exercise price reflects the closing market price of our common stock on the day of the grant.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(2)
</TD>
<TD>
	The grant date fair value of the stock and option awards is calculated in accordance with FASB ASC Topic 718 and using a Black-Scholes
	valuation model. Assumptions used in the calculation of these amounts are included in Note 9 of the audited financial statements
	included elsewhere in this Annual Report on Form 10-K.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	Employment Agreements
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<B>
	Dr. Jason Slakter
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	On August 5, 2015, the Company&rsquo;s Board of
	Directors authorized the restructuring of certain management positions, all of which became effective as of August 7, 2015. Jason
	S. Slakter, MD was appointed Chief Executive Officer of the Company succeeding Dr. Taraporewala. Dr. Slakter remained a director
	of the Company. Dr. Taraporewala was appointed Chief Technology Officer of the Company and remained President and a director of
	the Company. The employment of Dr. Taraporewala was terminated in December 2015 and he no longer holds any position in the Company.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 78; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	76
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage79"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	The Company anticipates entering into an employment
	agreement with Dr. Slakter. Until such time, Dr. Slakter will be paid $8,333.33 bi-monthly and will be eligible for equity grants
	under stockholder approved equity compensation plans.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
	Sam Backenroth
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	On January 6, 2015, the Company amended its employment
	agreement with Sam Backenroth, Chief Financial Officer and Vice President, Business Development, to extend the term to February
	28, 2016, and to provide for automatic one year extensions thereafter absent notice of termination. The employment agreement provides
	for an annual base salary of $200,000 for Mr. Backenroth.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
	Avner Ingerman
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	On February 26, 2015, the Company entered into an
	employment agreement with Dr. Ingerman, Chief Clinical Officer of the Company. The initial term of the Employment Agreement is
	until December 31, 2017, subject to automatic renewal for successive one year periods unless either party delivers written notice
	of non-renewal. Dr. Ingerman will receive (i) a base annual salary of $230,000 during the period from the hire date until December
	31, 2015, $250,000 during the 2016 calendar year, and $275,000 during the 2017 calendar year; (ii) a $50,000 sign-on bonus; (iii)
	five-year options for 200,000 shares of common stock, which will vest over the initial term; (iv) 60,000 shares of restricted stock
	which will vest over the initial term; and (v) will be eligible to receive a performance bonus of $120,000 for calendar 2015, plus,
	at the discretion of the Company&rsquo;s Compensation Committee, an additional bonus in the range of $50,000 to $100,000, and,
	at the end of each of calendar 2016 and 2017, and any subsequent renewal period, a bonus to be awarded at the discretion of the
	Compensation Committee, expected to be in the range of $100,000 to $300,000. Dr. Ingerman will also receive standard employee benefits
	during the term of his employment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	The Company&rsquo;s Board of Directors reviews the
	executives&rsquo; salaries on an annual basis. Each executive may also receive an annual bonus at the discretion of the Board,
	in accordance with any bonus plan adopted by the Board, and will participate in the Company&rsquo;s employee benefit programs,
	stock based incentive compensation plans and other benefits. See &ldquo;Compensation Committee Report&rdquo; and &ldquo;Compensation
	Discussion and Analysis.&rdquo; See &ldquo;Annual Incentive Compensation&rdquo; below concerning discretionary bonuses for fiscal
	2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Change in Control Benefits
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Change in control benefits are intended to diminish
	the distraction that executives would face by virtue of the personal uncertainties created by a pending or threatened change in
	control and to assure that the Company will continue to have the executive&rsquo;s full attention and services at all time. Our
	change in control benefits are designed to be competitive with similar benefits available at companies with which we compete for
	executives&rsquo; talent. These benefits, as one element of our total compensation program, help the Company attract, retain and
	motivate highly talented executives.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 79; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	77
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage80"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
	Sam Backenroth
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Mr. Backenroth is entitled to (1) severance pay
	and benefits if his employment is terminated, whether at the end of the term of his employment agreement or termination without
	cause, equal to 50% of his base salary at the time of termination, or (2) alternatively, in the event of a change in control of
	the Company, upon (i) his termination without cause, (ii) expiration of the term of his employment agreement, or (iii) as a result
	of a constructive termination (that is, his resignation because he has reasonably determined in good faith that his titles, authorities,
	responsibilities, salary, bonus opportunities or benefits have been materially diminished, that a material adverse change in his
	working conditions has occurred, that his services are no longer required in light of the Company&rsquo;s business plan, or the
	Company has breached his employment agreement) which occurs: (x) concurrently with the change in control, or (y) within 12 months
	of the change in control, he will be entitled to receive (A) severance pay in an amount equal to $400,000, (B) the value of any
	accrued but unused vacation time, (C) the amount of all accrued but previously unpaid base salary through the date of termination,
	and (D) all of his then current employment benefits for the longer of twelve (12) months or the full un-expired term of his employment
	agreement. Mr. Backenroth has the right, for a period of 30 days following termination of his employment to exercise his Company
	options to the extent such options are otherwise vested and exercisable as of the date of termination.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-STYLE: NORMAL">
<B>
	Avner
	Ingerman
</B>
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-STYLE: NORMAL">
	Dr. Ingerman
	is entitled to (1) severance pay and benefits if his employment is terminated, whether at the end of the term of his employment
	agreement or termination without cause, equal to 50% of his base salary at the time of termination, or (2) alternatively, in the
	event of a change in control of the Company, upon (i) his termination without cause, or (iii) as a result of a constructive termination
	(that is, his resignation because he has reasonably determined in good faith that his titles, authorities, responsibilities, salary,
	bonus opportunities or benefits have been materially diminished, that a material adverse change in his working conditions has occurred,
	that his services are no longer required in light of the Company&rsquo;s business plan, or the Company has materially breached
	his employment agreement) which occurs: (x) concurrently with the change in control, or (y) within 12 months of the change in control,
	he will be entitled to receive (A) severance pay in an amount equal to $350,000, (B) the value of any accrued but unused vacation
	time, (C) the amount of all accrued but previously unpaid base salary through the date of termination, and (D) all of his then
	current employment benefits for the longer of twelve (12) months or the full un-expired term of his employment agreement. Dr. Ingerman
	has the right, for a period of 30 days following termination of his employment to exercise his Company options to the extent such
	options are otherwise vested and exercisable as of the date of termination
</FONT>
	.
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	Equity compensation plans and other benefit plans
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-WEIGHT: NORMAL">
<I>
<U>
	Ohr Pharmaceutical,
	Inc. 2016 Consolidated Stock Incentive Plan
</U>
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
<I>
	General Information
</I>
</B>
	. The Board of
	Directors adopted the Ohr Pharmaceutical, Inc. 2016 Consolidated Stock Incentive Plan (the &ldquo;2016 Plan&rdquo;) on January
	7, 2016 and the shareholders approved the plan on March 17, 2016 to assist the Company in recruiting and retaining individuals
	with ability and initiative by enabling them to receive awards and participate in the future success of the Company by associating
	their interests with those of the Company and its stockholders. The 2016 Plan is intended to permit the grant of stock options
	(both incentive stock options (&ldquo;ISOs&rdquo;) and non-qualified stock options (&ldquo;NQSOs&rdquo;)), stock appreciation rights
	(&ldquo;SARs&rdquo;), restricted stock (&ldquo;Restricted Stock Awards&rdquo;), restricted stock units (&ldquo;RSUs&rdquo;) and
	other incentive awards (&ldquo;Incentive Awards&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 80; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	78
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage81"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
<I>
	Prior Plans
</I>
</B>
	. We
	previously maintained each of the Ohr Pharmaceutical, Inc. 2014 Stock Incentive Plan (the &ldquo;2014 Plan&rdquo;) and the
	Ohr Pharmaceutical, Inc. 2009 Stock Incentive Plan (the &ldquo;2009 Plan&rdquo;). The 2016 Plan is intended to consolidate the 2014 Plan
	and the 2009 Plan into a new plan, with an aggregate number of shares available for issuance under the 2016 Plan as set forth
	below under &ldquo;- Shares Subject to Plan.&rdquo; For Options and Restricted Stock Awards granted under the 2014 Plan and
	the 2009 Plan prior to January 7, 2016, the terms and conditions of the 2014 Plan and the 2009 Plan and the applicable award
	agreements will control, except that the our Compensation Committee (the &ldquo;Committee&rdquo;), in its discretion may
	allow a participant to pay all or part of the option price (i) by surrendering shares of common stock to the Company that the
	participant already owns and, if necessary to avoid adverse accounting consequences, has held for at least six months; (ii)
	by a cashless exercise through a broker; (iii) by means of a &ldquo;net exercise&rdquo; procedure, (iv) by such other medium
	of payment as the Committee in its discretion shall authorize or (v) by any combination of the aforementioned methods of
	payment. If shares of common stock are used to pay all or part of the Option price, the sum of the cash and cash equivalent
	and the fair market value (determined as of the day preceding the date of exercise) of the shares surrendered shall equal the
	Option price of the shares for which the Option is being exercised.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
<I>
	Written Agreements
</I>
</B>
	. All awards granted
	under the 2016 Plan will be governed by separate written agreements between the Company and the participants. The written agreements
	will specify when the award may become vested, exercisable or payable, as well as other terms and conditions that may apply to
	the award. No right or interest of a participant in any award will be subject to any lien, obligation or liability of the participant.
	The laws of the State of Delaware govern the 2016 Plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	No awards may be granted after January 7, 2026, the date which is 10 years after the adoption of
	the 2016 Plan by the Board.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
<I>
	Tax Treatment
</I>
</B>
	. It is intended that
	awards granted under the 2016 Plan shall be exempt from treatment as &ldquo;deferred compensation&rdquo; subject to Section 409A
	of the Internal Revenue Code of 1986 (and any amendments thereto) (the &ldquo;Code&rdquo;).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
<I>
	Administration
</I>
</B>
	. The Company bears
	all expenses of administering the 2016 Plan. The Committee administers the 2016 Plan. The Committee has the authority to grant
	awards to such persons and upon such terms and conditions (not inconsistent with the provisions of the 2016 Plan), as it may consider
	appropriate. The Committee may delegate to one or more officers of the Company all or part of its authority and duties with respect
	to awards to individuals who are not subject to Section 16 of the Exchange Act.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 81; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	79
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage82"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
<I>
	Eligibility for Participation
</I>
</B>
	. Any
	of the Company&rsquo;s employees or service providers, including any employees or service providers of our Affiliates (as defined
	in the 2016 Plan), and any non-employee member of our Board of Directors or the boards of directors of our Affiliates, is eligible
	to receive an award under the 2016 Plan. However, ISOs may only be granted to employees of the Company or an Affiliate.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
<I>
	Shares Subject to Plan
</I>
</B>
	. The
	maximum number of shares of Common Stock that may be issued under the life of the 2016 Plan pursuant to awards will be (a)
	5,833,334 shares minus (b) the number of shares of Common Stock that previously have been issued pursuant to the exercise of
	options under the 2009 Plan or 2014 Plan or the number of shares of restricted stock granted under the 2014 Plan and the
	2009 Plan that, as of December 14, 2016 are no longer subject to a substantial risk of forfeiture. One hundred percent (100%)
	of such shares may be issued pursuant to Options (including Incentive Stock Options), SARs, Restricted Stock Awards,
	Restricted Stock Units or Incentive Awards or any combination of Awards. Of the 5,833,334 shares, 333,334 previously were
	authorized under the 2009 Plan and 2,750,000 previously were authorized under the 2014 Plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Shares of Common Stock covered by an Award shall
	only be counted as issued to the extent they are actually issued. A share of Common Stock issued in connection with any Award under
	the 2016 Plan shall reduce the total number of shares of Common Stock available for issuance under the 2016 Plan by one; provided,
	however, that a share of Common Stock covered under a stock-settled SAR shall reduce the total number of shares of Common Stock
	available for issuance under the 2016 Plan by one even though the shares of Common Stock are not actually issued in connection
	with settlement of the SAR. Except as otherwise provided in the 2016 Plan, any shares of Common Stock related to an Award which
	terminates by expiration, forfeiture, cancellation or otherwise without issuance of shares of Common Stock, which is settled in
	cash in lieu of Common Stock or which is exchanged, with the Committee&rsquo;s permission, prior to the issuance of shares of Common
	Stock, for Awards not involving shares of Common Stock, shall again be available for issuance under the 2016 Plan. The following
	shares of Common Stock, however, may not again be made available for issuance as Awards under the 2016 Plan: (i) shares of Common
	Stock not issued or delivered as a result of a net settlement of an outstanding Award, (ii) shares of Common Stock tendered or
	held to pay the exercise price, purchase price or withholding taxes relating to an outstanding Award, or (iii) shares of Common
	Stock repurchased on the open market with the proceeds of the exercise price of an Award.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	In any calendar year, no participant may be granted
	options, SARs, Restricted Stock Awards, RSUs, or any combination thereof that relate to more than 500,000 shares of Common Stock.
	In any calendar year, no participant may be granted an Incentive Award (i) with reference to a specified dollar limit for more
	than $3,000,000 million and (ii) with reference to a specified number of shares of Common Stock for more than 500,000 shares of
	Common Stock. The maximum number of shares of Common Stock that may be issued pursuant to awards, the per individual limits on
	awards and the terms of outstanding awards will be adjusted as the Committee in its sole discretion determines is equitably required
	in the event of corporate transactions and other appropriate events.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 82; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	80
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage83"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
	Options
</B>
	. A stock option entitles the participant
	to purchase from the Company a stated number of shares of Common Stock. The Committee will determine whether the option is intended
	to be an ISO or a NQSO and specify the number of shares of Common Stock subject to the option. In the case of ISOs, the aggregate
	fair market value (determined as of the date of grant) of Common Stock with respect to which an ISO may become exercisable for
	the first time during any calendar year cannot exceed $100,000; and if this limitation is exceeded, the ISOs which cause the limitation
	to be exceeded will be treated as NQSOs. The exercise price per share of Common Stock may not be less than the fair market value
	of the Common Stock on the date the option is granted. With respect to an ISO granted to a participant who beneficially owns more
	than 10% of the combined voting power of the Company or any Affiliate (determined by applying certain attribution rules), the exercise
	price per share may not be less than 110% of the fair market value of the Common Stock on the date the option is granted. The exercise
	price may be paid in cash or, if the agreement so provides, the Committee may allow a participant to pay all or part of the exercise
	price by tendering shares of Common Stock the participant already owns, through a broker-assisted cashless exercise, by means of
	&ldquo;net exercise&rdquo; procedure, any other specified medium of payment or a combination.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
	Stock Appreciation Rights. (&ldquo;SARs&rdquo;)
</B>
	.
	A SAR entitles the participant to receive, upon exercise, the excess of the fair market value on that date of each share of Common
	Stock subject to the exercised portion of the SAR over the fair market value of each such share on the date of the grant of the
	SAR. A SAR can be granted alone or in tandem with an option. A SAR granted in tandem with an option is called a Corresponding SAR
	and entitles the participant to exercise the option or the SAR at which time the other tandem award expires. The Committee will
	specify the number of shares of Common Stock subject to a SAR and whether the SAR is a Corresponding SAR. No participant may be
	granted Corresponding SARs in tandem with ISOs which are first exercisable in any calendar year for shares of Common Stock having
	an aggregate fair market value (determined as of the date of grant) that exceeds $100,000; and if this limitation is exceeded the
	tandem option will be treated as NQSOs. A Corresponding SAR may be exercised only to the extent that the related option is exercisable
	and the fair market value of the Common Stock on the date of exercise exceeds the exercise price of the related option. As set
	forth in the agreement, the amount payable as a result of the exercise of a SAR may be settled in cash, shares of Common Stock
	or a combination of each.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
	Restricted Stock Awards
</B>
	. A Restricted Stock
	Award is the grant or sale of shares of Common Stock, which may be subject to forfeiture restrictions. The Committee will prescribe
	whether the Restricted Stock Award is forfeitable and the conditions to which it is subject. If the participant must pay for a
	Restricted Stock Award, payment for the award generally shall be made in cash or, if the agreement so provides, by surrendering
	shares of Common Stock the participant already owns or any other medium of payment. Prior to vesting or forfeiture, a participant
	will have all rights of a shareholder with respect to the shares underlying the Restricted Stock Award, including the right to
	receive dividends and vote the underlying shares; provided, however, the participant may not transfer the shares. The Company may
	retain custody of the certificates evidencing the shares until they are no longer forfeitable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
	RSUs
</B>
	. An RSU entitles the participant to
	receive shares of Common Stock when certain conditions are met. The Committee will prescribe when the RSUs shall become payable.
	The Company will pay the participant one share of Common Stock for each RSU that becomes earned and payable.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 83; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	81
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage84"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
	Incentive Awards
</B>
	. An Incentive Award entitles
	the participant to receive cash or Common Stock or a combination of each when certain conditions are met. The Committee will prescribe
	the terms and conditions of the Incentive Award. As set forth in the participant&rsquo;s agreement, an Incentive Award may be paid
	in cash, shares of Common Stock or a combination of each.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
	Performance Objectives
</B>
	. The Committee has
	discretion to establish objectively-determinable performance conditions for when awards will become vested, exercisable and payable.
	Objectively-determinable performance conditions are performance conditions (i) that are established in writing (a) at the time
	of grant (b) no later than the earlier of (x) 90 days after the beginning of the period of service to which they relate and (y)
	before the lapse of 25% of the period of service to which they relate; (ii) that are uncertain of achievement at the time they
	are established; and (iii) the achievement of which is determinable by a third party with knowledge of the relevant facts. These
	performance conditions may include any or any combination of the following: (a) gross, operating or net earnings before or after
	taxes; (b) return on equity; (c) return on capital; (d) return on sales; (e) return on investments; (f) return on assets or net
	assets; (g) earnings per share; (h) cash flow per share; (i) book value per share; (j) gross margin; (k) customers; (l) cash flow
	or cash flow from operations; (m) fair market value of the Company or any Affiliate or shares of Common Stock; (n) share price
	or total shareholder return; (o) market share; (p) level of expenses or other costs; (q) gross, operating or net revenue; (r) earnings
	before interest and taxes; (s) adjusted earnings before interest and taxes; (t) profitability; (u) earnings before interest, taxes,
	depreciation and amortization; (v) adjusted earnings before interest, taxes, depreciation and amortization; (w) adjusted earnings
	before interest, taxes, depreciation and amortization less capital expenditures; (x) research and development milestones; (y) business
	development objectives, partnerships and other collaborations; or (z) peer group comparisons of any of the aforementioned performance
	conditions. Performance conditions may be related to a specific customer or group of customers or geographic region. The form of
	the performance conditions also may be measured on a Company, Affiliate, division, business unit, service line, segment or geographic
	basis or a combination thereof. Performance goals may reflect absolute entity performance or a relative comparison of entity performance
	to the performance of a peer group of entities or other external measure of the selected performance conditions. Profits, earnings
	and revenues used for any performance condition measurement may exclude any extraordinary or nonrecurring items. The performance
	conditions may, but need not, be based upon an increase or positive result under the aforementioned performance criteria and could
	include, for example and not by way of limitation, maintaining the status quo or limiting the economic losses (measured, in each
	case, by reference to the specific business criteria). An award that is intended to become exercisable, vested or payable on the
	achievement of performance conditions means that the award will not become exercisable, vested or payable solely on mere continued
	employment or service. However, such an award, in addition to performance conditions, may be subject to continued employment or
	service by the participant. Additionally, the vesting, exercise or payment of an award can be conditioned on mere continued employment
	or service if it is not intended to qualify as qualified performance-based compensation under Section 162(m) of the Code.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 84; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	82
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage85"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
	Change in Control
</B>
	. In the event of or in
	anticipation of a &ldquo;Change in Control&rdquo; (as defined in the 2016 Plan), the Committee in its discretion may terminate
	outstanding awards (i) by giving the participants an opportunity to exercise the awards that are then exercisable and then terminating,
	without any payment, all awards that have not been exercised (including those that were not then exercisable) or (ii) by paying
	the participant the value of the awards that are then vested, exercisable or payable without payment for any awards that are not
	then vested, exercisable or payable or that have no value. Alternatively, the Committee may take such other action as the Committee
	determines to be reasonable under the circumstances to permit the participant to realize the vested value of the award. The Committee
	may provide that a participant&rsquo;s outstanding awards become fully exercisable or payable on and after a Change in Control
	or immediately before the date the awards will be terminated in connection with a Change in Control. Awards will not be terminated
	to the extent they are to be continued after the Change in Control.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
	Stockholder Rights
</B>
	. No participant shall
	have any rights as a shareholder of the Company until the award is settled by the issuance of Common Stock (other than a Restricted
	Stock Award or RSUs for which certain shareholder rights may be granted).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
	Transferability
</B>
	. An award is non-transferable
	except by will or the laws of descent and distribution, and during the lifetime of the participant to whom the award is granted,
	the award may only be exercised by, or payable to, the participant. The holder of the transferred award will be bound by the same
	terms and conditions that governed the award during the period that it was held by the participant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
	Maximum Award Period
</B>
	. No award shall be exercisable
	or become vested or payable more than ten years after the date of grant. An ISO granted to a participant who beneficially owns
	more than 10% of the combined voting power of the Company or any Affiliate (determined by applying certain attribution rules) or
	a Corresponding SAR that relates to such an ISO may not be exercisable more than five years after the date of grant.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
	Compliance With Applicable Law
</B>
	. No award
	shall be exercisable, vested or payable except in compliance with all applicable federal and state laws and regulations (including,
	without limitation, tax and securities laws), any listing agreement with any stock exchange to which the Company is a party, and
	the rules of all domestic stock exchanges on which the Company&rsquo;s shares may be listed.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
	Amendment and Termination of Plan
</B>
	. The Board
	of Directors may amend or terminate the 2016 Plan at any time; provided, however, that no amendment may adversely impair the rights
	of a participant with respect to outstanding awards without the participant&rsquo;s consent. An amendment will be contingent on
	approval of the Company&rsquo;s shareholders, to the extent required by law, by the rules of any stock exchange on which the Company&rsquo;s
	securities are then traded or if the amendment would (i) increase the benefits accruing to participants under the 2016 Plan, including
	without limitation, any amendment to the 2016 Plan or any agreement to permit a repricing or decrease in the exercise price of
	any outstanding options or SARs, (ii) increase the aggregate number of shares of Common Stock that may be issued under the 2016
	Plan, (iii) modify the requirements as to eligibility for participation in the 2016 Plan or (iv) change the stated performance
	conditions for qualified performance-based compensation under Section 162(m) of the Code. Additionally, to the extent the Board
	deems necessary for the 2016 Plan to continue to grant awards that are intended to comply with the performance-based exception
	to the deduction limits of Code Section 162(m), the Board will submit the material terms of the stated performance conditions to
	the Company&rsquo;s shareholders for approval no later than the first shareholder meeting that occurs in the fifth year following
	the year in which the shareholders previously approved the material terms of the performance goals.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 85; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	83
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage86"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Notwithstanding any other provision of the 2016
	Plan, the Committee may amend any outstanding award without participant&rsquo;s consent if, as determined by the Committee in its
	sole discretion, such amendment is required either to (i) confirm exemption from Section 409A of the Code, (ii) comply with Section
	409A of the Code or (iii) prevent the Participant from being subject to any tax or penalty under Section 409A of the Code.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<B>
	Forfeiture Provisions
</B>
	. Awards do not confer
	upon any individual any right to continue in the employ or service of the Company or any Affiliate. All rights to any award that
	a participant has will be immediately forfeited if the participant is discharged from employment or service for &ldquo;Cause&rdquo;
	(as defined in the 2016 Plan).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Material U.S. Federal Income Tax Consequences
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	The following discussion summarizes the material
	United States federal income tax consequences associated with awards granted under the 2016 Plan to U.S. citizens. The discussion
	is based on laws, regulations, rulings and court decisions currently in effect, all of which are subject to change.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<I>
	ISOs
</I>
	. A participant will not recognize taxable
	income on the grant or exercise of an ISO. A participant will recognize taxable income when he or she disposes of the shares of
	Common Stock acquired under the ISO. If the disposition occurs more than two years after the grant of the ISO and more than one
	year after its exercise (the &ldquo;ISO holding period&rdquo;), the participant will recognize long-term capital gain (or loss)
	to the extent the amount realized from the disposition exceeds (or is less than) the participant&rsquo;s tax basis in the shares
	of Common Stock. A participant&rsquo;s tax basis in shares of the Common Stock generally will be the amount the participant paid
	for the shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	If Common Stock acquired under an ISO is disposed
	of before the expiration of the ISO holding period described above, the participant will recognize as ordinary income in the year
	of the disposition the excess of the fair market value of the Common Stock on the date of exercise of the ISO over the exercise
	price. Any additional gain will be treated as long-term or short-term capital gain, depending on the length of time the participant
	held the shares. A special rule applies to such a disposition where the amount realized is less than the fair market value of the
	Common Stock on the date of exercise of the ISO. In that case, the ordinary income the participant will recognize will not exceed
	the excess of the amount realized on the disposition over the exercise price. If the amount realized is less than the exercise
	price, the participant will recognize a capital loss (long-term if the stock was held more than one year and short-term if held
	one year or less). A participant will receive different tax treatment if the exercise price is paid by delivery of Common Stock
	the participant already owns.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 86; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	84
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage87"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Neither the Company nor any of its Affiliates will
	be entitled to a federal income tax deduction with respect to the grant or exercise of an ISO. However, in the event a participant
	disposes of Common Stock acquired under an ISO before the expiration of the ISO holding period described above, the Company or
	its Affiliate will be entitled to a federal income tax deduction equal to the amount of ordinary income the participant recognizes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<I>
	NQSOs
</I>
	. A participant will not recognize any
	taxable income on the grant of a NQSO. On the exercise of a NQSO, the participant will recognize as ordinary income the excess
	of the fair market value of the Common Stock acquired over the exercise price. A participant&rsquo;s tax basis in the Common Stock
	is the amount paid plus any amounts included in income on exercise. The participant&rsquo;s holding period for the stock begins
	on acquisition of the shares. Any gain or loss that a participant realizes on a subsequent disposition of Common Stock acquired
	on the exercise of a NQSO generally will be treated as long-term or short-term capital gain or loss, depending on the length of
	time the participant held such shares. The amount of the gain (or loss) will equal the amount by which the amount realized on the
	subsequent disposition exceeds (or is less than) the participant&rsquo;s tax basis in his or her shares. A participant will receive
	different tax treatment if the exercise price is paid by delivery of Company Stock the participant already owns.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	The exercise of a NQSO will entitle the Company
	or its Affiliate to claim a federal income tax deduction equal to the amount of ordinary income the participant recognizes. If
	the participant is an employee, that ordinary income will constitute wages subject to withholding and employment taxes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<I>
	SARs
</I>
	. A participant will not recognize any
	taxable income at the time the SARs are granted. The participant at the time of receipt will recognize as ordinary income the amount
	of cash and the fair market value of the Common Stock that he or she receives. The Company or its Affiliate will be entitled to
	a federal income tax deduction equal to the amount of ordinary income the participant recognizes. If the participant is an employee,
	that ordinary income will constitute wages subject to withholding and employment taxes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<I>
	Restricted Stock Awards
</I>
	. A participant will
	recognize ordinary income on account of a Restricted Stock Award on the first day that the shares are either transferable or not
	subject to a substantial risk of forfeiture. The ordinary income recognized will equal the excess of the fair market value of the
	Common Stock on such date over the amount, if any, the participant paid for the Restricted Stock Award. However, even if the shares
	under a Restricted Stock Award are both nontransferable and subject to a substantial risk of forfeiture, the participant may make
	a special &ldquo;83(b) election&rdquo; within 30 days of the grant date to recognize income, and have his or her tax consequences
	determined, as of the date the Restricted Stock Award is made. The participant&rsquo;s tax basis in the shares received will equal
	the income recognized plus the price, if any, paid for the Restricted Stock Award. Any gain (or loss) that a participant realizes
	upon the sale of any Common Stock acquired pursuant to a Restricted Stock Award will be equal to the amount by which the amount
	realized on the disposition exceeds (or is less than) the participant&rsquo;s tax basis in the shares and will be treated as long-term
	(if the shares are held for more than one year) or short-term (if the shares are held for one year or less) capital gain or loss.
	The participant&rsquo;s holding period for the stock begins on the date the shares are either transferable or not subject to a
	substantial risk of forfeiture, except that the holding period will begin on the date of grant if the participant makes the special
	&ldquo;83(b) election.&rdquo; The Company or its Affiliate will be entitled to a federal income tax deduction equal to the ordinary
	income the participant recognizes. If the participant is an employee, that ordinary income will constitute wages subject to withholding
	and employment taxes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 87; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	85
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage88"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<I>
	RSUs
</I>
	. The participant will not recognize
	any taxable income at the time the RSUs are granted. When the terms and conditions to which the RSUs are subject have been satisfied
	and the RSUs are paid, the participant, at the time of receipt, will recognize as ordinary income the fair market value of the
	Common Stock he or she receives. The participant&rsquo;s holding period in the Common Stock will begin on the date the stock is
	received. The participant&rsquo;s tax basis in the Common Stock will equal the amount he or she includes in ordinary income. Any
	gain or loss that a participant realizes on a subsequent disposition of the shares will be treated as long-term or short-term capital
	gain or loss, depending on the participant&rsquo;s holding period for the stock (long-term if the shares are held for more than
	one year; short-term if one year or less). The amount of the gain (or loss) will equal the amount by which the amount realized
	on the disposition exceeds (or is less than) the participant&rsquo;s tax basis in the Common Stock. The Company or its Affiliate
	will be entitled to a federal income tax deduction equal to the ordinary income the participant recognizes. If the participant
	is an employee, that ordinary income will constitute wages subject to withholding and employment taxes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<I>
	Incentive Awards
</I>
	. A participant will not
	recognize any taxable income at the time an Incentive Award is granted. When the terms and conditions to which an Incentive Award
	is subject have been satisfied and the award is paid, the participant, at the time of receipt, will recognize as ordinary income
	the amount of cash and the fair market value of the Common Stock he or she receives. The participant&rsquo;s holding period in
	any Common Stock received will begin on the date of receipt. The participant&rsquo;s tax basis in the Common Stock will equal the
	amount he or she includes in ordinary income with respect to such shares. Any gain or loss that a participant realizes on a subsequent
	disposition of the Common Stock will be treated as long-term or short-term capital gain or loss, depending on the participant&rsquo;s
	holding period for the Common Stock (long-term if the shares are held for more than one year; short-term if one year or less).
	The amount of the gain (or loss) will equal the amount by which the amount realized on the disposition exceeds (or is less than)
	the participant&rsquo;s tax basis in the Common Stock. The Company or its Affiliate will be entitled to a federal income tax deduction
	equal to the amount of ordinary income the participant recognizes. If the participant is an employee, that ordinary income will
	constitute wages subject to withholding and employment taxes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<I>
	Limitation on Deductions
</I>
	. The deduction for
	a publicly-held corporation for otherwise deductible compensation to a &ldquo;covered employee&rdquo; generally is limited to $1
	million per year. An individual is a covered employee if he or she is the chief executive officer or one of the other three highest
	compensated officers for the year (other than the chief executive officer or chief financial officer). The $1 million limit does
	not apply to compensation payable solely because of the attainment of performance conditions that meet the requirements set forth
	in Section 162(m) of the Code and the regulations thereunder. Compensation is considered performance-based only if (a) it is paid
	solely on the achievement of one or more performance conditions; (b) two or more &ldquo;outside directors&rdquo; set the performance
	conditions; (c) before payment, the material terms under which the compensation is to be paid, including the performance conditions,
	are disclosed to, and approved by, the shareholders and (d) before payment, two or more &ldquo;outside directors&rdquo; certify
	in writing that the performance conditions have been met. The 2016 Plan has been designed to enable the Committee to structure
	awards that are intended to meet the requirements for qualified performance-based compensation that would not be subject to the
	$1 million per year deduction limit under Section 162(m) of the Code.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 88; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	86
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage89"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Any grant, exercise, vesting or payment of an award
	may be postponed if the Company reasonably believes that its or any applicable Affiliate&rsquo;s deduction with respect to such
	award would be limited or eliminated by application of Code Section 162(m) to the extent permitted by Section 409A of the Code;
	provided, however, such delay will last only until the earliest date at which the Company reasonably anticipates the deduction
	will not be limited or eliminated under Code Section 162(m).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<I>
	Other Tax Rules
</I>
	. The 2016 Plan is designed
	to enable the Committee to structure awards that are intended to not be subject to Code Section 409A, which imposes certain restrictions
	and requirements on deferred compensation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<U>
	2014 Stock Incentive Plan
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	The Ohr Pharmaceutical, Inc.
	2014 Stock Incentive Plan (the &ldquo;2014 Plan&rdquo;) was first adopted by the Board on January 31, 2014, and by the shareholders
	on March 31, 2014, as amended by the Board on January 6, 2015, and by the shareholders on March 10, 2015.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	The 2014 Plan is designed to
	advance the Company&rsquo;s interests by enhancing its ability to attract and retain employees and others in a position to make
	significant contributions to the success of the Company through ownership of shares of common stock. The 2014 Plan provides for
	the grant of ISOs, NQSOs, restricted stock, and combinations of the above. Awards under the 2014 Plan may also include provision
	for payment of dividend equivalents with respect to the shares subject to the award.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	The 2014 Plan is administered
	by the Compensation Committee. All employees of the Company and any of its subsidiaries and other persons or entities (including
	non-employee directors of the Company and its subsidiaries) who, in the opinion of the Board, are in a position to make a significant
	contribution to the success of the Company or its subsidiaries are eligible to participate in the 2014 Plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	Summary of the 2014 Plan
</B>
	.
	The exercise price of an ISO granted under the 2014 Plan may not be less than 100% (110% in the case of 10% stockholders) of the
	fair market value of the common stock at the time of grant. The exercise price of a NQSO granted under the 2014 Plan is determined
	by the Board. The term of each option may be set by the Board but cannot exceed ten years from grant (five years from grant in
	the case of an incentive stock option granted to a 10% stockholder), and each option will be exercisable at such time or times
	as the Board specifies. The option price may be paid in cash or check acceptable to the Company or, if permitted by the Board
	and subject to certain additional limitations, by tendering shares of common stock, by using a promissory note, by delivering
	to the Company an unconditional and irrevocable undertaking by a broker promptly to deliver sufficient funds to pay the exercise
	price, or a combination of the foregoing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 89; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	87
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage90"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	Except as otherwise provided
	by the Board, if a participant dies, options held by such participant immediately prior to death, to the extent then exercisable,
	may be exercised by the participant&rsquo;s executor, administrator or transferee during a period of one year following such death
	(or for the remainder of their original term, if less). Except as otherwise determined by the Board, options not exercisable at
	a participant&rsquo;s death terminate. Outstanding awards of restricted common stock must be transferred to the Company upon a
	participant&rsquo;s death except as otherwise determined by the Board.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	In the case of termination
	of a participant&rsquo;s association with the Company for any reason other than death, options remain exercisable, to the extent
	they were exercisable immediately prior to termination, for 30 days (or for the remainder of their original term, if less), and
	shares of restricted common stock must be resold to the Company, unless otherwise determined by the Board. If any such association
	is terminated due to the participant&rsquo;s discharge for cause which, in the opinion of the Board, casts such discredit on the
	participant as to justify immediate termination of any award under the 2014 Plan, such participant&rsquo;s options may be terminated
	immediately.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	In the event of a consolidation
	or merger in which the Company is not the surviving corporation or which results in the acquisition of substantially all of the
	Company&rsquo;s outstanding Common Stock by a single person or entity or by a group of persons and/or entities acting in concert
	or in the event of the sale or transfer of substantially all of the Company&rsquo;s assets, the Board may determine that (i) each
	outstanding option will become immediately exercisable unless otherwise provided at the time of grant, and (ii) each outstanding
	share of restricted Common Stock will immediately become free of all restrictions and conditions. The Board may also arrange to
	have the surviving or acquiring corporation or affiliate assume any award held by a participant or grant a replacement award. If
	the optionee is terminated after a change in control by the Company without cause, or in the case of certain officers designated
	from time to time by the Board resigns under certain circumstances, within two years following the change in control, all unvested
	options will vest and all options will be exercisable for the shorter of four years or their original duration and all other awards
	will vest. If the option committee makes no such determination, outstanding awards to the extent not fully vested will be forfeited.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<U>
	2009 Stock Incentive Plan
</U>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	The Ohr Pharmaceutical, Inc.
	2009 Stock Incentive Plan (the &ldquo;2009 Plan&rdquo;) was first adopted by the Board in June 2009 and by the shareholders effective
	as of July 13, 2009.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	The 2009 Plan was designed
	to encourage ownership of common stock by employees, consultants and directors of the Company and its affiliates and to provide
	additional incentive for them to promote the success of the Company&rsquo;s business. The 2009 Plan provided for the grant of ISOs,
	NQSOs, restricted stock, and combinations of the above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 90; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	88
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage91"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	The 2009 Plan is administered
	by the Compensation Committee. An award under the 2009 Plan
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	may grant to any employee of
	or consultant to one or more of the Company and its affiliates or to any non-employee member of the Board or of any board of directors
	(or similar governing authority) of any affiliate.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	Summary of the 2009 Plan
</B>
	.
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	If any Option expires, terminates, or is cancelled for any reason without having been exercised
	in full, or if any award of restricted stock is forfeited by the recipient, the shares not purchased by the optionee or forfeited
	by the recipient shall again be available for awards to be granted under the 2009 Plan.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	The exercise price of an ISO
	granted under the 2009 Plan may not be less than 100% (110% in the case of 10% stockholders) of the fair market value of the common
	stock at the time of grant. The exercise price of a NQSO granted under the 2009 Plan is determined by the Board. The term of each
	option may be set by the Board but cannot exceed ten years from grant (five years from grant in the case of an incentive stock
	option granted to a 10% stockholder), and each option will be exercisable at such time or times as the Board specifies. The option
	price may be paid in cash or check acceptable to the Company or, if permitted by the Board and subject to certain additional limitations,
	by tendering shares of common stock, by using a promissory note, by delivering to the Company an unconditional and irrevocable
	undertaking by a broker promptly to deliver sufficient funds to pay the exercise price, or a combination of the foregoing.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	The option price may be paid
	in cash or check acceptable to the Company or, if permitted by the Board and subject to certain additional limitations, by (i)
	shares of stock having a market value equal to the exercise price of the shares to be purchased, or (ii) by using a promissory
	note.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	If
	a participant&rsquo;s employment or other association with the Company and its affiliates ends for any reason, any outstanding
	option of the participant will cease to be exercisable in any respect not later than 30 days following that event and, for the
	period it remains exercisable following that event, will be exercisable only to the extent exercisable at the date of that event.
	Military or sick leave or other bona fide leave will not be deemed a termination of employment or other association.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	Unless
	the Compensation Committee provided otherwise for any award of restricted stock, upon termination of a participant&rsquo;s employment
	or other association with the Company and its affiliates for any reason during the restriction period, all shares of restricted
	stock subject to forfeiture will be forfeited or otherwise subject to return to or repurchase by the Company on the terms specified
	in the award agreement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	In
	the event of a Change in Control (as defined in the 2009 Plan), any restricted stock award still then subject to a forfeiture and
	any outstanding option not then exercisable in full shall vest under the terms of the award.&nbsp;The Compensation Committee shall
	have the discretion, exercisable either in advance of a change in control or at the time thereof, to provide (upon such terms as
	it may deem appropriate) for (i)&nbsp;the automatic acceleration of one or more outstanding options that do not otherwise accelerate
	by reason of the change in control, and/or (ii)&nbsp;the subsequent termination of one or more of the Company&rsquo;s repurchase
	rights with respect to restricted stock awards that do not otherwise terminate at that time, in the event that the employment of
	the respective grantees of such awards should subsequently terminate following such change in control.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 91; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	89
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage92"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<B>
	Material U.S. Federal Income
	Tax Consequences For the 2014 Plan and the 2009 Plan
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	The following discussion summarizes
	the principal United States federal income tax consequences associated with awards granted under the 2014 Plan and 2009 Plan to
	U.S. citizens. The discussion is based on laws, regulations, rulings and court decisions currently in effect, all of which are
	subject to change.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<I>
	ISOs.
</I>
	A participant
	will not recognize taxable income on the grant or exercise of an ISO. A participant will recognize taxable income when he or she
	disposes of the shares of Common Stock acquired under the ISO. If the disposition occurs more than two years after the grant of
	the ISO and more than one year after its exercise (the &ldquo;ISO holding period&rdquo;), the participant will recognize long-term
	capital gain (or loss) to the extent the amount realized from the disposition exceeds (or is less than) the participant&rsquo;s
	tax basis in the shares of Common Stock. A participant&rsquo;s tax basis in shares of the Common Stock generally will be the amount
	the participant paid for the shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	If Common Stock acquired under
	an ISO is disposed of before the expiration of the ISO holding period described above, the participant will recognize as ordinary
	income in the year of the disposition the excess of the fair market value of the Common Stock on the date of exercise of the ISO
	over the exercise price. Any additional gain will be treated as long-term or short-term capital gain, depending on the length of
	time the participant held the shares. A special rule applies to such a disposition where the amount realized is less than the fair
	market value of the Common Stock on the date of exercise of the ISO. In that case, the ordinary income the participant will recognize
	will not exceed the excess of the amount realized on the disposition over the exercise price. If the amount realized is less than
	the exercise price, the participant will recognize a capital loss (long-term if the stock was held more than one year and short-term
	if held one year or less). A participant will receive different tax treatment if the exercise price is paid by delivery of Common
	Stock the participant already owns.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	Neither the Company nor any
	of its Affiliates will be entitled to a federal income tax deduction with respect to the grant or exercise of an ISO. However,
	in the event a participant disposes of Common Stock acquired under an ISO before the expiration of the ISO holding period described
	above, the Company or its Affiliate will be entitled to a federal income tax deduction equal to the amount of ordinary income the
	participant recognizes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<I>
	NQSOs.
</I>
	A participant
	will not recognize any taxable income on the grant of a NQSO. On the exercise of a NQSO, the participant will recognize as ordinary
	income the excess of the fair market value of the Common Stock acquired over the exercise price. A participant&rsquo;s tax basis
	in the Common Stock is the amount paid plus any amounts included in income on exercise. The participant&rsquo;s holding period
	for the stock begins on acquisition of the shares.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 92; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	90
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage93"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	Any gain or loss that a participant
	realizes on a subsequent disposition of Common Stock acquired on the exercise of a NQSO generally will be treated as long-term
	or short-term capital gain or loss, depending on the length of time the participant held such shares. The amount of the gain (or
	loss) will equal the amount by which the amount realized on the subsequent disposition exceeds (or is less than) the participant&rsquo;s
	tax basis in his or her shares. A participant will receive different tax treatment if the exercise price is paid by delivery of
	Company Stock the participant already owns.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	The exercise of a NQSO will
	entitle the Company or its Affiliate to claim a federal income tax deduction equal to the amount of ordinary income the participant
	recognizes. If the participant is an employee, that ordinary income will constitute wages subject to withholding and employment
	taxes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<I>
	Restricted Stock Awards.
</I>
	A participant will recognize ordinary income on account of a Restricted Stock Award on the first day that the shares are either
	transferable or not subject to a substantial risk of forfeiture. The ordinary income recognized will equal the excess of the fair
	market value of the Common Stock on such date over the amount, if any, the participant paid for the Restricted Stock Award. However,
	even if the shares under a Restricted Stock Award are both nontransferable and subject to a substantial risk of forfeiture, the
	participant may make a special &ldquo;83(b) election&rdquo; to recognize income, and have his or her tax consequences determined,
	as of the date the Restricted Stock Award is made. The participant&rsquo;s tax basis in the shares received will equal the income
	recognized plus the price, if any, paid for the Restricted Stock Award. Any gain (or loss) that a participant realizes upon the
	sale of any Common Stock acquired pursuant to a Restricted Stock Award will be equal to the amount by which the amount realized
	on the disposition exceeds (or is less than) the participant&rsquo;s tax basis in the shares and will be treated as long-term (if
	the shares are held for more than one year) or short-term (if the shares are held for one year or less) capital gain or loss. The
	participant&rsquo;s holding period for the stock begins on the date the shares are either transferable or not subject to a substantial
	risk of forfeiture, except that the holding period will begin on the date of grant if the participant makes the special &ldquo;83(b)
	election.&rdquo; The Company or its Affiliate will be entitled to a federal income tax deduction equal to the ordinary income the
	participant recognizes. If the participant is an employee, that ordinary income will constitute wages subject to withholding and
	employment taxes.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	Any grant, exercise, vesting
	or payment of an award may be postponed if the Company reasonably believes that its or any applicable Affiliate&rsquo;s deduction
	with respect to such award would be limited or eliminated by application of Code Section&nbsp;162(m) to the extent permitted by
	Section&nbsp;409A of the Code; provided, however, such delay will last only until the earliest date at which the Company reasonably
	anticipates the deduction will not be limited or eliminated under Code Section&nbsp;162(m).
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT; TEXT-INDENT: 0.5IN">
<I>
	Other Tax Rules.
</I>
	The
	Incentive Plan is designed to enable the Compensation Committee to structure awards that are intended to not be subject to Code
	Section&nbsp;409A, which imposes certain restrictions and requirements on deferred compensation.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 93; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	91
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage94"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Outstanding
	Equity Awards at Fiscal Year-End
</FONT>
</P>
<P STYLE="FONT: ITALIC BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	following table provides certain information with respect to outstanding individual grants through the fiscal year ended September
	30, 2016 to each of our named executive officers of common share purchase options relating to our common shares:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 14%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 9%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 9%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 6%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 3%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 7%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 2%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 7%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 7%">
	&nbsp;
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; WIDTH: 1%">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD COLSPAN="16" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Option
	Awards
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="15" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Stock
	Awards
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Name
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Number
	of
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Securities
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Underlying
	Unexercised
</B>
</FONT>
<BR>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Options
	Exercisable
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Number
	of
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Securities
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Underlying
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Unexercised
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Options
	Unexercisable
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Option
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Exercise
</B>
</FONT>
<BR>
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Price
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Option
</B>
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Expiration
	Date
</B>
</FONT>
</P>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Number of Shares or Units of Stock That Have Not Vested
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Market
	Value of Shares or Units of Stock That Have Not Vested (9)
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; PADDING-LEFT: 2PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Jason
	Slakter
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	25,000
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	25,000
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.14
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3/10/2020
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	$&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; PADDING-BOTTOM: 1PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 2PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	$&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	350,358
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	(2)
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1,583,618
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 2PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Sam
	Backenroth
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	133,333
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(3)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.71
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3/9/2017
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	187,500
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(4)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	62,500
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(4)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	$
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.11
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2/3/2017
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; BACKGROUND-COLOR: WHITE; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
	&mdash;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	30,000
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(5)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	30,000
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(5)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10.14
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3/10/2020
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 2PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: WHITE">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	130,000
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(6)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	587,600
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 2PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Avner
	Ingerman
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(7)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	100,000
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(7)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	7.06
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3/1/2020
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	$&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 2PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	30,000
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(8)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	293,400
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	(8)
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(1)
	One quarter of the options vested immediately and on March 10, 2016, and one quarter of the options will vest on each of March
	10, 2017 and March 10, 2018.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(2)
	175,000 shares of restricted stock vest on January 9, 2017 and 175,358 shares of restricted stock vest on January 9, 2018.
</FONT>
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(3)
	One quarter of the options vested immediately, and one quarter of the options vested on each of March 9, 2013, March 9, 2014 and
	March 9, 2015.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(4)
	One quarter of the options vested on each of February 3, 2014 and February 3, 2015, and February 3, 2016 and one quarter of
	the options will vest on February 3, 2017.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(5)
	One quarter of the options vested immediately and on March 10, 2016, and one quarter of the options will vest on each of March
	10, 2017 and March 10, 2018.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(6)
	One half of the shares of restricted stock vest on January 9, 2017 and one half of the shares of restricted stock
	vest on January 9, 2018.&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(7)
	One quarter of the options vested on each of March 1, 2015 and December 31, 2015, and one quarter of the options will vest on
	each of December 31, 2016, and December 31, 2017.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 94; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	92
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage95"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(8)
	30,000 restricted stock units vested on January 1, 2016 and 15,000 restricted
	stock units will vest on each of January 1, 2017 and January 1, 2018.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(9)
	The amounts in this column reflect the aggregate grant date fair value of equity awards, calculated in accordance with FASB ASC
	Topic 718.
<BR CLEAR="ALL">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 95; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	93
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage96"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Compensation
	of Directors
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	During
	the fiscal year 2016, the following options were granted to directors serving in fiscal 2016:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; TEXT-INDENT: -4.4PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Name
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Grant
	Date
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	All
	other stock awards: Number of shares of stock or units
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	All
	other option awards: Number of securities underlying
</B>
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	options
</B>
</FONT>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Exercise
<BR>
	Price(1)
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Grant
	Date Fair Value of Stock and Option Awards(2)
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 32%; PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Ira
	Greenstein
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1/7/2016
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	60,000
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5.14
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	201,678
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
	Chairman
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1/22/2016
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	80,000
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	$
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3.62
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	189,708
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 20PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Orin
	Hirschman
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1/7/2016
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	60,000
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5.14
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	201,678
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Thomas
	Riedhammer
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1/7/2016
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	60,000
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;5.14
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	201,678
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	June
	Almenoff
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1/7/2016
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	60,000
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;5.14
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	201,678
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT; PADDING-LEFT: 0.125IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 20%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(1)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The exercise
	price reflects the closing market price of our common stock on the day of the grant.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(2)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The grant
	date fair value of the option grants is calculated in accordance with FASB ASC Topic
	718 and using a Black-Scholes valuation model. Assumptions used in the calculation of
	these amounts are included in Note 9 of the audited financial statements included elsewhere
	in this Annual Report on Form 10-K.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
</P>
<!-- FIELD: PAGE; SEQUENCE: 96; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	94
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage97"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	following table shows the number of outstanding options held by our non-executive directors at the end of fiscal 2016:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="11" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Number
	of Securities Underlying
</B>
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Unexercised
</B>
</FONT>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="11" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Options
	(#)(1)
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-BOTTOM: 1PT; PADDING-LEFT: 4.4PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Exercisable
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Unexercisable
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Unearned
</B>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Option
</B>
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Exercise Price
</B>
</FONT>
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Option
	Expiration
</B>
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<BR>
<FONT STYLE="FONT-SIZE: 10PT">
<B>
	Date
</B>
</FONT>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 35%; PADDING-LEFT: 4.4PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Ira
	Greenste
<FONT STYLE="FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	in
</FONT>
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	100,000
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	1.71
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 10%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	3/8/2017
</FONT>
</TD>
<TD STYLE="WIDTH: 1%; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Chairman
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	42,000
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	42,000
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	10.14
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	3/10/2020
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	20,000
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	40,000
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	5.14
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	1/6/2021
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	26,666
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	53,334
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	3.62
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	1/21/2021
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Orin
	Hirschman
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	100,000
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	1.71
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	3/8/2017
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Director
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	42,000
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	42,000
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	10.14
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	3/10/2020
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	20,000
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	40,000
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	5.14
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	1/6/2021
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Thomas
	Ricdhammer
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	116,667
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	4.74
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	4/29/2018
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Director
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	42,000
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	42,000
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	10.14
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	3/10/2020
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	20,000
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	40,000
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
	$
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	5.14
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	1/6/2021
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	June
	Almenoff
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	116,667
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	4.68
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	5/16/2018
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	Director
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	42,000
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	42,000
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	10.14
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	3/10/2020
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255); FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	20,000
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	40,000
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&mdash;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	$
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	5.14
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	1/6/2021
</FONT>
</TD>
<TD STYLE="FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; FONT-WEIGHT: NORMAL; FONT-STYLE: NORMAL">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(1)
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Option numbers represent options to acquire shares of common stock.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	following table shows the compensation of our non-executive directors for fiscal 2016:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 4.4PT; TEXT-ALIGN: CENTER; TEXT-INDENT: -4.4PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Name
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Fees
	Earned or Paid in Cash
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Stock
	Awards
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Option
	Awards
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Non-Equity
	Incentive Plan Compensation
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Change
	in Pension Value and Non-Qualified Deferred Compensation Earnings
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	All
	Other Compensation
</B>
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2" STYLE="TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
<B>
	Total
</B>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 4.4PT; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 23%; PADDING-LEFT: 4.4PT; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Ira
	Greenstein
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10,000
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	391,386
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="WIDTH: 8%; TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	401,386
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Chairman
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 4.4PT; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	June
	Almenoff
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10,000
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	201,678
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	211,678
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 4.4PT; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Orin
	Hirschman
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10,000
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	201,678
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	211,678
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="PADDING-LEFT: 4.4PT; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; TEXT-INDENT: -4.4PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Thomas
	Reidhammer
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	10,000
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	201,678
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&mdash;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	$
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	211,678
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; TEXT-INDENT: 10PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Director
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 97; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	95
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage98"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Compensation
	Committee Report
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Notwithstanding
	anything to the contrary set forth in any of our previous or future filings under the Securities Act of 1933 or the Securities
	Exchange Act of 1934 that might incorporate this Annual Report on Form 10-K, in whole or in part, the following report of the
	Compensation Committee shall not be deemed to be incorporated by reference into any such filings and shall not otherwise be deemed
	filed under such Acts.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis contained in this Annual Report on
	Form 10-K with management and, based on that review and discussion, the Compensation Committee recommended to the Board of
	Directors that the Compensation Discussion and Analysis be included in this Annual Report on Form 10-K.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Submitted
	by: The Compensation Committee
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Thomas
	Riedhammer, Chairman
<BR>
	June Almenoff
<BR>
	Ira Greenstein
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Compensation
	Discussion and Analysis
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Compensation
	Program Objectives
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company&rsquo;s compensation programs are competitive, designed to attract and retain highly qualified directors, officers and
	employees, encourage high performance, promote accountability and assure that employee interests are aligned with the interests
	of the Company&rsquo;s stockholders.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	To
	achieve these objectives, we seek to design our executive compensation program and set compensation levels that
	are comparable to those of other companies that compete with us for executive talent. We use both objective and
	subjective criteria to evaluate Company and individual performance. This approach should allow the Compensation Committee to
	exercise discretion and not rely solely on rigid formulas and quantitative analyses. We historically provided long-term
	compensation in the form of stock options that generally vest over a two to three-year period and restricted stock that vest
	over a period of up to three years. We believe these awards allow the executive officers and all employees to participate in
	the long-term success of the Company, to align their interests with those of our stockholders, and to incentivize future
	performance, helping us retain talented executive management personnel.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	believe that the Company&rsquo;s compensation program for its executive officers is competitive and appropriately designed to
	attract and retain key employees, reward superior performance and promote long-term stockholder value. The Compensation Committee
	plans to continue to review the compensation payable to the Company&rsquo;s executive officers, periodically evaluate the Company&rsquo;s
	compensation practices, and make any changes it deems appropriate to the Company&rsquo;s compensation structure to ensure that
	the programs are designed and implemented to achieve the Committee&rsquo;s stated goals.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
</P>
<!-- FIELD: PAGE; SEQUENCE: 98; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	96
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage99"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	rely on various sources of information to assist us in evaluating the competitiveness of the Company&rsquo;s executive compensation
	program, setting compensation levels for the executive officers and meeting the Compensation Committee&rsquo;s stated compensation
	objectives and the experience and knowledge of our Compensation Committee and senior management. We have not retained an independent
	third party compensation consultant.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Highlights
	of Company Performance in 2016
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	fiscal 2016, the Company made important progress toward achieving its goals. The Company has achieved the following milestones:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Obtained
	FDA agreement on a Special Protocol Assessment for the Phase 3 clinical program for Squalamine
	in combination with Lucentis&reg; for patients with exudative AMD. The first Phase 3
	trial began enrollment in April 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Appointed
	David Brown, MD, as Chairman of the Steering Committee overseeing the Phase 3 trial.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Demonstrated
	in vivo sustained release of a novel small molecule anti-angiogenic compound (OHR3031)
	in a pharmacokinetic study in December 2015.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	May 2016, demonstrated sustained pharmacological anti-angiogenic activity of OHR3031
	in a rabbit model of laser-induced CNV which was comparable to that seen with a currently
	approved anti-VEGF agent conducted in a previous study.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Multiple
	posters and presentations at major medical meetings for both Squalamine as well as the
	sustained release platform technology. Advanced ex-US regulatory discussions to facilitate
	the second Phase 3 Squalamine study.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Continued
	progress on our ongoing discussions with several parties regarding a potential partnership
	transaction for Squalamine.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.75IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Significant
	progress with our active sustained release programs.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Peer
	Group Analysis
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In
	reviewing fiscal 2016, the Compensation Committee reevaluated the Company&rsquo;s peer group of companies and benchmarked executive
	compensation against this group. The objective of this reevaluation and analysis was to develop a peer group of companies in line
	with our revenue, market capitalization and phase of clinical trials and to compare our executive compensation practices to those
	of our peer companies. The Compensation Committee believes that it is important when making its compensation decisions to be informed
	as to the current practices of comparable, publicly held companies headquartered in the United States. To that end, we monitor
	developments in the Company, including growth in its products under development and market capitalization, and in the market generally
	that might change the selection of companies we consider comparable and benchmark our executive compensation against the most
	recently applicable companies. While benchmarking might not always be appropriate as a stand-alone tool for setting compensation
	due to the aspects of our business and objectives that might be unique to us, we generally believe that gathering this information
	is an important part of our compensation-related decision-making process.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 99; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	97
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage100"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We
	recognize that to attract, retain and motivate key individuals, such as our named executive officers, the Compensation Committee
	might determine that it is in our best interests to negotiate total compensation packages with our executive management that may
	deviate from the general principle of targeting total compensation at the median level for the peer group. Actual pay for each
	named executive officer is determined around this structure, driven by the performance of the executive over time, as well as
	our annual performance.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	For
	purposes of compensation decisions based on 2016 performance and compensation, our peer group of companies consisted of the following:
	Eleven Biotherapeutics, Inc., Inotek Pharmaceuticals, Corp., Alimera Sciences, Inc., Ocular Therapeutix, Inc., and pSivida Corp.
	These companies were chosen based on their comparable profile, stage of development, market capitalization, and therapeutic area
	of focus.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Say-on-Pay
	and Say-on-Frequency Feedback from Stockholders
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Board and the Compensation Committee value the opinions of our stockholders, and consider the outcome of advisory stockholder
	votes when making future compensation decisions for our named executive officers. At our 2014 annual meeting, 99.06% of the votes
	cast approved our advisory resolution regarding the compensation of our named executive officers. In addition, 86.93% of the votes
	cast voted that an advisory vote on executive compensation should occur every three years; consequently, the Company&rsquo;s next
	advisory vote on executive compensation will occur at our next annual meeting of stockholders. With stockholders showing strong
	support of our executive compensation program, the Compensation Committee continued its regular practice of evaluating the program
	to reflect continued linkage between pay and company performance and carefully considered actual compensation payouts, seeking
	to provide compensation that follows our compensation philosophy and meets our compensation objectives described above. In light
	of all pertinent considerations, the Compensation Committee believes that the Company&rsquo;s compensation programs embody a pay-for-performance
	philosophy that is well suited for these purposes.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Executive
	Compensation Policy
</I>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	principal components of compensation for the Company&rsquo;s executive officers are base salary, discretionary annual cash incentive
	awards and long-term incentive compensation in the form of options, restricted common stock or other forms of equity.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The
	Company also provides severance benefits upon a change in control of the Company, a 401(k) plan and a group health plan. The Company
	does not maintain supplemental retirement programs for its executive officers because we believe that the existing compensation
	arrangements enable the Company&rsquo;s executive officers to adequately plan for their retirement.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 100; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	98
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage101"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Compensation Program Elements
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<U>
	Base Salary
</U>
	. Ohr&rsquo;s base salary is designed
	to recognize the duties and responsibilities of each executive officer and the experience, knowledge, ability and skill of the
	executive officer that holds each such position. We believe that base salaries are an important component of the Company&rsquo;s
	executive compensation program and are critical in attracting and retaining executive talent. The Compensation Committee reviews
	base salaries of the Company&rsquo;s executive officers on an annual basis. In setting annual base salaries, the Compensation Committee
	considers the Company&rsquo;s overall financial and operating performance in the prior year, the Company-wide target for base salary
	increases for all employees, market and competitive salary information, including for our peer companies as noted above, inflation,
	changes in the scope of an executive officer&rsquo;s job responsibilities, other components of compensation and other relevant
	factors. The Compensation Committee also reviews the executive officer&rsquo;s individual performance.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<U>
	Annual Incentive Cash Compensation
</U>
	. This
	component of compensation provides an incentive to the executive officers to achieve both Company and individual performance objectives
	and to be rewarded for those achievements.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Our plan is that after each fiscal year, the Compensation
	Committee will determine the bonus for the named executive officers, for that year. In all cases, the Committee seeks to establish
	bonuses that are designed to ensure that total cash compensation is competitive and reflects performance in that year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	The size of the final discretionary bonuses paid
	to the named executive officers are not based on a specific formula or level of achievement, but rather at the discretion of the
	Compensation Committee taking into account the factors discussed above.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Based on the Company&rsquo;s corporate and
	operational performance in fiscal year 2016 and the individual performance of each named executive officer, in January 2017
	the Compensation Committee will convene to determine executive bonuses. In determining the amounts of these payments, the
	Compensation Committee will consider the importance of retaining our key employees and motivating them to implement our
	long-term strategic plan to develop additional products and to acquire potential products.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	The Compensation Committee believes its
	approach to cash incentive awards properly motivates and rewards the Company&rsquo;s executive officers and provides the
	Compensation Committee with appropriate discretion and flexibility to set awards that reflect both the Company&rsquo;s performance and
	each named executive officer&rsquo;s contributions for the given year.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<U>
	Perquisites and Other Benefits
</U>
	. The Company&rsquo;s
	philosophy is not to provide executive perquisites or other special benefits. Instead, we maintain broad-based benefits that we
	provide to all employees, including our executive officers. These benefits include a 401(k) retirement savings plan (without matching
	contributions from the Company) and a group health plan.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 101; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	99
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage102"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
<U>
	Stock-Based Awards
</U>
	. Stock-based awards under
	our 2016 Consolidated Stock Incentive Plan are the primary form of long-term compensation offered to our named executive officers.
	Under our 2016 Consolidated Stock Incentive Plan, the Compensation Committee may grant named executive officers and other employees
	eligible to participate in the Plan, incentive and nonqualified stock options and restricted stock awards.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	The Compensation Committee grants
	option awards to named executive officers and other employees eligible to participate in our 2016 Consolidated Stock
	Incentive Plan. Typically, a small portion of the option awards vest immediately and the remaining portions vest over time,
	subject to continued employment.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	The Compensation Committee believes its option and stock award
	program is consistent with its stated objective of establishing a performance-based executive compensation system to reward and
	incentivize the named executive officers and other employees and consultants because the value of the options and stock generally
	will be tied to the Company&rsquo;s financial and operating performance over time. The Compensation Committee believes this link to longer-term
	performance aligns the interests of the named executive officers, employees and consultants with the interests of our stockholders.
	In addition, the vesting schedule for most option or stock awards helps the Company retain executive talent because unvested options
	or stock awards are automatically forfeited upon the termination of an executive officer&rsquo;s employment. Thus, the recipient
	of an option or stock award is incentivized to remain with the Company during the vesting period.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Policy on Timing of Equity Grants
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	We do not have any formal plan or practice to time
	equity grants in coordination with our public release or disclosure of material nonpublic information, but we generally only make
	grants at times when we do not have any material nonpublic information about our Company. We also do not time our release of material
	nonpublic information for purposes of affecting the value of compensation to employees, including our officers.
</P>
</EFX_COMPENSATION>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 1IN; TEXT-ALIGN: LEFT">
<A NAME="OHRP-10K_093016_HTM_OHRPA018">
</A>
	ITEM 12
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
	AND RELATED STOCKHOLDER MATTERS
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	The following table provides information about the
	beneficial ownership of our common stock as of December 14, 2016.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	each person or entity known by us to own beneficially more than five percent of our common stock;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	the named executive officers;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	each of our directors; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	all of our directors and executive officers as a group.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 102; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	100
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage103"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	In accordance with Securities and Exchange Commission
	rules, beneficial ownership includes any shares for which a person or entity has sole or shared voting power or investment power
	and any shares for which the person or entity has the right to acquire beneficial ownership within 60 days after December 14, 2016
	through the exercise of any option, warrant or otherwise. Except as noted below, we believe that the persons named in the table
	have sole voting and investment power with respect to the shares of common stock set forth opposite their names. Percentage of
	beneficial ownership is based on 35,961,396 shares of common stock outstanding as of December 14, 2016, plus any shares of common
	stock issuable upon exercise of presently exercisable common stock options or common stock warrants held by such person or entity.
	All shares included in the &ldquo;Right to Acquire&rdquo; column represent shares subject to outstanding stock options or warrants
	that are exercisable within 60 days after December 14, 2016. The address of each of our directors and executive officers is c/o
	Ohr Pharmaceutical, Inc., 800 Third Avenue, 11th Floor, New York, New York 10022.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 103; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	101
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage104"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<EFX_BENEFICIAL_OWNERS>
<A NAME="FIS_BENEFICIAL_OWNERS"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Name and Address of Beneficial Owner
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Shares
<BR>
	Owned
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Right to
<BR>
	Acquire (1)
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Common
</B>
<BR>
<B>
	and
</B>
<BR>
<B>
	Warrant
</B>
<BR>
<B>
	Shares
</B>
<BR>
<B>
	Owned
<BR>
	Beneficially
</B>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
<B>
	Fully Diluted
</B>
<BR>
<B>
	Ownership
</B>
<BR>
<B>
	Percentage (2)
</B>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 44%; PADDING-LEFT: 4.4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	Orin Hirschman (3)
</TD>
<TD STYLE="WIDTH: 2%; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,376,939
</TD>
<TD STYLE="WIDTH: 1%; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	333,000
</TD>
<TD STYLE="WIDTH: 1%; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,709,939
</TD>
<TD STYLE="WIDTH: 1%; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 2%; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 10%; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	7.5
</TD>
<TD STYLE="WIDTH: 1%; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	Jason Slakter (4)
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,120,764
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	25,000
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	2,145,764
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	6.0
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	Ira Greenstein (5)
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	331,051
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	235,334
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	566,385
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1.6
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	Sam Backenroth (6)
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	141,167
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	413,333
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	554,500
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1.5
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	%
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	Thomas Riedhammer (7)
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	8,000
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	198,667
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	206,667
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	*
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	June Almenoff (8)
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	16,900
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	198,667
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	215,567
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	*
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	Avner Ingerman (9)
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	61,000
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	100,000
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	161,000
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	*
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="PADDING-LEFT: 4.4PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="PADDING-LEFT: 20PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-INDENT: -4.4PT">
	All Officers and Directors as a Group
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	5,055,821
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	1,504,001
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	6,559,822
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF; TEXT-ALIGN: RIGHT">
	17.5
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	%
</TD>
</TR>
</TABLE>
</EFX_BENEFICIAL_OWNERS>
<P STYLE="MARGIN-TOP: 0; MARGIN-BOTTOM: 0">
	&nbsp;&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 1PT SOLID; WIDTH: 20%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
	* Less than 1%.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(1)
</TD>
<TD>
	Only includes vested and exercisable securities, including securities exercisable within 60 days after December 14, 2016.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(2)
</TD>
<TD>
	Calculated on the basis of shares of Common Stock outstanding plus the number of shares such holder has the right to acquire.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(3)
</TD>
<TD>
	Mr. Hirschman is the sole member of AIGH Investment Partners LLC (&ldquo;AIGH&rdquo;) and directly determines investment and
	voting decisions, and AIGH directly owns shares and warrants to purchase common stock. Mr. Hirschman indirectly owns shares as custodian of accounts for the benefit of his minor children. Mr. Hirschman shares voting and dispositive
	power over shares and warrants held by The Tzedakah Fund.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(4)
</TD>
<TD>
	Consists of 925,000 shares of common stock held by Dr. Slakter directly and 1,195,724 shares of common stock held by SKS Ocular
	I LLC, an affiliate of Dr. Slakter. Dr. Slakter has sole voting and dispositive power over shares and options held by Dr. Slakter
	personally. Dr. Slakter shares voting and dispositive power over shares held by SKS Ocular I LLC.
	Dr. Slakter disclaims any beneficial ownership of the 1,195,724 shares of common stock held by SKS Ocular
	I LLC except to the extent of his pecuniary interest therein.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 104; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	102
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage105"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(5)
</TD>
<TD>
	Includes shares currently issuable upon exercise of options granted to Mr. Greenstein.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(6)
</TD>
<TD>
	Includes shares currently issuable upon exercise of options granted to Mr. Backenroth.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(7)
</TD>
<TD>
	Includes shares currently issuable upon exercise of options granted to Dr. Riedhammer.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(8)
</TD>
<TD>
	Includes shares currently issuable upon exercise of options granted to Dr. Almenoff.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0">
</TD>
<TD STYLE="WIDTH: 0.5IN">
	(9)
</TD>
<TD>
	Includes shares currently issuable upon exercise of options granted to Dr. Ingerman.
</TD>
</TR>
</TABLE>
</EFX_SECURITY_OWNERS>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
	&nbsp;
</P>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 1IN; TEXT-ALIGN: LEFT">
<A NAME="OHRP-10K_093016_HTM_OHRPA019">
</A>
	ITEM 13
</TD>
<TD>
	CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS, AND DIRECTOR
	INDEPENDENCE
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	Policies and procedures for related person transactions
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Our Board has adopted a written related policy with
	respect to related person transactions. This policy governs the review, approval or ratification of covered related person transactions.
	The Audit Committee of our Board manages this policy.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	For purposes of this policy, a &ldquo;related person
	transaction&rdquo; is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships)
	in which we (or any of our subsidiaries) were, are or will be a participant, and the amount involved exceeds $120,000 and in which
	any related person had, has or will have a direct or indirect interest. For purposes of determining whether a transaction is a
	related person transaction, the Audit Committee relies upon Item 404 of Regulation S-K, promulgated under the Securities Exchange
	Act of 1934, as amended.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	A &ldquo;related person&rdquo; is defined as:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	any person who is, or at any time since the beginning of our last fiscal year was, one of our directors or executive officers
	or a nominee to become one of our directors;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	any person who is known to be the beneficial owner of more than five percent of any class of our voting securities;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	any immediate family member of any of the foregoing persons, which means any child, stepchild, parent, stepparent, spouse,
	sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law of the director, executive
	officer, nominee or more than five percent beneficial owner, and any person (other than a tenant or employee) sharing the household
	of such director, executive officer, nominee or more than five percent beneficial owner; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 105; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	103
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage106"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	any firm, corporation, or other entity in which any of the foregoing persons is employed or is a general partner or principal
	or in a similar position or in which such person has a ten percent or greater beneficial ownership interest.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	The policy generally provides that we may enter
	into a related person transaction only if:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	the Audit Committee pre-approves such transaction in accordance with the guidelines set forth in the policy;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	the transaction is on terms comparable to those that could be obtained in arm&rsquo;s length dealings with an unrelated third
	party and the Audit Committee (or the chairperson of the Audit Committee) approves or ratifies such transaction in accordance with
	the guidelines set forth in the policy;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	the transaction is approved by the disinterested members of the Board; or
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	the transaction involves compensation approved by the Compensation Committee of the Board.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	In the event a related person transaction is not
	pre-approved by the Audit Committee and our management determines to recommend such related person transaction to the Audit Committee,
	such transaction must be reviewed by the Audit Committee. After review, the Audit Committee will approve or disapprove such transaction.
	When our Chief Financial Officer in consultation with our Chief Executive Officer, determines that it is not practicable or desirable
	for us to wait until the next Audit Committee meeting, the chairperson of the Audit Committee possesses delegated authority to
	act on behalf of the Audit Committee. The Audit Committee (or the chairperson of the Audit Committee) may approve only those related
	person transactions that are in, or not inconsistent with, our best interests and the best interests of our shareholders, as the
	Audit Committee (or the chairperson of the Audit Committee) determines in good faith.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	The Audit Committee has determined that certain
	types of related person transactions are deemed to be pre-approved by the Audit Committee. Our related person transaction policy
	provides that the following transactions, even if the amount exceeds $120,000 in the aggregate, are considered to be pre-approved
	by the Audit Committee:
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	any employment of certain named executive officers that would be publicly disclosed;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	director compensation that would be publicly disclosed;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	transactions with other companies where the related person&rsquo;s only relationship is as a director or owner of less than
	ten percent of said company (other than a general partnership), if the aggregate amount involved does not exceed the greater of
	$200,000 or five percent of that company&rsquo;s consolidated gross revenues;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 106; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	104
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage107"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	transactions where all shareholders receive proportional benefits;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	transactions involving competitive bids;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	transactions with a related person involving the rendering of services at rates or charges fixed in conformity with law or
	governmental authority; and
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9679;
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	transactions with a related person involving services as a bank depositary of funds, transfer agent, registrar, trustee under
	a trust indenture or similar services.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	In addition, the Audit Committee will review the
	policy at least annually and recommend amendments to the policy to the Board from time to time.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	The policy provides that all related person transactions
	will be disclosed to the Audit Committee, and all material related person transactions will be disclosed to the Board. Additionally,
	all related person transactions requiring public disclosure will be properly disclosed, as applicable, on our various public filings.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	The Audit Committee will review all relevant information
	available to it about the related person transaction. The policy provides that the Audit Committee may approve or ratify the related
	person transaction only if the Audit Committee determines that, under all of the circumstances, the transaction is in, or is not
	inconsistent with, our best interests. The policy provides that the Audit Committee may, in its sole discretion, impose such conditions
	as it deems appropriate on us or the related person in connection with approval of the related person transaction.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-STYLE: NORMAL">
<B>
	Interest of Management in
	Certain Transactions
</B>
</FONT>
</P>
<P STYLE="FONT: ITALIC 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	In May 2014, the Company acquired
	certain assets of SKS Ocular (and affiliates; collectively referred to as &ldquo;SKS&rdquo;), which is a related person of
	Dr. Slakter, currently a director of the Company and its Chief Executive Officer. In consideration thereof, the Company paid
	$3.5 million in cash and 1,194,862 shares of the Company&rsquo;s common stock. Dr. Slakter was not a director of the Company
	at the time of the transaction. In the acquisition, the Company entered into a consulting agreement with Dr. Slakter, and
	agreed to appoint a designee of SKS as a director of the Company. The Company is also obliged to grant to SKS Ocular up to
	an aggregate of 1,493,577 shares of the common stock upon reaching certain milestones. In December 2015, milestone 1
	was achieved, and in May 2016, milestone 2 was achieved, resulting in the issuance of 995,718 shares of Ohr common stock to
	SKS Ocular 1 LLC. The Company also indirectly paid a total of $91,280 in fiscal year 2015, and was invoiced $267,680 in
	fiscal 2016, from Digital Angiography Reading Center, an affiliate of Dr. Slakter, for services rendered to the Company. In
	addition, in fiscal year 2015, the Company paid a total of $172,308 to Dr. Slakter in consulting fees.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	Our CRO running our phase 3 trial has contracted with Jason S. Slakter, M.D., P.C., d/b/a Digital Angiography
	Reading Center (&ldquo;DARC&rdquo;), a well-known digital reading center, which is owned by Dr. Jason Slakter, our CEO, pursuant
	to our related party transactions policy, with the review and approval of the Audit Committee, to provide digital reading and imaging
	services in connection with the Phase 3 study. We are advised that DARC has implemented a standard operating procedure (SOP) to
	firewall interactions between DARC employees and Dr. Slakter.&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 107; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: LEFT; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	105
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_OFFICER_TRANSACTIONS>
<A NAME="eolPage108"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN; TEXT-ALIGN: LEFT">
</TD>
<TD STYLE="WIDTH: 1IN; TEXT-ALIGN: LEFT">
<A NAME="OHRP-10K_093016_HTM_OHRPA020">
</A>
	ITEM 14
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	PRINCIPAL ACCOUNTANT FEES AND SERVICES
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	The Board of Directors has selected MaloneBailey
	as the Company&rsquo;s independent auditors for the fiscal year ended September 30, 2016. MaloneBailey, LLP has audited Ohr
	Pharmaceutical&rsquo;s financial statements since 2012.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
<B>
	Principal Accountant Fees and Services.
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0 0PT 0.5IN; TEXT-INDENT: 0IN; TEXT-ALIGN: LEFT">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN; TEXT-ALIGN: LEFT">
	For fiscal year 2016, MaloneBailey charged the Company
	a total of $59,000 for independent accounting and review fees. For fiscal year 2015, MaloneBailey charged the Company a total of
	$92,500 for independent accounting and review fees.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="BORDER-COLLAPSE: COLLAPSE; WIDTH: 100%; FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="7" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	Fiscal Year Ended
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
	&nbsp;
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	September 30,
<BR>
	2016 (1)
</TD>
<TD STYLE="FONT-WEIGHT: BOLD; PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD COLSPAN="3" STYLE="FONT-WEIGHT: BOLD; TEXT-ALIGN: CENTER; BORDER-BOTTOM: BLACK 1PT SOLID">
	September 30,
<BR>
	2015 (2)
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="WIDTH: 56%; TEXT-ALIGN: LEFT; TEXT-INDENT: -4.7PT; PADDING-LEFT: 4.7PT">
	Audit Fees &amp; Audit-Related Fees
</TD>
<TD STYLE="WIDTH: 8%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	59,000
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 8%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="WIDTH: 12%; TEXT-ALIGN: RIGHT">
	92,500
</TD>
<TD STYLE="WIDTH: 1%; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; TEXT-INDENT: -4.7PT; PADDING-LEFT: 4.7PT">
	Tax Fees
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	8,124
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="TEXT-ALIGN: RIGHT">
	3,500
</TD>
<TD STYLE="TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: RGB(204,238,255)">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 1PT; TEXT-INDENT: -4.7PT; PADDING-LEFT: 4.7PT">
	All Other Fees
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: RIGHT">
	&mdash;&nbsp;&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: WHITE">
<TD STYLE="TEXT-ALIGN: LEFT; PADDING-BOTTOM: 2.5PT; TEXT-INDENT: -4.7PT; PADDING-LEFT: 4.7PT">
	Total Fees
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	67,124
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT">
	&nbsp;
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: LEFT">
	$
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 2.5PT DOUBLE; TEXT-ALIGN: RIGHT">
	96,000
</TD>
<TD STYLE="PADDING-BOTTOM: 2.5PT; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%">
<FONT STYLE="FONT-SIZE: 10PT">
	(1)
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Fees billed to the Company through September 30, 2016.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0 0 0 0.5IN; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -0.5IN">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%">
<FONT STYLE="FONT-SIZE: 10PT">
	(2)
</FONT>
</TD>
<TD STYLE="WIDTH: 95%; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-SIZE: 10PT">
	Fees billed to the Company through September 30, 2015.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0">
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	Pre-Approval of Audit and Non-Audit Services
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	The Board has not approved any formal policy concerning
	pre-approval of the auditors to perform both audit and non-audit services (services other than audit, review and attest services).
	Instead, on a case by case basis, any audit or non-audit services proposed to be performed are considered by and, if deemed appropriate,
	approved by the Board in advance of the performance of such services.
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 108; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	106
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_ACCOUNTANT_FEES>
</EFX_PART_III>
<A NAME="eolPage109"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
	&nbsp;
</P>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<P STYLE="MARGIN: 0">
<A NAME="OHRP-10K_093016_HTM_OHRPA021">
</A>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Part IV
</B>
</FONT>
</P>
<P STYLE="FONT: BOLD 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 1IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A NAME="OHRP-10K_093016_HTM_OHRPA022">
</A>
	ITEM 15
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	EXHIBITS,
	FINANCIAL STATEMENT SCHEDULES
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Documents
	listed below are filed as exhibits to this Annual Report on Form 10-K. (a) Exhibit Index:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-INDENT: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; WIDTH: 10%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Exhibit
	Number
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; WIDTH: 43%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Description
	of Exhibit &nbsp; &nbsp;
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; WIDTH: 43%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	The
	filings referenced
</B>
<BR>
<B>
	for incorporation by reference
<BR>
	are Ohr Pharmaceutical, Inc.
</B>
<BR>
<B>
	(File No.
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	001-35963
</FONT>
	) &nbsp; &nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Contribution Agreement, dated May 14, 2014, among Ohr Pharmaceutical,
	Inc., certain affiliates of Ohr, SKS Ocular, LLC, SKS Ocular 1, LLC, and the controlling members of SKS &nbsp;
<B>
	&nbsp;
</B>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	May 16, 2014, Form 8-K, Exhibit 2.1 &nbsp; &nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Agreement and Plan of Merger, dated May 30, 2014, Ohr Pharmaceutical,
	Inc., Ohr Holdco, Inc., and Ohr Merger Sub, Inc. &nbsp; &nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	June 2, 2014, Form 8-K, Exhibit 2.2
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Asset Purchase Agreement, dated August 21, 2009, between Ohr
	Pharmaceutical, Inc. and Genaera Liquidating Trust &nbsp; &nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	August 26, 2009, Exhibit 10.01 &nbsp; &nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Certificate of Incorporation of Ohr Pharmaceutical, Inc.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	June 2, 2014, Form 8-K, Exhibit 3.1(a)
<B>
	&nbsp;
</B>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Certificate of Amendment to Certificate of Incorporation of Ohr
	Pharmaceutical, Inc.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	June 2, 2014, Form 8-K, Exhibit 3.1(b)
<B>
	&nbsp;
</B>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3.3
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	By-Laws of Ohr Pharmaceutical, Inc.
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	June 2, 2014, Form 8-K, Exhibit 3.2
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	4.1(a)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Form of Class J Common Stock Purchase Warrant issued on December
	16,
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	2011
</FONT>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	December 20, 2011, Form 8-K, Exhibit 10.25 &nbsp;
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	4.1(b)
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Amendment, dated March 11, 2014, to Class J Common Stock Purchase
	Warrants &nbsp; &nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	March 14, 2014, Form 8-K, Exhibit 10.39
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	4.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Form of Consulting Warrants
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	June 30, 2011, Form 10-Q, Exhibit 10.21
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	4.3
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Form of Series A Warrant
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	December 8, 2016, Form 8-K, Exhibit 4.1
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	4.4
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
	Form of Series B Warrant
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
	December 8, 2016, Form 8-K, Exhibit 4.2
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.1*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Form of Non-Qualified Option Agreement &nbsp;
<B>
	&nbsp;
</B>
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	March 15, 2012, Form 8-K, Exhibit 10.26 &nbsp; &nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.2(a)*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Employment Agreement, dated January 8, 2014, between Ohr Pharmaceutical,
	Inc. and Sam Backenroth
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	January 10, 2014, Form 8-K, Exhibit 10.38
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 109; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	107
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage110"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; WIDTH: 10%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Exhibit
	Number
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; WIDTH: 43%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Description
	of Exhibit &nbsp; &nbsp;
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; WIDTH: 43%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	The
	filings referenced
</B>
<BR>
<B>
	for incorporation by reference
<BR>
	are Ohr Pharmaceutical, Inc.
</B>
<BR>
<B>
	(File No.
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	001-35963
</FONT>
	) &nbsp; &nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.2(b)*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Amendment 1, dated as of January 6, 2015, to the Employment Agreement,
	dated January 8, 2014, between Ohr Pharmaceutical, Inc. and Sam Backenroth &nbsp; &nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	January 8, 2015, Form 8-K, Exhibit 10.51 &nbsp; &nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.2(c)*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Proprietary Information and Inventions Agreement, dated April
	10, 2010, between Ohr Pharmaceutical, Inc. and Sam Backenroth
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	September 30, 2015, form 10-K, Exhibit 10.3(c)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.3*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Employment
	Agreement, dated as of February 24, 2015, between Ohr Pharmaceutical, Inc. and Avner Ingerman
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	February 26, 2015, Form 8-K, Exhibit 10.52
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.4
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Assignment and Assumption Agreement, dated as of
	May 30, 2014, between Ohr Pharmaceutical, Inc. and Ohr Holdco, Inc. &nbsp; &nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	June 2, 2014, Form 8-K, Exhibit 10.44
<B>
	&nbsp;
</B>
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.5
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Subscription Agreement, dated as of April 8, 2014,
	among Ohr Pharmaceutical, Inc. and the purchasers identified on the signature page thereto &nbsp;&nbsp; &nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	April 8, 2014, Form 8-K, Exhibit 10.41 &nbsp; &nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.6
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Placement Agency Agreement, dated as of April 8,
	2014, among Ohr Pharmaceutical, Inc. and Chardan Capital Markets, LLC and Brean Capital, LLC &nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	April 8, 2014, Form 8-K, Exhibit 10.40 &nbsp; &nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.7
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Securities Purchase Agreement, dated December 7, 2016, by and
	among Ohr Pharmaceuticals, Inc. and to purchasers listed therein
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
	December 8, 2016, Form 8-K, Exhibit 10.1 &nbsp; &nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	10.8
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	Letter Agreement, dated December 2, 2016, by and betweeen Ohr Pharmaceutical, Inc. and H.C. Wainwright &amp; Co., LLC
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	December 8, 2016, Form 8-K, Exhibit 10.2
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.9
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Ohr Pharmaceutical, Inc. 2016 Consolidated Stock
	Incentive Plan
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	March 21, 2016, Form 8-K, Exhibit 10.1
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.10(a)*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
	The Ohr Pharmaceutical, Inc. 2014
	Stock Incentive Plan
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	April 14, 2014, Form 8-K, Exhibit 10.42
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.10(b)*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Amendment to Ohr Pharmaceutical, Inc. 2014 Stock Incentive Plan
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	September 30, 2015, Form 10-K, Exhibit 10.8(b)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.11*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Form of Stock Option Agreement
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	March 31, 2015, Form 10-Q, Exhibit 10.53
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.12*
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Ohr Pharmaceutical, Inc. 2009 Stock Incentive Plan
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	March 31, 2010, Form 10-Q, Exhibit 10.1
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 110; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	108
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage111"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; WIDTH: 10%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Exhibit
	Number
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; WIDTH: 43%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Description
	of Exhibit &nbsp; &nbsp;
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; TEXT-ALIGN: CENTER; WIDTH: 2%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; TEXT-ALIGN: CENTER; WIDTH: 43%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	The
	filings referenced
</B>
<BR>
<B>
	for incorporation by reference
<BR>
	are Ohr Pharmaceutical, Inc.
</B>
<BR>
<B>
	(File No.
<FONT STYLE="BACKGROUND-COLOR: WHITE">
	001-35963
</FONT>
	) &nbsp; &nbsp;
</B>
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	14
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Code of Ethics
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	September 30, 2015, Form 10-K, 10.8(b)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	21
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#EX21_HTM">
	Subsidiaries of the Registrant
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Filed herewith &nbsp; &nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	23
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#EX23_HTM">
	Consent of Independent Registered Public Accounting Firm
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Filed herewith &nbsp; &nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	31.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#EX31-1_HTM">
	Section 302 Certification of Chief Executive Officer
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Filed herewith
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	31.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#EX31-2_HTM">
	Section 302 Certification of Chief Financial Officer
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Filed herewith
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	32.1
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#EX32-1_HTM">
	Section 906 Certification of Chief Executive Officer
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Filed herewith
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	32.2
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<A HREF="#EX32-2_HTM">
	Section 906 Certification of Chief Financial Officer
</A>
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Filed herewith
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	101.INS
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	XBRL Instance Document
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Filed herewith
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	101.SCH
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	XBRL Taxonomy Extension Schema Document
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Filed herewith
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	101.CAL
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	XBRL Taxonomy Extension Calculation Linkbase Document
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Filed herewith
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	101.DEF
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	XBRL Taxonomy Extension Definition Linkbase Document
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Filed herewith
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	101.LAB
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	XBRL Taxonomy Extension Label Linkbase Document
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Filed herewith
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	101.PRE
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	XBRL Taxonomy Extension Presentation Linkbase Document
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Filed herewith
</FONT>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0PT; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.25IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	*
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Management
	contract or compensation plan or arrangement.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
</P>
<!-- FIELD: PAGE; SEQUENCE: 111; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	109
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_EXHIBITS>
</EFX_PART_IV>
<A NAME="eolPage112"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.25IN">
	&nbsp;
</P>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN-TOP: 0PT; MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;
</FONT>
<B>
	SIGNATURES
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 7PT 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Pursuant
	to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
	to be signed on its behalf by the undersigned, thereunto duly authorized.&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 7PT 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	REGISTRANT:
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	OHR PHARMACEUTICAL, INC.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="2">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD STYLE="WIDTH: 5%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Dated:
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 44%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	December 22
</FONT>
	, 2016
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	By:
</FONT>
</TD>
<TD STYLE="WIDTH: 47%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; BACKGROUND-COLOR: WHITE">
<I>
	/s/
</I>
</FONT>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	JASON SLAKTER
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Jason Slakter, CEO (Principal Executive Officer)
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Dated:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	December 22
</FONT>
	, 2016
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	By:
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	/s/ SAM BACKENROTH
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Sam Backenroth, CFO
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: BOTTOM">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(Principal Accounting and Financial Officer)
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Pursuant
	to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
	of the registrant and in the capacities and on the dates indicated.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Dated:
</FONT>
</TD>
<TD STYLE="WIDTH: 1%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 44%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	December 22, 2016
</FONT>
</TD>
<TD STYLE="WIDTH: 3%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	By:
</FONT>
</TD>
<TD STYLE="WIDTH: 47%; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	/s/ JASON
	SLAKTER
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Jason Slakter, Director
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Dated:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	December 22
</FONT>
	, 2016
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	By:
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	/s/ IRA GREENSTEIN &nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Ira Greenstein, Director
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Dated:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	December 22
</FONT>
	, 2016
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	By:
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	/s/ ORIN HIRSCHMAN &nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Orin Hirschman, Director
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Dated:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	December 22
</FONT>
	, 2016
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	By:
</FONT>
</TD>
<TD STYLE="BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	/s/ JUNE ALMENOFF &nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	June Almenoff, Director
</FONT>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Dated:
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	December 22
</FONT>
	, 2016
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	By:
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	/s/
	THOMAS RIEDHAMMER &nbsp; &nbsp; &nbsp;
</FONT>
</TD>
</TR>
<TR>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Thomas Riedhammer, Director
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<!-- FIELD: PAGE; SEQUENCE: 112; VALUE: 1 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	110
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_SIGNATURES>
<!-- FIELD: /PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN, TIMES, SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage113"></A>
<A NAME="EX21_HTM"></A>
<EFX_EXHIBIT_21>
<A NAME="FIS_EXHIBIT_21"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 2PX SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="MARGIN: 0">
<A HREF="#OHRP-10K_093016_HTM">
	OHR Pharmaceutical, Inc. - 10-K
</A>
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Exhibit
	21
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
<B>
<U>
	List
	of Subsidiaries of Ohr Pharmaceutical. Inc.
</U>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Ohr
	Opco, Inc. (incorporated in Delaware)
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0">
</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN-TOP: 0; MARGIN-BOTTOM: 0; WIDTH: 100%">
<TR STYLE="VERTICAL-ALIGN: TOP; TEXT-ALIGN: JUSTIFY">
<TD STYLE="WIDTH: 0IN">
</TD>
<TD STYLE="WIDTH: 0.5IN; TEXT-ALIGN: LEFT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
</TD>
<TD STYLE="TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Ohr
	Pharma, LLC (organized in Delaware)
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: NEWSECTION; VALUE: 111 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	111
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_21>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage114"></A>
<A NAME="EX23_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="LEFT" STYLE="MARGIN-TOP: 3PT; MARGIN-BOTTOM: 3PT">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 2PX SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="MARGIN: 0">
<A HREF="#OHRP-10K_093016_HTM">
	OHR Pharmaceutical, Inc. - 10-K
</A>
</P>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Exhibit
	23
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Consent
	of Independent Registered Public Accounting Firm
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	We
	hereby consent to the incorporation by reference in the Registration Statement on Form S-3&nbsp;(No.&nbsp;333-201368) of Ohr
	Pharmaceutical, Inc. of our report dated December 22, 2016, relating to the consolidated financial statements for the year
	ended September 30, 2016 and the effectiveness of internal control over financial reporting as of
	September 30, 2016, which report appears in this Annual Report on Form 10-K for the fiscal year ended September 30,
	2016.
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-INDENT: 24.5PT; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 30%; FONT-FAMILY: TIMES NEW ROMAN,SERIF; BORDER-BOTTOM: BLACK 1PT SOLID">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	/s/
	MaloneBailey, LLP
</FONT>
</TD>
<TD STYLE="WIDTH: 70%; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	www.malone-bailey.com
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Houston,
	Texas
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	December
	22, 2016
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: NEWSECTION; VALUE: 112 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	112
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_EXPERTS_CONSENT>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage115"></A>
<A NAME="EX31-1_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: WHITE">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 2PX SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT;">
<A HREF="#OHRP-10K_093016_HTM">
	OHR Pharmaceutical, Inc. - 10-K
</A>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: WHITE">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Exhibit
	31.1
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: WHITE">
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Certification
	of Chief Executive Officer
<BR>
	Pursuant to Section 302 of the
<BR>
	Sarbanes-Oxley Act of 2002
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	I,
	Jason Slakter, certify that:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	I
	have reviewed this report on Form 10-K of Ohr Pharmaceutical, Inc;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Based
	on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
	to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
	to the period covered by this report;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Based
	on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
	material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
	presented in this report;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
	and procedures (as defined in Exchange Act Rules 13a-15(e)) and internal control over financial reporting (as defined in Exchange
	Act Rules 13a- 15(f) and 15(d)-15(f)) for the registrant and have:
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	a.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Designed
	such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
	to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
	us by others within those entities, particularly during the period in which this report is being prepared;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	b.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Designed
	such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
	our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
	statements for external purposes in accordance with generally accepted accounting principles;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	c.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Evaluated
	the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
	about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
	on such evaluation; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	d.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Disclosed
	in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
	most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
	affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
	and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
	over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
	(or persons performing the equivalent functions):
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: NEWSECTION; VALUE: 113 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	113
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage116"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	a.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	All
	significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
	are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
	information; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	b.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Any
	fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
	internal control over financial reporting.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0 0PT 24PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0 0PT 24PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dated:
	December 22
</FONT>
	, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0 0PT 24PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 30%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
<B>
<I>
	/s/
	Jason Slakter
</I>
</B>
</FONT>
</TD>
<TD STYLE="WIDTH: 70%; PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Jason
	Slakter
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Chief
	Executive Officer
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN: 0">
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; VALUE: 113 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	114
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_CERTIFICATION>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage117"></A>
<A NAME="EX31-2_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
	&nbsp;
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 2PX SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A HREF="#OHRP-10K_093016_HTM">
	OHR Pharmaceutical, Inc. - 10-K
</A>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Exhibit
	31.2
</FONT>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Certification
	of Chief Financial Officer
<BR>
	Pursuant to Section 302 of the
<BR>
	Sarbanes-Oxley Act of 2002
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0 0PT 24PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	I,
	Sam Backenroth, certify that:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0 0PT 24PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	I
	have reviewed this report on Form 10-K of Ohr Pharmaceutical, Inc.;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Based
	on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
	to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
	to the period covered by this report;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	3.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Based
	on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
	material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
	presented in this report;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	4.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
	(as defined in Exchange Act Rules 13a-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
	13a- 15(f) and 15(d)-15(f)) for the registrant and have:
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	a.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Designed
	such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
	to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
	us by others within those entities, particularly during the period in which this report is being prepared;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	b.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Designed
	such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
	our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
	statements for external purposes in accordance with generally accepted accounting principles;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	c.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Evaluated
	the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
	about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
	on such evaluation; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	d.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Disclosed
	in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
	most recent fiscal quarter (the registrant &lsquo;s fourth fiscal quarter in the case of an annual report) that has materially
	affected, or is reasonably likely to materially affect, the registrant &lsquo;s internal control over financial reporting;
	and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0.25IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	5.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
	over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
	(or persons performing the equivalent functions):
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: NEWSECTION; VALUE: 115 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	115
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
<A NAME="eolPage118"></A>
<DIV STYLE="PAGE-BREAK-BEFORE: ALWAYS; MARGIN-TOP: 6PT; MARGIN-BOTTOM: 12PT">
	&nbsp;
</DIV>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 4%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; WIDTH: 3%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY; WIDTH: 93%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	a.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	All
	significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
	are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
	information; and
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 0IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 0.25IN; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	b.
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Any
	fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
	internal control over financial reporting.
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0 0PT 24PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dated:
	December 22
</FONT>
	, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0 0PT 24PT; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: -24PT">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 30%; BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
<B>
	/s/
</B>
</FONT>
<B>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<I>
	Sam Backenroth
</I>
</FONT>
</B>
</TD>
<TD STYLE="WIDTH: 70%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Sam
	Backenroth
</FONT>
</TD>
<TD>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Chief
	Financial Officer and Principal Accounting Officer
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 2; VALUE: 115 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	116
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_CERTIFICATION>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage119"></A>
<A NAME="EX32-1_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<P STYLE="MARGIN: 0">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 2PX SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A HREF="#OHRP-10K_093016_HTM">
	OHR Pharmaceutical, Inc. - 10-K
<B>
	&nbsp;
</B>
</A>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Exhibit
	32.1
</FONT>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
</FONT>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Certification
	of Chief Executive Officer
<BR>
	Pursuant to 18 U.S.C Section 1350,
<BR>
	As Adopted Pursuant to Section 906 of the
<BR>
	Sarbanes-Oxley Act of 2002
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Not
	Filed Pursuant to the Securities Exchange Act of 1934
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0PT 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	connection with the Annual Report of Ohr Pharmaceutical, Inc. (the
<I>
	&ldquo;Company&rdquo;
</I>
	) on Form 10-K for the fiscal year
	ended September 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the
<I>
	&ldquo;Report&rdquo;
</I>
	),
	I, Jason Slakter, Chief Executive Officer, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
	Section 906 of the Sarbanes-Oxley Act of 2002, that:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 3%; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 3%; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
	of the Company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dated:
	December 22, 2016
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE; FONT-SIZE: 10PT">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
<I>
	/s/
	Jason Slakter
</I>
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 5%; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Name:
</FONT>
</TD>
<TD STYLE="WIDTH: 25%; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Jason
	Slakter
</FONT>
</TD>
<TD STYLE="WIDTH: 75%; FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Title:
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Chief
	Executive Officer
</FONT>
</TD>
<TD STYLE="FONT-FAMILY: TIMES NEW ROMAN,SERIF">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: NEWSECTION; VALUE: 117 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	117
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_CERTIFICATION>
<!-- FIELD: /PAGE -->
<P STYLE="MARGIN: 0">
</P>
</EFX_EXHIBIT_32>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage120"></A>
<A NAME="EX32-2_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32_2"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</P>
<!-- FIELD: RULE-PAGE -->
<DIV ALIGN="CENTER">
<DIV STYLE="FONT-SIZE: 1PT; BORDER-TOP: BLACK 2PX SOLID; WIDTH: 100%">
	&nbsp;
</DIV>
</DIV>
<!-- FIELD: /RULE-PAGE -->
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<B>
</B>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: LEFT">
<A HREF="#OHRP-10K_093016_HTM">
	OHR Pharmaceutical, Inc. - 10-K
</A>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
<B>
	Exhibit
	32.2
</B>
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_4"></A>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Certification
	of Chief Financial Officer
<BR>
	Pursuant to 18 U.S.C Section 1350,
<BR>
	As Adopted Pursuant to Section 906 of the
<BR>
	Sarbanes-Oxley Act of 2002
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Not
	Filed Pursuant to the Securities Exchange Act of 1934
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: CENTER">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0PT 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	In
	connection with the Annual Report of Ohr Pharmaceutical, Inc. (the
<I>
	&ldquo;Company
</I>
	&rdquo;) on Form 10-K for the fiscal year
	ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the
<I>
	&ldquo;Report&rdquo;
</I>
	),
	I, Sam Backenroth, Chief Financial Officer, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
	Section 906 of the Sarbanes-Oxley Act of 2002, that:
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 3%; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	1.
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 8PT 0PT 0; TEXT-ALIGN: JUSTIFY; TEXT-INDENT: 0.5IN">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="WIDTH: 6%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
<TD STYLE="WIDTH: 3%; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	2.
</FONT>
</TD>
<TD STYLE="WIDTH: 91%; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	The
	information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
	of the Company.
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Dated:
	December 22
</FONT>
	, 2016
</P>
<P STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; MARGIN: 0PT 0; TEXT-ALIGN: JUSTIFY">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="FONT-SIZE: 10PT; WIDTH: 100%; BORDER-COLLAPSE: COLLAPSE">
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD COLSPAN="2" STYLE="BORDER-BOTTOM: BLACK 1PT SOLID; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT; BACKGROUND-COLOR: WHITE">
	/s/
<B>
<I>
	Sam Backenroth
</I>
</B>
</FONT>
</TD>
<TD STYLE="PADDING-BOTTOM: 1PT; FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; WIDTH: 5%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Name:
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; WIDTH: 20%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Sam
	Backenroth
</FONT>
</TD>
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF; WIDTH: 75%">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	&nbsp;
</FONT>
</TD>
</TR>
<TR STYLE="VERTICAL-ALIGN: TOP">
<TD STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Title:
</FONT>
</TD>
<TD COLSPAN="2" STYLE="FONT: 10PT TIMES NEW ROMAN,SERIF">
<FONT STYLE="FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; FONT-SIZE: 10PT">
	Chief
	Financial Officer and Principal Accounting Officer
</FONT>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN: 0">
	&nbsp;
</P>
<!-- FIELD: PAGE; SEQUENCE: 1; OPTIONS: NEWSECTION; VALUE: 118 -->
<DIV STYLE="MARGIN-TOP: 12PT; MARGIN-BOTTOM: 6PT; BORDER-BOTTOM: BLACK 1PT SOLID">
<P STYLE="MARGIN-TOP: 0PT; TEXT-ALIGN: CENTER; MARGIN-BOTTOM: 0PT; FONT: NORMAL 10PT TIMES NEW ROMAN, TIMES, SERIF">
<!-- FIELD: SEQUENCE; TYPE: ARABIC; NAME: PAGENO -->
	118
<!-- FIELD: /SEQUENCE -->
	&nbsp;
</P>
</DIV>
</EFX_CERTIFICATION>
<!-- FIELD: /PAGE -->
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
